Christopher P. Cannon, MD - Department of Medicine

Previous

|

|

Return to Search Results

|

Next

Christopher P. Cannon, MD

View Physician Profile

Senior Physician, Brigham and Women's Hospital
Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Cardiovascular
75 Francis Street
Boston, MA 02115

Education:	Columbia University, College of Physicians and Surgeons, 1986, MD

Keywords (MeSH):	Fibrinolytic Agents Platelet Aggregation Inhibitors Myocardial Infarction Angina, Unstable Acute Coronary Syndrome Thrombolytic Therapy

Link to PubMed:	View Cannon's Publications in PubMed.

Publications (Pulled from Harvard Catalyst Profiles): 1. Mogabgab O, Wiviott SD, Antman EM, Foody JM, Wang TY, Sabatine MS, Cannon CP, Li S, Giugliano RP. Relation Between Time of Symptom Onset of ST-Segment Elevation Myocardial Infarction and Patient Baseline Characteristics: From the National Cardiovascular Data Registry. Clin Cardiol. 2013 Apr; 36(4):222-7. 2. Steen DL, Cannon CP, Lele SS, Rajapurkar MM, Mukhopadhyay B, Scirica BM, Murphy SA, Morrow DA. Prognostic evaluation of catalytic iron in patients with acute coronary syndromes. Clin Cardiol. 2013 Mar; 36(3):139-45. 3. Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross JT, Drozda JP, Fesmire FM, Fintel DJ, Fonarow GC, Fox KA, Gray DT, Harrington RA, Hicks KA, Hollander JE, Krumholz H, Labarthe DR, Long JB, Mascette AM, Meyer C, Peterson ED, Radford MJ, Roe MT, Richmann JB, Selker HP, Shahian DM, Shaw RE, Sprenger S, Swor R, Underberg JA, Van de Werf F, Weiner BH, Weintraub WS. 2013 ACCF/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). J Am Coll Cardiol. 2013 Mar 5; 61(9):992-1025. 4. Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross JT, Drozda JP, Fesmire FM, Fintel DJ, Fonarow GC, Fox KA, Gray DT, Harrington RA, Hicks KA, Hollander JE, Krumholz H, Labarthe DR, Long JB, Mascette AM, Meyer C, Peterson ED, Radford MJ, Roe MT, Richmann JB, Selker HP, Shahian DM, Shaw RE, Sprenger S, Swor R, Underberg JA, Van de Werf F, Weiner BH, Weintraub WS. 2013 ACCF/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). Circulation. 2013 Mar 5; 127(9):1052-89. 5. Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ, Ardissino D, Maurer G, Morais J, Nicolau JC, Oto A, Storey RF, James SK, Cannon CP. Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study. Circulation. 2013 Feb 12; 127(6):673-80. 6. Kohli P, Cannon CP. The importance of matching language to type of evidence: avoiding the pitfalls of reporting outcomes data. Clin Cardiol. 2012; 35(12):714-7. 7. Cannon C. Statement on Matching Language to the Type of Evidence Used in Describing Outcomes Data: Editors of the HEART Group Journals. Clin Cardiol. 2012; 35(12):713. 8. Davidson M, Liu SX, Barter P, Brinton EA, Cannon CP, Gotto AM, Leary ET, Shah S, Stepanavage M, Mitchel Y, Dansky HM. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. J Lipid Res. 2013 Feb; 54(2):467-72. 9. Mogabgab O, Giugliano RP, Sabatine MS, Cannon CP, Mohanavelu S, Wiviott SD, Antman EM, Braunwald E. Circadian Variation in Patient Characteristics and Outcomes in ST-Segment Elevation Myocardial Infarction. Chronobiol Int. 2012 Dec; 29(10):1390-6. 10. Rassi AN, Cavender MA, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED, Peacock WF, Laskey WK, Rosas SE, Zhao X, Schwamm LH, Bhatt DL. Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. J Am Coll Cardiol. 2013 Jan 8; 61(1):35-40. show all 11. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL. ß-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012 Oct 3; 308(13):1340-9. 12. Varenhorst C, Alström U, Scirica BM, Hogue CW, Asenblad N, Storey RF, Steg PG, Horrow J, Mahaffey KW, Becker RC, James S, Cannon CP, Brandrup-Wognsen G, Wallentin L, Held C. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol. 2012 Oct 23; 60(17):1623-30. 13. Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, Cannon CP, Heras M, Lopes RD, Morais J, Mahaffey KW, Bach RG, Wojdyla D, Wallentin L. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes. 2012 Sep 1; 5(5):680-8. 14. Somma KA, Bhatt DL, Fonarow GC, Cannon CP, Cox M, Laskey W, Peacock WF, Hernandez AF, Peterson ED, Schwamm L, Saxon LA. Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012 Sep 1; 5(5):654-61. 15. Kumbhani DJ, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED, Peacock WF, Laskey WK, Pan W, Schwamm LH, Bhatt DL. Predictors of adherence to performance measures in patients with acute myocardial infarction. Am J Med. 2013 Jan; 126(1):74.e1-9. 16. Boyer NM, Laskey WK, Cox M, Hernandez AF, Peterson ED, Bhatt DL, Cannon CP, Fonarow GC. Trends in clinical, demographic, and biochemical characteristics of patients with acute myocardial infarction from 2003 to 2008: a report from the american heart association get with the guidelines coronary artery disease program. J Am Heart Assoc. 2012 Aug; 1(4):e001206. 17. Cannon CP, Kohli P. Danger ahead: watch out for indirect comparisons! J Am Coll Cardiol. 2012 Aug 21; 60(8):747-8. 18. Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol. 2012 Sep 4; 60(10):875-81. 19. Bui AH, Bonaca MP, Sabatine MS, Ray KK, Rifai N, Cannon CP, Morrow DA. Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Thromb Thrombolysis. 2012 Aug; 34(2):222-8. 20. O'Donoghue ML, Vaidya A, Afsal R, Alfredsson J, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, Fox KA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Swahn E, Windhausen F, Sabatine MS. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. J Am Coll Cardiol. 2012 Jul 10; 60(2):106-11. 21. Vasaiwala S, Cannon CP, Fonarow GC, Peacock WF, Laskey W, Schwamm LH, Liang L, Hernandez AF, Peterson ED, Rosas SE, Bhatt DL. Quality of care and outcomes among patients with acute myocardial infarction by level of kidney function at admission: report from the get with the guidelines coronary artery disease program. Clin Cardiol. 2012 Sep; 35(9):541-7. 22. Medina HM, Cannon CP, Fonarow GC, Grau-Sepulveda MV, Hernandez AF, Frank Peacock W, Laskey W, Peterson ED, Schwamm L, Bhatt DL. Reperfusion strategies and quality of care in 5339 patients age 80 years or older presenting with ST-elevation myocardial infarction: analysis from get with the guidelines-coronary artery disease. Clin Cardiol. 2012 Oct; 35(10):632-40. 23. Grinstein J, Cannon CP. Aspirin resistance: current status and role of tailored therapy. Clin Cardiol. 2012 Nov; 35(11):673-80. 24. Bangalore S, Fonarow GC, Peterson ED, Hellkamp AS, Hernandez AF, Laskey W, Peacock WF, Cannon CP, Schwamm LH, Bhatt DL. Age and gender differences in quality of care and outcomes for patients with ST-segment elevation myocardial infarction. Am J Med. 2012 Oct; 125(10):1000-9. 25. Kohli P, Cannon CP. Dabigatran associated with increased risk of acute coronary events. Evid Based Med. 2013 Feb; 18(1):e9. 26. Cannon CP, Cannon PJ. Physiology. COX-2 inhibitors and cardiovascular risk. Science. 2012 Jun 15; 336(6087):1386-7. 27. Joshi PH, Chaudhari S, Blaha MJ, Jones SR, Martin SS, Post WS, Cannon CP, Fonarow GC, Wong ND, Amsterdam E, Hirshfeld JW, Blumenthal RS. A point-by-point response to recent arguments against the use of statins in primary prevention: this statement is endorsed by the American Society for Preventive Cardiology. Clin Cardiol. 2012; 35(7):404-9. 28. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, Hernandez AF, Fonarow GC. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012 Jul 3; 126(1):65-75. 29. Kohli P, Cannon CP. A new approach to managing the 'statin-intolerant' patient? Eur Heart J. 2012 May; 33(9):1040-3. 30. Martin SS, Metkus TS, Horne A, Blaha MJ, Hasan R, Campbell CY, Yousuf O, Joshi P, Kaul S, Miller M, Michos ED, Jones SR, Gluckman TJ, Cannon CP, Sperling LS, Blumenthal RS. Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the meantime, some challenges and recommendations. Am J Cardiol. 2012 Jul 15; 110(2):307-13. 31. Rivers EP, Katranji M, Jaehne KA, Brown S, Abou Dagher G, Cannon C, Coba V. Early interventions in severe sepsis and septic shock: a review of the evidence one decade later. Minerva Anestesiol. 2012 Jun; 78(6):712-24. 32. Sampath J, Dietze DT, Toth PP, Cannon CP, Breslan SA. Are continuing medical education activities effective in improving the competence and performance of clinicians? Evidence from activities for primary care clinicians who manage patients with acute coronary syndromes. Crit Pathw Cardiol. 2012 Mar; 11(1):1-9. 33. Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ, Mahaffey KW, Angiolillo DJ, Husted S, Cannon CP, James SK, Kilhamn J, Steg PG, Harrington RA, Wallentin L. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012 Feb 28; 125(8):978-86. 34. Qian F, Ling FS, Deedwania P, Hernandez AF, Fonarow GC, Cannon CP, Peterson ED, Peacock WF, Kaltenbach LA, Laskey WK, Schwamm LH, Bhatt DL. Care and outcomes of Asian-American acute myocardial infarction patients: findings from the American Heart Association Get With The Guidelines-Coronary Artery Disease program. Circ Cardiovasc Qual Outcomes. 2012 Jan; 5(1):126-33. 35. Kohli P, Cannon CP. Triglycerides: how much credit do they deserve? Med Clin North Am. 2012 Jan; 96(1):39-55. 36. Huang PH, Kim CX, Lerman A, Cannon CP, Dai D, Laskey W, Peacock WF, Hernandez AF, Peterson ED, Smith EE, Fonarow GC, Schwamm LH, Bhatt DL. Trends in smoking cessation counseling: experience from American Heart Association-get with the guidelines. Clin Cardiol. 2012; 35(7):396-403. 37. Steen DL, Cannon CP. Atherosclerosis. Effects of evacetrapib administered as monotherapy or in combination with statins. Rev Cardiovasc Med. 2012; 13(1):e48-51. 38. Kohli P, Cannon CP. Acute coronary syndromes in 2011: Walking the tightrope between efficacy and bleeding. Nat Rev Cardiol. 2012 Feb; 9(2):69-71. 39. Reed GW, Cannon CP. Personalized therapy following drug-eluting stenting using platelet function testing and C-reactive protein. J Am Coll Cardiol. 2011 Dec 13; 58(25):2640-1. 40. Stowell SA, Cannon CP, Hoekstra JW, Peterson ED, Miller SC. Take heart: a one-on-one peer-based strategy to improve acute coronary syndrome patient care. Crit Pathw Cardiol. 2011 Dec; 10(4):164-8. 41. Kohli P, Cannon CP. Statins and safety: can we finally be reassured? Lancet. 2011 Dec 10; 378(9808):1980-1. 42. Grandin EW, Jarolim P, Murphy SA, Ritterova L, Cannon CP, Braunwald E, Morrow DA. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem. 2012 Jan; 58(1):267-73. 43. Cannon CP. High-density lipoprotein cholesterol as the Holy Grail. JAMA. 2011 Nov 16; 306(19):2153-5. 44. Motivala AA, Cannon CP, Srinivas VS, Dai D, Hernandez AF, Peterson ED, Bhatt DL, Fonarow GC. Changes in myocardial infarction guideline adherence as a function of patient risk: an end to paradoxical care? J Am Coll Cardiol. 2011 Oct 18; 58(17):1760-5. 45. Eapen ZJ, Fonarow GC, Dai D, O'Brien SM, Schwamm LH, Cannon CP, Heidenreich PA, Bhatt DL, Peterson ED, Hernandez AF. Comparison of composite measure methodologies for rewarding quality of care: an analysis from the American Heart Association's Get With The Guidelines program. Circ Cardiovasc Qual Outcomes. 2011 Nov 1; 4(6):610-8. 46. Meadows TA, Bhatt DL, Cannon CP, Gersh BJ, Röther J, Goto S, Liau CS, Wilson PW, Salette G, Smith SC, Steg PG. Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry. Mayo Clin Proc. 2011 Oct; 86(10):960-7. 47. O'Donoghue ML, Braunwald E, White HD, Serruys P, Steg PG, Hochman J, Maggioni AP, Bode C, Weaver D, Johnson JL, Cicconetti G, Lukas MA, Tarka E, Cannon CP. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J. 2011 Oct; 162(4):613-619.e1. 48. White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad F. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011 Oct; 162(4):620-626.e1. 49. Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, Steg PG, Khurmi NS, Emanuelsson H, Lim ST, Cannon CP, Katus HA, Wallentin L. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). Am J Cardiol. 2011 Dec 1; 108(11):1542-6. 50. Bird GC, Cannon CP, Kennison RH. Results of a survey assessing provider beliefs of adherence barriers to antiplatelet medications. Crit Pathw Cardiol. 2011 Sep; 10(3):134-41. 51. Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation. 2011 Sep 6; 124(10):1132-7. 52. Medina HM, Cannon CP, Zhao X, Hernandez AF, Bhatt DL, Peterson ED, Liang L, Fonarow GC. Quality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD). Am Heart J. 2011 Aug; 162(2):283-290.e2. 53. Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, Steg PG, Khurmi NS, Emanuelsson H, Cooper A, Cairns R, Cannon CP, Wallentin L. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J. 2011 Dec; 32(23):2945-53. 54. Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, Horrow J, Harrington RA, Wallentin L. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011 Aug 2; 124(5):544-54. 55. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011 Jun 22; 305(24):2556-64. 56. James SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S, Katus H, Morais J, Steg PG, Storey RF, Stevens S, Wallentin L, Harrington RA. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011; 342:d3527. 57. Acharjee S, Cannon CP. Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism. Crit Pathw Cardiol. 2011 Jun; 10(2):84-6. 58. Krum H, Swergold G, Gammaitoni A, Peloso PM, Smugar SS, Curtis SP, Brater DC, Wang H, Kaur A, Laine L, Weir MR, Cannon CP. Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. Cardiovasc Ther. 2012 Dec; 30(6):342-50. 59. Wilson SR, Sabatine MS, Wiviott SD, Ray KK, De Lemos JA, Zhou S, Rifai N, Cannon CP, Morrow DA. Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). Am Heart J. 2011 Jun; 161(6):1147-55.e1. 60. Scirica BM, Cannon CP, Emanuelsson H, Michelson EL, Harrington RA, Husted S, James S, Katus H, Pais P, Raev D, Spinar J, Steg PG, Storey RF, Wallentin L. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol. 2011 May 10; 57(19):1908-16. 61. Ahmed S, Michael Gibson C, Cannon CP, Murphy SA, Sabatine MS. Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis. J Thromb Thrombolysis. 2011 May; 31(4):493-500. 62. Truong QA, Murphy SA, McCabe CH, Armani A, Cannon CP. Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22. Circ Cardiovasc Qual Outcomes. 2011 May; 4(3):328-36. 63. Patti G, Cannon CP, Murphy SA, Mega S, Pasceri V, Briguori C, Colombo A, Yun KH, Jeong MH, Kim JS, Choi D, Bozbas H, Kinoshita M, Fukuda K, Jia XW, Hara H, Cay S, Di Sciascio G. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation. 2011 Apr 19; 123(15):1622-32. 64. Ruff CT, Morrow DA, Jarolim P, Ren F, Contant CF, Kaur A, Curtis SP, Laine L, Cannon CP, Brune K. Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. J Rheumatol. 2011 Jun; 38(6):1071-8. 65. Abtahian F, Olenchock B, Ou FS, Kontos MC, Saucedo JF, Scirica BM, Desai N, Peterson E, Roe M, Cannon CP, Wiviott SD. Effect of prior stroke on the use of evidence-based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry). Am J Cardiol. 2011 May 15; 107(10):1441-6. 66. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Stillablower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011 Mar 16; 305(11):1097-105. 67. Natarajan P, Cannon CP. Myocardial infarction vaccine? Evidence supporting the influenza vaccine for secondary prevention. Eur Heart J. 2011 Jul; 32(14):1701-3. 68. Cannon CP. Clopidogrel: to test or not to test? That is the question--still. Clin Chem. 2011 May; 57(5):659-61. 69. Cannon CP, Hoekstra JW, Larson DM, Karcher RB, Mencia WA, Berry CA, Stowell SA. A report of quality improvement in the care of patients with acute coronary syndromes. Crit Pathw Cardiol. 2011 Mar; 10(1):29-34. 70. Nazer B, Ray KK, Sloan S, Scirica B, Morrow DA, Cannon CP, Braunwald E. Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome. Eur Heart J. 2011 Jun; 32(11):1390-7. 71. Mathews R, Peterson ED, Chen AY, Wang TY, Chin CT, Fonarow GC, Cannon CP, Rumsfeld JS, Roe MT, Alexander KP. In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™. Am J Cardiol. 2011 Apr 15; 107(8):1136-43. 72. Javed U, Deedwania PC, Bhatt DL, Cannon CP, Dai D, Hernandez A, Peterson ED, Fonarow GC. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospita participating in Get With The Guidelines (GWTG). Am Heart J. 2011 Feb; 161(2):418-424.e1-3. 73. Vaughan-Shaw PG, Cannon C. Venous thromboembolism prevention in medical patients: a framework for improving practice. Phlebology. 2011 Mar; 26(2):62-8. 74. Alexander KP, Wang TY, Li S, Lytle BL, Slattery LE, Calhoun S, Poteat J, Roe MT, Rumsfeld JS, Cannon CP, Peterson ED. Randomized trial of targeted performance feedback to facilitate quality improvement in acute myocardial infarction care. Circ Cardiovasc Qual Outcomes. 2011 Jan 1; 4(1):129-35. 75. Benziger DP, Pertel PE, Donovan J, Yankelev S, Schwab RJ, Swan SK, Cannon C. Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Clin Nephrol. 2011 Jan; 75(1):63-9. 76. Chin CT, Chen AY, Wang TY, Alexander KP, Mathews R, Rumsfeld JS, Cannon CP, Fonarow GC, Peterson ED, Roe MT. Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: the acute coronary treatment and intervention outcomes network (ACTION) registry-get with the guidelines (GWTG) acute myocardial infarction mortality model and risk score. Am Heart J. 2011 Jan; 161(1):113-122.e2. 77. Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, Harrington RA, Horrow J, Husted S, James SK, Mahaffey KW, Nicolau JC, Scirica BM, Storey RF, Vintila M, Ycas J, Wallentin L. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011 Feb 8; 57(6):672-84. 78. Acharjee S, Cannon CP. Duration of dual antiplatelet therapy following percutaneous coronary intervention with drug-eluting stents: a review of recent evidence. Crit Pathw Cardiol. 2010 Dec; 9(4):203-6. 79. Javed U, Deedwania PC, Bhatt DL, Cannon CP, Dai D, Hernandez AF, Peterson ED, Fonarow GC. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). Am Heart J. 2010 Dec; 160(6):1130-6, 1136.e1-3. 80. Marchini J, Morrow D, Resnic F, Manica A, Kirshenbaum J, Cannon C, Croce K. An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention. Crit Pathw Cardiol. 2010 Dec; 9(4):192-8. 81. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010 Dec 16; 363(25):2406-15. 82. Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP. What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation. 2010 Nov 23; 122(21):2142-51. 83. Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, Emanuelsson H, Finkelstein A, Husted S, Katus H, Kilhamn J, Olofsson S, Storey RF, Weaver WD, Wallentin L. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010 Nov 23; 122(21):2131-41. 84. Cannon CP. An overview of stroke and the impact of atrial fibrillation. Am J Manag Care. 2010 Nov; 16(10 Suppl):S273-7. 85. Natarajan P, Cannon CP. Could direct inhibition of inflammation be the "next big thing" in treating atherosclerosis? Arterioscler Thromb Vasc Biol. 2010 Nov; 30(11):2081-3. 86. Kadakia MB, Desai NR, Alexander KP, Chen AY, Foody JM, Cannon CP, Wiviott SD, Scirica BM. Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines). JACC Cardiovasc Interv. 2010 Nov; 3(11):1166-77. 87. Cannon CP, Stecker EC. New options for stroke prevention in atrial fibrillation. Am J Manag Care. 2010 Nov; 16(10 Suppl):S291-7. 88. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010 Oct 27; 304(16):1821-30. 89. Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon CP, Becker RC, Wallentin L. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol. 2010 Oct 26; 56(18):1456-62. 90. Bonaca MP, Morrow DA, Braunwald E, Cannon CP, Jiang S, Breher S, Sabatine MS, Kempf T, Wallentin L, Wollert KC. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2011 Jan; 31(1):203-10. 91. Rich JD, Cannon CP, Murphy SA, Qin J, Giugliano RP, Braunwald E. Prior aspirin use and outcomes in acute coronary syndromes. J Am Coll Cardiol. 2010 Oct 19; 56(17):1376-85. 92. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010 Nov 11; 363(20):1909-17. 93. White H, Held C, Stewart R, Watson D, Harrington R, Budaj A, Steg PG, Cannon CP, Krug-Gourley S, Wittes J, Trivedi T, Tarka E, Wallentin L. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J. 2010 Oct; 160(4):655-61. 94. Krishnaswamy A, Lincoff AM, Cannon CP. Bleeding complications of unfractionated heparin. Expert Opin Drug Saf. 2011 Jan; 10(1):77-84. 95. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Aliment Pharmacol Ther. 2010 Nov; 32(10):1240-8. 96. Boden WE, Cherr GS, Eagle KA, Cannon CP, Califf RM, Hirsch AT, Alberts MJ, Criqui M, Creager MA, Massaro JM, D'Agostino RB, Steg PG, Bhatt DL. Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosis. Crit Pathw Cardiol. 2010 Sep; 9(3):116-25. 97. Birtcher KK, Pan W, Labresh KA, Cannon CP, Fonarow GC, Ellrodt G. Performance achievement award program for Get With The Guidelines--Coronary Artery Disease is associated with global and sustained improvement in cardiac care for patients hospitalized with an acute myocardial infarction. Crit Pathw Cardiol. 2010 Sep; 9(3):103-12. 98. Acharjee S, Cannon CP. Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers. Crit Pathw Cardiol. 2010 Sep; 9(3):156-9. 99. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K, Wojdyla D, Wallentin L. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010 Sep 14; 122(11):1056-67. 100. Bangalore S, Bhatt DL, Röther J, Alberts MJ, Thornton J, Wolski K, Goto S, Hirsch AT, Smith SC, Aichner FT, Topakian R, Cannon CP, Steg PG. Late outcomes after carotid artery stenting versus carotid endarterectomy: insights from a propensity-matched analysis of the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation. 2010 Sep 14; 122(11):1091-100. 101. Peterson ED, Roe MT, Chen AY, Fonarow GC, Lytle BL, Cannon CP, Rumsfeld JS. The NCDR ACTION Registry-GWTG: transforming contemporary acute myocardial infarction clinical care. Heart. 2010 Nov; 96(22):1798-802. 102. Khera AV, Wolfe ML, Cannon CP, Qin J, Rader DJ. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study). Am J Cardiol. 2010 Aug 15; 106(4):451-6. 103. Roe MT, Messenger JC, Weintraub WS, Cannon CP, Fonarow GC, Dai D, Chen AY, Klein LW, Masoudi FA, McKay C, Hewitt K, Brindis RG, Peterson ED, Rumsfeld JS. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardiol. 2010 Jul 20; 56(4):254-63. 104. Ray KK, Nazer B, Cairns R, Michael Gibson C, Cannon CP. Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes. J Thromb Thrombolysis. 2010 Jul; 30(1):10-3. 105. Scirica BM, Morrow DA, Bode C, Ruzyllo W, Ruda M, Oude Ophuis AJ, Lopez-Sendon J, Swedberg K, Ogorek M, Rifai N, Lukashevich V, Maboudian M, Cannon CP, McCabe CH, Braunwald E. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J. 2010 Aug; 31(16):1993-2005. 106. Cannon CP. Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE): updated standing orders for ST-segment elevation myocardial infarction and unstable angina/non-ST-segment elevation myocardial infarction. Crit Pathw Cardiol. 2010 Jun; 9(2):55-81. 107. Sherwood MW, Morrow DA, Scirica BM, Jiang S, Bode C, Rifai N, Gerszten RE, Gibson CM, Cannon CP, Braunwald E, Sabatine MS. Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28. Am Heart J. 2010 Jun; 159(6):964-971.e1. 108. Vidovich MI, Vasaiwala S, Cannon CP, Peterson ED, Dai D, Hernandez AF, Fonarow GC. Association of insurance status with inpatient treatment for coronary artery disease: findings from the Get With the Guidelines program. Am Heart J. 2010 Jun; 159(6):1026-36. 109. Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010 May 1; 375(9725):1536-44. 110. Husted S, Storey RF, Harrington RA, Emanuelsson H, Cannon CP. Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. Clin Cardiol. 2010 Apr; 33(4):206-12. 111. Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol. 2010 Mar 30; 55(13):1283-99. 112. Califf RM, Lokhnygina Y, Cannon CP, Stepanavage ME, McCabe CH, Musliner TA, Pasternak RC, Blazing MA, Giugliano RP, Harrington RA, Braunwald E. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J. 2010 May; 159(5):705-9. 113. Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM, van Es GA, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Fitzgerald PJ, Nesto RW. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation. 2010 Mar 16; 121(10):1176-87. 114. Laskey W, Spence N, Zhao X, Mayo R, Taylor R, Cannon CP, Hernandez AF, Peterson ED, Fonarow GC. Regional differences in quality of care and outcomes for the treatment of acute coronary syndromes: an analysis from the get with the guidelines coronary artery disease program. Crit Pathw Cardiol. 2010 Mar; 9(1):1-7. 115. Gibler KB, Huskamp HA, Sabatine MS, Murphy SA, Cohen DJ, Cannon CP. Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction. Crit Pathw Cardiol. 2010 Mar; 9(1):14-8. 116. Krishnaswamy A, Lincoff AM, Cannon CP. The use and limitations of unfractionated heparin. Crit Pathw Cardiol. 2010 Mar; 9(1):35-40. 117. Acharjee S, Qin J, Murphy SA, McCabe C, Cannon CP. Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial). Am J Cardiol. 2010 Mar 1; 105(5):619-23. 118. Mega S, Patti G, Cannon CP, Di Sciascio G. Preprocedural statin therapy to prevent myocardial damage in percutaneous coronary intervention: a review of randomized trials. Crit Pathw Cardiol. 2010 Mar; 9(1):19-22. 119. Cannon CP, Hoekstra JW, Larson DM, Carter RD, Cornish J, Karcher RB, Mencia WA, Berry CA, Stowell SA. Physician practice patterns in acute coronary syndromes: an initial report of an individual quality improvement program. Crit Pathw Cardiol. 2010 Mar; 9(1):23-9. 120. Cannon CP. Balancing the benefits of statins versus a new risk-diabetes. Lancet. 2010 Feb 27; 375(9716):700-1. 121. Xian Y, Pan W, Peterson ED, Heidenreich PA, Cannon CP, Hernandez AF, Friedman B, Holloway RG, Fonarow GC. Are quality improvements associated with the Get With the Guidelines-Coronary Artery Disease (GWTG-CAD) program sustained over time? A longitudinal comparison of GWTG-CAD hospitals versus non-GWTG-CAD hospitals. Am Heart J. 2010 Feb; 159(2):207-14. 122. Maree AO, Vangjeli C, Jneid H, Ryan J, Cox D, Cannon CP, Shields DC, Fitzgerald DJ. G-protein beta3 subunit polymorphism and bleeding in the orbofiban in patients with unstable coronary syndromes-thrombolysis in myocardial infarction 16 trial. J Thromb Haemost. 2010 May; 8(5):934-41. 123. Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, Husted S, Katus H, Keltai M, Khurmi NS, Kontny F, Lewis BS, Steg PG, Storey RF, Wojdyla D, Wallentin L. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010 Jan 23; 375(9711):283-93. 124. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, Saucedo JF, Kontos MC, Wiviott SD. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010 Jan 26; 121(3):357-65. 125. Cannon CP, Rhee KE, Califf RM, Boden WE, Hirsch AT, Alberts MJ, Cable G, Shao M, Ohman EM, Steg PG, Eagle KA, Bhatt DL. Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol. 2010 Feb 15; 105(4):445-52. 126. Truong Q, Kallianos K, Cannon C. Coronary artery disease. Calcium score of zero: not a gatekeeper to rule out coronary artery disease. Rev Cardiovasc Med. 2010; 11(4):271-3. 127. Truong QA, Garrido-Castro AC, Cannon CP. Patent foramen ovale. Incidental patent foramen ovale during cardiothoracic surgery: to repair or not to repair? Rev Cardiovasc Med. 2010; 11(1):53-6. 128. Waheed S, Cannon CP. Cardiac rehabilitation. Cardiac rehabilitation reduces the long-term risk of death and cardiovascular complications. Rev Cardiovasc Med. 2010; 11(3):e181-4. 129. Harkness JR, Sabatine MS, Braunwald E, Morrow DA, Sloan S, Wiviott SD, Giugliano RP, Antman EM, Cannon CP, Scirica BM. Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. Am Heart J. 2010 Jan; 159(1):55-62. 130. Kumar A, Cannon CP. News and views from the literature. Antiplatelet therapy. Ticagrelor in acute coronary syndrome: a new frontier in platelet inhibition. Rev Cardiovasc Med. 2010; 11(2):117-20. 131. Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009 Dec 15; 54(25):2358-62. 132. Gibson CM, Pride YB, Hochberg CP, Sloan S, Sabatine MS, Cannon CP. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. J Am Coll Cardiol. 2009 Dec 8; 54(24):2290-5. 133. Meadows TA, Bhatt DL, Hirsch AT, Creager MA, Califf RM, Ohman EM, Cannon CP, Eagle KA, Alberts MJ, Goto S, Smith SC, Wilson PW, Watson KE, Steg PG. Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry. Am Heart J. 2009 Dec; 158(6):1038-45. 134. Kumbhani DJ, Cannon CP, Fonarow GC, Liang L, Askari AT, Peacock WF, Peterson ED, Bhatt DL. Association of hospital primary angioplasty volume in ST-segment elevation myocardial infarction with quality and outcomes. JAMA. 2009 Nov 25; 302(20):2207-13. 135. Berger JS, Bhatt DL, Cannon CP, Chen Z, Jiang L, Jones JB, Mehta SR, Sabatine MS, Steinhubl SR, Topol EJ, Berger PB. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol. 2009 Nov 17; 54(21):1935-45. 136. Ambardekar AV, Fonarow GC, Dai D, Peterson ED, Hernandez AF, Cannon CP, Krantz MJ. Quality of care and in-hospital outcomes in patients with coronary heart disease in rural and urban hospitals (from Get With the Guidelines-Coronary Artery Disease Program). Am J Cardiol. 2010 Jan 15; 105(2):139-43. 137. Depta JP, Cannon CP, Fonarow GC, Zhao X, Peacock WF, Bhatt DL. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol. 2009 Nov 1; 104(9):1171-8. 138. Kumar A, Cannon CP. Acute coronary syndromes: Diagnosis and management, part II. Mayo Clin Proc. 2009 Nov; 84(11):1021-36. 139. Lewis WR, Ellrodt AG, Peterson E, Hernandez AF, LaBresh KA, Cannon CP, Pan W, Fonarow GC. Trends in the use of evidence-based treatments for coronary artery disease among women and the elderly: findings from the get with the guidelines quality-improvement program. Circ Cardiovasc Qual Outcomes. 2009 Nov; 2(6):633-41. 140. Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC. Use of aldosterone antagonists in heart failure. JAMA. 2009 Oct 21; 302(15):1658-65. 141. Cannon CP, Dansky HM, Davidson M, Gotto AM, Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 2009 Oct; 158(4):513-519.e3. 142. Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc. 2009 Oct; 84(10):917-38. 143. Kumar A, Fonarow GC, Eagle KA, Hirsch AT, Califf RM, Alberts MJ, Boden WE, Steg PG, Shao M, Bhatt DL, Cannon CP. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry. Crit Pathw Cardiol. 2009 Sep; 8(3):104-11. 144. Smith EE, Liang L, Hernandez A, Reeves MJ, Cannon CP, Fonarow GC, Schwamm LH. Influence of stroke subtype on quality of care in the Get With The Guidelines-Stroke Program. Neurology. 2009 Sep 1; 73(9):709-16. 145. Peterson ED, Roe MT, Rumsfeld JS, Shaw RE, Brindis RG, Fonarow GC, Cannon CP. A call to ACTION (acute coronary treatment and intervention outcomes network): a national effort to promote timely clinical feedback and support continuous quality improvement for acute myocardial infarction. Circ Cardiovasc Qual Outcomes. 2009 Sep; 2(5):491-9. 146. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10; 361(11):1045-57. 147. Cannon CP. Should we manage patients with non-ST segment elevation myocardial infarction with renal failure with an invasive strategy? Circulation. 2009 Sep 8; 120(10):828-30. 148. Mega JL, Morrow DA, Brown A, Cannon CP, Sabatine MS. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol. 2009 Sep; 29(9):1310-5. 149. Wang TY, Fonarow GC, Hernandez AF, Liang L, Ellrodt G, Nallamothu BK, Shah BR, Cannon CP, Peterson ED. The dissociation between door-to-balloon time improvement and improvements in other acute myocardial infarction care processes and patient outcomes. Arch Intern Med. 2009 Aug 10; 169(15):1411-9. 150. Brown TM, Hernandez AF, Bittner V, Cannon CP, Ellrodt G, Liang L, Peterson ED, Piña IL, Safford MM, Fonarow GC. Predictors of cardiac rehabilitation referral in coronary artery disease patients: findings from the American Heart Association's Get With The Guidelines Program. J Am Coll Cardiol. 2009 Aug 4; 54(6):515-21. 151. Brilakis ES, Hernandez AF, Dai D, Peterson ED, Banerjee S, Fonarow GC, Cannon CP, Bhatt DL. Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program. Circulation. 2009 Aug 18; 120(7):560-7. 152. Storey RF, Melissa Thornton S, Lawrance R, Husted S, Wickens M, Emanuelsson H, Cannon CP, Heptinstall S, Armstrong M. Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3. Platelets. 2009 Aug; 20(5):341-8. 153. Roe MT, Chen AY, Cannon CP, Rao S, Rumsfeld J, Magid DJ, Brindis R, Klein LW, Gibler WB, Ohman EM, Peterson ED. Temporal changes in the use of drug-eluting stents for patients with non-ST-Segment-elevation myocardial infarction undergoing percutaneous coronary intervention from 2006 to 2008: results from the can rapid risk stratification of unstable angina patients supress ADverse outcomes with early implementation of the ACC/AHA guidelines (CRUSADE) and acute coronary treatment and intervention outcomes network-get with the guidelines (ACTION-GWTG) registries. Circ Cardiovasc Qual Outcomes. 2009 Sep; 2(5):414-20. 154. Laine L, Connors L, Griffin MR, Curtis SP, Kaur A, Cannon CP. Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines. Aliment Pharmacol Ther. 2009 Oct; 30(7):767-74. 155. Gilbert NF, Yasko AW, Oates SD, Lewis VO, Cannon CP, Lin PP. Allograft-prosthetic composite reconstruction of the proximal part of the tibia. An analysis of the early results. J Bone Joint Surg Am. 2009 Jul; 91(7):1646-56. 156. Pride YB, Appelbaum E, Lord EE, Sloan S, Cannon CP, Sabatine MS, Gibson CM. Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction. Am J Cardiol. 2009 Aug 15; 104(4):475-9. 157. Eagle KA, Hirsch AT, Califf RM, Alberts MJ, Steg PG, Cannon CP, Brennan DM, Bhatt DL. Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the united states: insights from the REACH Registry. Crit Pathw Cardiol. 2009 Jun; 8(2):91-7. 158. Charytan DM, Wallentin L, Lagerqvist B, Spacek R, De Winter RJ, Stern NM, Braunwald E, Cannon CP, Choudhry NK. Early angiography in patients with chronic kidney disease: a collaborative systematic review. Clin J Am Soc Nephrol. 2009 Jun; 4(6):1032-43. 159. Price MJ, Berger PB, Angiolillo DJ, Teirstein PS, Tanguay JF, Kandzari DE, Cannon CP, Topol EJ. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J. 2009 May; 157(5):818-24, 824.e1. 160. Forman DE, Cannon CP, Hernandez AF, Liang L, Yancy C, Fonarow GC. Influence of age on the management of heart failure: findings from Get With the Guidelines-Heart Failure (GWTG-HF). Am Heart J. 2009 Jun; 157(6):1010-7. 161. Krum H, Curtis SP, Kaur A, Wang H, Smugar SS, Weir MR, Laine L, Brater DC, Cannon CP. Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. Eur J Heart Fail. 2009 Jun; 11(6):542-50. 162. Desai NR, Mega JL, Jiang S, Cannon CP, Sabatine MS. Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol. 2009 Apr 14; 53(15):1273-8. 163. Krum H, Swergold G, Curtis SP, Kaur A, Wang H, Smugar SS, Weir MR, Laine L, Brater DC, Cannon CP. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. J Hypertens. 2009 Apr; 27(4):886-93. 164. James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009 Apr; 157(4):599-605. 165. Husted S, Harrington RA, Cannon CP, Storey RF, Mitchell P, Emanuelsson H. Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial. Int J Clin Pract. 2009 Apr; 63(4):667-70. 166. Bhatt DL, Peterson ED, Harrington RA, Ou FS, Cannon CP, Gibson CM, Kleiman NS, Brindis RG, Peacock WF, Brener SJ, Menon V, Smith SC, Pollack CV, Gibler WB, Ohman EM, Roe MT. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009 May; 30(10):1195-202. 167. Cannon CP. Can the polypill save the world from heart disease? Lancet. 2009 Apr 18; 373(9672):1313-4. 168. Pollack CV, Hollander JE, Chen AY, Peterson ED, Bangalore S, Peacock FW, Cannon CP, Canto JG, Gibler BW, Ohman ME, Roe MT. Non-ST-elevation myocardial infarction patients who present during off hours have higher risk profiles and are treated less aggressively, but their outcomes are not worse: a report from Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation of the ACC/AHA Guidelines CRUSADE initiative. Crit Pathw Cardiol. 2009 Mar; 8(1):29-33. 169. Cannon CP, Hoekstra JW, Larson DM, Mencia WA, Cornish J, Carter RD, Berry CA, Karcher RB. Individual quality improvement in acute coronary syndromes: a performance improvement initiative. Crit Pathw Cardiol. 2009 Mar; 8(1):43-8. 170. Nallamothu BK, Krumholz HM, Peterson ED, Pan W, Bradley E, Stern AF, Masoudi FA, Janicke DM, Hernandez AF, Cannon CP, Fonarow GC. Door-to-balloon times in hospitals within the get-with-the-guidelines registry after initiation of the door-to-balloon (D2B) Alliance. Am J Cardiol. 2009 Apr 15; 103(8):1051-5. 171. Truong QA, Cannon CP, Zakai NA, Rogers IS, Giugliano RP, Wiviott SD, McCabe CH, Morrow DA, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial. Am Heart J. 2009 Apr; 157(4):673-9.e1. 172. Tung P, Wiviott SD, Cannon CP, Murphy SA, McCabe CH, Gibson CM. Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study). Am J Cardiol. 2009 Apr 15; 103(8):1056-60. 173. Combe B, Swergold G, McLay J, McCarthy T, Zerbini C, Emery P, Connors L, Kaur A, Curtis S, Laine L, Cannon CP. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford). 2009 Apr; 48(4):425-32. 174. Cannon CP, Paraliticci GU, Lin PP, Lewis VO, Yasko AW. Functional outcome following endoprosthetic reconstruction of the proximal humerus. J Shoulder Elbow Surg. 2009 Sep-Oct; 18(5):705-10. 175. Laine L, Goldkind L, Curtis SP, Connors LG, Yanqiong Z, Cannon CP. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol. 2009 Feb; 104(2):356-62. 176. Diercks DB, Kontos MC, Chen AY, Pollack CV, Wiviott SD, Rumsfeld JS, Magid DJ, Gibler WB, Cannon CP, Peterson ED, Roe MT. Utilization and impact of pre-hospital electrocardiograms for patients with acute ST-segment elevation myocardial infarction: data from the NCDR (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. J Am Coll Cardiol. 2009 Jan 13; 53(2):161-6. 177. Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2009 Mar; 29(3):424-30. 178. Hartwig KA, Burich D, Cannon C, Massari L, Mueller L, Dembry LM. Critical challenges ahead in bioterrorism preparedness training for clinicians. Prehosp Disaster Med. 2009 Jan-Feb; 24(1):47-53. 179. Cannon CP. Introduction: Update on the evaluation and treatment of chronic angina. Rev Cardiovasc Med. 2009; 10 Suppl 1:S1-2. 180. Cannon CP, Kumar A. Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options. Clin Cornerstone. 2009; 9(4):55-68; discussion 69-71. 181. Truong QA, Siegel E, Cannon CP. Cardiac CT angiography--radiation dose-how effective are we in reducing radiation dose from cardiac CT angiography? Rev Cardiovasc Med. 2009; 10(4):236-9. 182. Cannon CP, Waheed S. Evaluating medical, percutaneous coronary intervention, and coronary artery bypass surgery options for chronic angina: an update of the revised guidelines. Rev Cardiovasc Med. 2009; 10 Suppl 1:S21-9. 183. Truong QA, Okada DR, Cannon CP. Cardiac risk - coronary calcium scoring for all? Rev Cardiovasc Med. 2009; 10(2):121-4. 184. Truong QA, Cannon CP. Cardiac resynchronization therapy. A perspective on PROSPECT and the continued search for predictors to CRT response. Rev Cardiovasc Med. 2009; 10(1):59-61. 185. Gelfand CV, Cannon CP. Unstable angina and non-ST-elevation myocardial infarction. Gelfand CV, Cannon CP, editors. Management of Acute Coronary Syndromes. 2009; 37-78. 186. Gelfand CV, Cannon CP. ST-segment-elevation myocardial infarction. Gelfand CV, Cannon CP, editors. Management of Acute Coronary Syndromes. 2009; 79-121. 187. Cannon CP. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications. Am J Cardiol. 2008 Dec 22; 102(12A):5L-9L. 188. Schwamm LH, Fonarow GC, Reeves MJ, Pan W, Frankel MR, Smith EE, Ellrodt G, Cannon CP, Liang L, Peterson E, Labresh KA. Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation. 2009 Jan 6; 119(1):107-15. 189. Scirica BM, Cannon CP, Sabatine MS, Jarolim P, Sloane S, Rifai N, Braunwald E, Morrow DA. Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death. Clin Chem. 2009 Feb; 55(2):265-73. 190. Masoudi FA, Bonow RO, Brindis RG, Cannon CP, Debuhr J, Fitzgerald S, Heidenreich PA, Ho KK, Krumholz HM, Leber C, Magid DJ, Nilasena DS, Rumsfeld JS, Smith SC, Wharton TP. ACC/AHA 2008 statement on Performance Measurement and Reperfusion Therapy: a report of the ACC/AHA Task Force on Performance Measures (Work Group to address the challenges of Performance Measurement and Reperfusion Therapy). J Am Coll Cardiol. 2008 Dec 9; 52(24):2100-12. 191. Jneid H, Fonarow GC, Cannon CP, Hernandez AF, Palacios IF, Maree AO, Wells Q, Bozkurt B, Labresh KA, Liang L, Hong Y, Newby LK, Fletcher G, Peterson E, Wexler L. Sex differences in medical care and early death after acute myocardial infarction. Circulation. 2008 Dec 16; 118(25):2803-10. 192. Cannon CP. Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) ST-segment elevation myocardial infarction critical pathway toolkit. Crit Pathw Cardiol. 2008 Dec; 7(4):223-31. 193. Syed Z, Scirica BM, Mohanavelu S, Sung P, Michelson EL, Cannon CP, Stone PH, Stultz CM, Guttag JV. Relation of death within 90 days of non-ST-elevation acute coronary syndromes to variability in electrocardiographic morphology. Am J Cardiol. 2009 Feb 1; 103(3):307-11. 194. Olenchock BA, Fonarow GG, Pan W, Hernandez A, Cannon CP. Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. Am J Cardiol. 2009 Feb 1; 103(3):295-300. 195. Matheny ME, Morrow DA, Ohno-Machado L, Cannon CP, Sabatine MS, Resnic FS. Validation of an automated safety surveillance system with prospective, randomized trial data. Med Decis Making. 2009 Mar-Apr; 29(2):247-56. 196. Masoudi FA, Bonow RO, Brindis RG, Cannon CP, Debuhr J, Fitzgerald S, Heidenreich PA, Ho KK, Krumholz HM, Leber C, Magid DJ, Nilasena DS, Rumsfeld JS, Smith SC, Wharton TP, DeLong E, Estes NA, Goff DC, Grady K, Green LA, Loth AR, Peterson ED, Radford MJ, Rumsfeld JS, Shahian DM. ACC/AHA 2008 statement on performance measurement and reperfusion therapy: a report of the ACC/AHA Task Force on Performance Measures (Work Group to address the challenges of performance measurement and reperfusion therapy). Circulation. 2008 Dec 9; 118(24):2649-61. 197. Lewis WR, Fonarow GC, LaBresh KA, Cannon CP, Pan W, Super DM, Sorof SA, Schwamm LH. Differential use of warfarin for secondary stroke prevention in patients with various types of atrial fibrillation. Am J Cardiol. 2009 Jan 15; 103(2):227-31. 198. Truong QA, Singh JP, Cannon CP, Sarwar A, Nasir K, Auricchio A, Faletra FF, Sorgente A, Conca C, Moccetti T, Handschumacher M, Brady TJ, Hoffmann U. Quantitative analysis of intraventricular dyssynchrony using wall thickness by multidetector computed tomography. JACC Cardiovasc Imaging. 2008 Nov; 1(6):772-81. 199. Sachdeva A, Cannon CP, Deedwania PC, Labresh KA, Smith SC, Dai D, Hernandez A, Fonarow GC. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J. 2009 Jan; 157(1):111-117.e2. 200. Ratner RE, Cannon CP, Gerstein HC, Nesto RW, Serruys PW, Van Es GA, Kolatkar NS, Kravitz BG, Zalewski A, Fitzgerald PJ. Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics. Am Heart J. 2008 Dec; 156(6):1074-9. 201. Ambardekar AV, Pan W, Peterson SL, Fonarow GC, Webb LE, Hernandez AF, Cannon CP, Peterson ED, Krantz MJ. Features and hospital outcomes for nonadherent patients with heart failure: Findings from GWTG-HF. Scientific Meeting Heart Failure Society of America. 2008. 202. Giraldez RR, Giugliano RP, Mohanavelu S, Murphy SA, McCabe CH, Cannon CP, Braunwald E. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. J Am Coll Cardiol. 2008 Sep 9; 52(11):914-20. 203. Lewis WR, Peterson ED, Cannon CP, Super DM, LaBresh KA, Quealy K, Liang L, Fonarow GC. An organized approach to improvement in guideline adherence for acute myocardial infarction: results with the Get With The Guidelines quality improvement program. Arch Intern Med. 2008 Sep 8; 168(16):1813-9. 204. Cannon CP, Greenberg BH. Risk stratification and prognostic factors in the post-myocardial infarction patient. Am J Cardiol. 2008 Sep 8; 102(5A):13G-20G. 205. Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RM. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008 Nov; 156(5):826-32. 206. Albanese J, Birnbaum M, Cannon C, Cappiello J, Chapman E, Paturas J, Smith S. Fostering disaster resilient communities across the globe through the incorporation of safe and resilient hospitals for community-integrated disaster responses. Prehosp Disaster Med. 2008 Sep-Oct; 23(5):385-90. 207. Laine L, Curtis SP, Langman M, Jensen DM, Cryer B, Kaur A, Cannon CP. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology. 2008 Nov; 135(5):1517-25. 208. Alexander D, Ou FS, Roe MT, Pollack CV, Ohman EM, Cannon CP, Gibler WB, Fintel DJ, Peterson ED, Brown DL. Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE). Am Heart J. 2008 Sep; 156(3):606-12. 209. Steinberg BA, Bhatt DL, Mehta S, Poole-Wilson PA, O'Hagan P, Montalescot G, Ballantyne CM, Cannon CP. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J. 2008 Oct; 156(4):719-27. 210. O'Donoghue M, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, Fox KA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Swahn E, Wallentin L, Windhausen F, Sabatine MS. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2008 Jul 2; 300(1):71-80. 211. Tickoo S, Fonarow GC, Hernandez AF, Liang L, Cannon CP. Weekend/holiday versus weekday hospital discharge and guideline adherence (from the American Heart Association's Get with the Guidelines--Coronary Artery Disease database). Am J Cardiol. 2008 Sep 15; 102(6):663-7. 212. Steinberg BA, French WJ, Peterson E, Frederick PD, Cannon CP. Is coding for myocardial infarction more accurate now that coding descriptions have been clarified to distinguish ST-elevation myocardial infarction from non-ST elevation myocardial infarction? Am J Cardiol. 2008 Sep 1; 102(5):513-7. 213. Mega JL, Morrow DA, de Lemos JA, Mohanavelu S, Cannon CP, Sabatine MS. Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes. J Am Coll Cardiol. 2008 Jun 24; 51(25):2422-9. 214. Krum H, Curtis SP, Brater DC, Laine L, Kaur A, Wang H, Smugar SS, Swergold G, Cannon CP, for the MEDAL Steering Committee. Which baseline parameters influence risk of congestive heart failure in arthritis patients receiving NSAIDs & COX-2 inhibitors? Multivariate analysis of 34,701 patients in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Program. Joint Congress of the European Society & International Society of Hypertension, Berlin, Germany. 2008. 215. Brilakis ES, de Lemos JA, Cannon CP, Wiviott SD, Murphy SA, Morrow DA, Sabatine MS, Banerjee S, Blazing MA, Califf RM, Braunwald E. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). Am J Cardiol. 2008 Sep 1; 102(5):552-8. 216. Hill NS, Farber HW. Pulmonary hypertension. Cannon CP, series editor. Contemporary Cardiology. 2008. 217. Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ, Steg G, Guyatt GH, Goodman SG. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):670S-707S. 218. Goodman SG, Menon V, Cannon CP, Steg G, Ohman EM, Harrington RA. Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):708S-775S. 219. Cannon CP. Acute coronary syndrome and peripheral arterial disease: Applying diagnostics for early detection and intervention. 2008. 220. Pollack C, Agostinelli N, Jiang S, Cannon C, Sabatine M. Impact of delay to lysis on outcomes and efficacy of clopidogrel in STEMI: An analysis from CLARITY-TIMI 28. Academic Emergency Medicine. 2008. 221. Jneid H, Fonarow GC, Cannon CP, Palacios IF, Kilic T, Moukarbel GV, Maree AO, LaBresh KA, Liang L, Newby LK, Fletcher G, Wexler L, Peterson E. Impact of time of presentation on the care and outcomes of acute myocardial infarction. Circulation. 2008 May 13; 117(19):2502-9. 222. Kumar A, Cannon CP. The role of statins in the prevention of heart failure after acute coronary syndrome. Heart Fail Clin. 2008 Apr; 4(2):129-39. 223. Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Després JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA. 2008 Apr 2; 299(13):1547-60. 224. Cannon CP. Combination therapy in the management of mixed dyslipidaemia. J Intern Med. 2008 Apr; 263(4):353-65. 225. Kumar A, Cannon CP. The role of statins in the prevention of heart failure after acute coronary syndrome. Fonarow GC, editor. Heart Failure Clinics. 2008; 4(2):129-39. 226. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, Rifai N, Cannon CP, Gerszten RE, Lee RT. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008 Apr 15; 117(15):1936-44. 227. O'Donoghue M, Morrow DA, Cannon CP, Guo W, Murphy SA, Gibson CM, Sabatine MS. Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. Eur Heart J. 2008 Apr; 29(8):984-91. 228. Morrow DA, Sabatine MS, Brennan ML, de Lemos JA, Murphy SA, Ruff CT, Rifai N, Cannon CP, Hazen SL. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J. 2008 May; 29(9):1096-102. 229. Desai NR, Mega JL, Guo W, Cannon CP, Sabatine MS. The smoker's paradox with a clopidogrel twist: Insights from CLARITY-TIMI 28. JACC. 2008; 51(10):A203. 230. Krum H, Curtis SP, Brater DC, Laine L, Weir MR, Kaur A, Wang H, Smugar SS, Swergold G, Cannon CP. Differential effect of baseline antihypertensive medications on blood pressure changes in patients with osteoarthritis long-term (MEDAL) study: A multivariate analysis. JACC. 2008; 51(10):A380. 231. Forman DE, Cannon CP, Albert NM, Fonarow GC, Yancy CW, Liang L, Hernandez AF, . Are guideline recommended therapies being applied to elderly patients hospitalized with heart failure?. JACC. 2008; 51(10):A239. 232. Harkness JR, Scirica BM, Sabatine MS, Morrow DA, Sloan S, Wiviott SD, Giugliano RP, Cannon CP, Braunwald E. Extent of ST segment resolution after fibrinolysis adds dynamic risk stratification to the TIMI rick score for STEMI. JACC. 2008; 51(10):A221. 233. Mega JL, Cannon CP, Sabatine MS. Influence of the Xbal polymorphism in the APOB gene on lipids, statin response, and recurrent cardiovascular events. JACC. 2008; 51(10):A331. 234. Mega JL, Thakuria JV, Cannon CP, Sabatine MS. Sequence variations in CYP metabolism genes and cardiovascular outcomes following treatment with clopidogrel: Insights from the CLARITY-TIMI 28 genomic study. JACC. 2008; 51(10):A206. 235. Roe MT, Cannon CP, Chen AY, Rao SV, Rumsfield JS, Klein LW, Ohman EM, Gibler WB, Peterson ED. Decline in the use of drug-eluting stents for patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: Results from the CRUSADE and ACTION Registries. JACC. 2008; 51(10):A211. 236. O'Donoghue M, Boden WE, Cannon CP, Clayton TC, de Winter RJ, Fox KAA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Swahn E, Wallentin L, Windhausen F, Sabatine MS. The benefit of an invasive strategy in diabetic versus non-diabetic subjects with non-ST-elevation acute coronary syndromes: A collaborative meta-analysis of randomized trials. JACC. 2008; 51(10):A216. 237. Mehta RH, Bufalino VJ, Pan W, Hernandez AF, Cannon CP, Fonarow GC, Peterson ED. Achieving rapid reperfusion with primary percutaneous coronary intervention remains a challenge: insights from American Heart Association's Get With the Guidelines program. Am Heart J. 2008 Jun; 155(6):1059-67. 238. Albert NM, Birtcher KK, Cannon CP, Goff DC, Mulgund J, Liang L, Fonarow GC. Factors associated with discharge lipid-lowering drug prescription in patients hospitalized for coronary artery disease (from the Get With the Guidelines database). Am J Cardiol. 2008 May 1; 101(9):1242-6. 239. Gibson CM, Pride YB, Buros JL, Kunadian V, Southard MC, Harrigan CJ, Ciaglo LN, Sabatine MS, Cannon CP, Braunwald E. Relation of hyperemic epicardial flow to outcomes among patients with ST-segment elevation myocardial infarction receiving fibrinolytic therapy. Am J Cardiol. 2008 May 1; 101(9):1232-8. 240. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I28-35. 241. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I2-9. 242. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Assessing the current role of platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I10-6. 243. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Antiplatelet therapy and platelet function testing. Introduction. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I1. 244. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I17-20. 245. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Investigating the mechanisms of hyporesponse to antiplatelet approaches. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I21-7. 246. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, Michelson AD, Peterson E, Wiviott S. Antiplatelet therapy and platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I36. 247. Cannon CP. Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) unstable angina/non-ST elevation myocardial infarction critical pathway toolkit. Crit Pathw Cardiol. 2008 Mar; 7(1):43-81. 248. Karha J, Cannon CP. ADP Receptor Antagonists. Bhatt DL, editor. Platelets in Cardiovascular Disease. 2008; 87-123. 249. Cannon CP, Roe MT, Chen AY, Rumsfeld JS, Brindis RG, Ohman EM, Gibler WB, Fonarow GC, Lambrew CT, Penney J, Peterson ED. Temporal improvements in door-to-balloon times for primary percutaneous coronary intervention. Results from the CRUSADE and ACTION Registries. 2008. 250. Cannon CP, Gruberg L. Antiplatelet regimens in NSTEMI: Current and future approaches CME. 2008. 251. Sabatine MS, Hamdalla HN, Mehta SR, Fox KA, Topol EJ, Steinhubl SR, Cannon CP. Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. Am Heart J. 2008 May; 155(5):910-7. 252. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008 Feb 19; 51(7):724-30. 253. Lotfi A, Schweiger MJ, Giugliano GR, Murphy SA, Cannon CP. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis. Am Heart J. 2008 May; 155(5):954-8. 254. Gibson CM, Pride YB, Buros JL, Lord E, Shui A, Murphy SA, Pinto DS, Zimetbaum PJ, Sabatine MS, Cannon CP, Josephson ME. Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2008 Feb 5; 51(5):546-51. 255. McLean DS, Ravid S, Blazing M, Gersh B, Shui A, Cannon CP. Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials. Am Heart J. 2008 Feb; 155(2):298-302. 256. Cannon CP. What is the difference between stable and unstable angina. Is it safe to fly when you have stable angina?. 2008. 257. Cannon CP. I have severe angina. Should I ask for supplemental oxygen during a commercial flight?. 2008. 258. Cannon CP. Efficacy and safety of the CBI cannabinoid receptor blocker rimonabant: Pooled analysis of the RIO Program. 2008. 259. Cannon CP. I recently had a heart attack treated with a stent. Can I drive my car?. 2008. 260. Cannon CP. When is it safe to take a plane after I have had a heart attack?. 2008. 261. Cannon CP. Is it true that some statins are better than others at raising good cholesterol?. 2008. 262. Cannon CP. What other symptoms besides angina can signal a heart attack?. 2008. 263. Cannon CP. I have been taking one of the statins. I heard that other brands of statins may be betters. Is this true?. 2008. 264. Cannon CP. Is it true that I should start taking the high dose of statin possible after a heart attack?. 2008. 265. Cannon CP. I have angina. Is it safe for me to drive my car?. 2008. 266. Cannon CP. What symptoms are suggestive of heart disease?. 2008. 267. Iakoubova OA, Sabatine MS, Rowland CM, Tong CH, Catanese JJ, Ranade K, Simonsen KL, Kirchgessner TG, Cannon CP, Devlin JJ, Braunwald E. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2008 Jan 29; 51(4):449-55. 268. Ahmed S, Cannon CP, Giugliano RP, Murphy SA, Morrow DA, Antman EM, Braunwald E, Gibson CM. The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes. Int J Cardiol. 2008 Dec 17; 131(1):105-12. 269. Cannon CP. Angioplasty for Sir Paul? Docs say possible. 2008. 270. Cannon CP. Cardiovascular disease and modifiable cardiometabolic risk factors. Clin Cornerstone. 2008; 9(2):24-38; discussion 39-41. 271. Cannon CP. Obesity-related cardiometabolic complications. Clin Cornerstone. 2008; 9(1):11-9; discussion 20-2. 272. Cannon CP, Acharjee S. Percutaneous coronary intervention. Cardiovascular outcomes and long-term clopidogrel use after PCI in patients with diabetes. Rev Cardiovasc Med. 2008; 9(4):280-2. 273. Cannon CP, Acharjee S. Acute coronary syndrome. Cardiovascular events after clopidogrel discontinuation. Rev Cardiovasc Med. 2008; 9(3):212-4. 274. Husted S, Cannon CP. Direct oral P2Y12 inhibition: AZD6140 (Ticagrelor). Clinical guide to the use of antithrombotic drugs in coronary artery disease. 2008; 85-97. 275. Olenchock BA, Fonarow GC, Wenqin P, Hernandez A, Cannon CP. Current use of beta-blockers in patients with reactive airway diseases who are hospitalized with acute coronary syndromes. QCOR. 2008. 276. Cannon CP. Can cholesterol make your heart healthy?. 2008. 277. Upchurch Jr. GR, Criado E, editors. Aortic aneurysms. Cannon CP, series editor. Contemporary Cardiology. 2008. 278. Wackers F J Th, Bruni W, Zaret BL. Nuclear cardiology: The basics. Cannon CP, series editor. Contemporary Cardiology. 2008. 279. Dawson B, Browning SR, Dai D, Hernandez AF, Cannon CP, Steinhub I. Quality improvement in patients with coronary artery disease from Rural America: Insightsfrom the AHA's GWTG-CAD Database [aka](Comparing the quality of cardiovascular care in rural and urban hospitals: Insights from the American Heart Association Get With the Guidelines CAD Program). QCOR. 2008. 280. Natale A, Jalife J. Atrial fibrillation: From bench to bedside. Cannon CP, series editor. Contemporary Cardiology. 2008. 281. Kwong RY, editor. Cardiovascular magnetic resonance imaging. Cannon CP, series editor. Contemporary Cardiology. 2008. 282. Cannon CP, Chen C, Curtis SP, Viscusi J, Ahmed T, DiBattiste PM. A comparison of cardiovascular biomarkers in patients treated for three months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo. Archives Drug Information. 2008; 1:4-13. 283. Storey RF, Cannon CP, Harrington RA, Sandset PM, Heptinstall S, Wickens M, Peters G, Emanuelsson H, Husted S. Final aggregation response is a more sensitive marker of the effects of P2Y12 receptor antagonists than maximal aggregation response. Eur Heart J. 2008. 284. Kumar A, Cannon CP. The Role of Thrombolysis in the Era of STEMI Interventions. Mehta S, editor. Textbook of STEMI Interventions. 2008. 285. Sabatine MS, Cannon CP. Unstable Angina/non-ST-segment-elevation myocardial infarction. Irwin RS, Rippe JM, editors. Irwin and Rippe's Intensive Care Medicine. 2008; 408-27. 286. Brown T, Hernandez AF, Bittner V, Cannon CP, Ellrodt G, Liang L, Peterson ED, Pina IL, Safford MM, Fonarow GC. Predictors of non-referral to cardiac rehabilitation in the American Heart Association's Get With the Guidelines Program. QCOR. 2008. 287. Ray KK, Cannon CP. Lipid lowering in coronary artery disease. Topol EJ, editor. Textbook of Interventional Cardiology. 2008; 183-201. 288. Wang T, Hernandez A, Fonarow G, Liang L, Ellrodt G, Cannon CP, Peterson E. Consistency of acute myocardial infarction (AMI) hospital quality performance improvement with efforts to improve door to balloon times. QCOR. 2008. 289. Kaur A, Curtis S, Cannon CP, Griffin M, Connors LG, Laine L. Physicians fail to provide protective co-therapy for high GI risk patients taking NSAIDS--even with direct interactive communication and free PPI: Results of a prospective outcomes trial. Gastroenterology. 2008. 290. Krum H, Curtis SP, Brater DC, Laine L, Kaur A, Wang H, Smugar SS, Cannon CP, for the MEDAL Steering Committee. Multivariate analysis of blood pressure change in patients in the Multinational Etoricoxib and Diclofenac Arthritis Long-Term (MEDAL) study. Am Soc Hypertension. 2008. 291. Krum H, Curtis SP, Brater DC, Laine L, Weir MR, Kaur A, Wang H, Smugar SS, Cannon CP, for the MEDAL Steering Committee. Differential effect of baseline antihypertensive medications of bood pressure changes in patients in the Multinational Etoricoxib and Diclofenac Arthritis Long-Term (MEDAL) study. Am Soc Hypertension. 2008. 292. Danias PG. Cardiovascular MRI: 150 multiple choice questions and answers. Cannon CP, series editor. Contemporary Cardiology. 2008. 293. Pinto DS, Kirtane AJ, Pride YB, Murphy SA, Sabatine MS, Cannon CP, Gibson CM. Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study). Am J Cardiol. 2008 Feb 1; 101(3):303-7. 294. Steinberg BA, Cannon CP. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential. Am J Cardiol. 2007 Dec 17; 100(12A):27P-32P. 295. Schreiner GC, Laine L, Murphy SA, Cannon CP. Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed. Crit Pathw Cardiol. 2007 Dec; 6(4):169-72. 296. Kumar A, Cannon CP. Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention. J Interv Cardiol. 2007 Dec; 20(6):447-57. 297. Kumar A, Cannon CP. Efficacy and safety of cholesterol-lowering treatment. Cardiology International. 2007; 128-36. 298. Kumar A, Cannon CP. The current role of statins in acute coronary syndrome. Arch Med Sci. 2007; 3(4A):S115-25. 299. Tang WH, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, Storrow AB, Christenson RH. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. Clin Biochem. 2008 Mar; 41(4-5):210-21. 300. Gibson CM, Murphy SA, Pride YB, Kirtane AJ, Aroesty JM, Stein EB, Ciaglo LN, Southard MC, Sabatine MS, Cannon CP, Braunwald E. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study. Am Heart J. 2008 Jan; 155(1):133-9. 301. Dibble CT, Gelfand EV, Cannon CP. Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients. Curr Atheroscler Rep. 2007 Nov; 9(5):359-66. 302. Morrow DA, Wang Y, Croce K, Sakuma M, Sabatine MS, Gao H, Pradhan AD, Healy AM, Buros J, McCabe CH, Libby P, Cannon CP, Braunwald E, Simon DI. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J. 2008 Jan; 155(1):49-55. 303. Morrow JP, Cannon CP, Reiffel JA. New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: what are our therapies likely to be by 2010 and beyond? Am Heart J. 2007 Nov; 154(5):824-9. 304. Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P, Cannon CP. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007 Nov 6; 50(19):1852-6. 305. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007 Nov 6; 50(19):1844-51. 306. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem. 2007 Dec; 53(12):2086-96. 307. Meadows TA, Bhatt DL, Hirsch AT, Creager MA, Califf RM, Ohman EM, Cannon CP, Eagle KA, Alberts M, Goto S, Wilson PW, Steg PG on behalf of the REACH Registry Investigators. Ethnic differences in the prevalence and treatment of cardiovascular risk factors in outpatients with peripheral arterial disease: Insights from the REACH Registry. Circulation. 2007; 116(16):II-775. 308. Bhatt DL, Peterson ED, Harrington RA, Ou F, Cannon CP, Gibson CM, Kleiman N, Brindis RG, Peacock WF, Brener SJ, Menon V, Smith SC, Pollack CV, Gibler WB, Ohman EM, Roe MT for the CRUSADE Investigators. Polyvascular disease - a novel risk factor for worse ischemic and bleeding outcomes in acute coronary syndromes. Circulation. 2007; 116(16):II-482. 309. Lackland DT, Cannon CP, Egan BM, Fonarow G, Yu Y, Hernandez AF, Robertson RM, Jones DW. Hypertension treatment and control among patients hospitalized with heart failure: An analysis of get with the guidelines heart failure. Circulation. 2007; 116(16):II-784. 310. Brikakis ES, de Lemos JA, Cannon CP, Wiviott SD, Murphy SA, Morrow DA, Sabatine MS, banerjee S, Blazing MA, Califf RM, Braunwald E. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting. Results from the Pravastatin or Atorvastatin evaluation and infection therapy (PROVE-IT-TIMI 22) and the Aggrastat to Zocor (A to Z) trials. Circulation. 2007; 116(16):II-314. 311. Pride YB, Buros JL, Lord E, Harrigan CJ, Lew M, Abraham J, Murphy SA, Cannon CP, Sabatine MS, Gibson CM. Angiographic perfusion score in patients treated with PCI at late angiography following fibrinolytic administration for ST-segment elevation myocardial infarction is associated with morbidity and mortality at 30 days. Circulation. 2007; 116(16):II-352. 312. Ho KK, Anderson HV, Shaw RE, Klein LW, Beachy JH, Cannon CP, Krumholz HM, Fitzgerald S, Hermann A, Mitchell K, Rumsfeld J, Brindis RG on behalf of the National Cardiovascular Data Registry. Absence of flow-limiting coronary artery disease among patients undergoing emergent cardiac catheterization for ST segment elevation myocardial infarction in the national cardiovascular data registry cathPCI registry: Implications for primary angioplasty programs. Circulation. 2007; 116(16):II-624. 313. Buros JL, Nguyen MC, Murphy SA, Southard MC, Ciaglo K, Takao ST, Hochberg C, Sabatine MS, Cannon CP, Braunwald E, Gibson CM. The association of culprit and non-culprit myocardial perfusion with clinical events following and ST-elevation MI (STEMI): An analysis from the CLARITY-TIMI 28 study. Circulation. 2007; 116(16):II-673. 314. Sabatine MS, Morrow DA, Jiang S, Rifai N, Cannon CP, Gerszten RE. Elevated levels of the atherosclerotic lesion metalloproteinase PAPPA are an independent predictor of cardiovascular death of CHF in STEMI: Results from the CLARITY-TIMI 28 biomarker study. Circulation. 2007; 116(16):II-363. 315. Deedwania PC, Fonarow GC, Cannon CP, Dai D. Are contemporary patients hospitalized with acute coronary syndrome being discharged on intensive lipid lowering therapy?: An analysis of 22,807 hospitalizations in GWTG-CAD. Circulation. 2007; 116(16):II-315. 316. Berger JS, Bhatt DL, Cannon CP, Chen Z, Jones JB, Mehta SR, Sabatine MS, Steinhubl SR, Topol RJ, Berger PB. The relative safety and efficacy of clopidogrel in women and men: Meta-analysis of 79,613 patients enrolled in CREDO, CURE, CLARITY-TIMI 28, COMMIT, and CHARISMA. Circulation. 2007; 116(16):II-483. 317. Matheny ME, Morrow DA, Ohno-Machado L, Cannon CP, Resnic FS. Validating an automated outcomes surveillance application using data from a terminated randomized, controlled trial (OPUS [TIMI-16]). AMIA Annu Symp Proc. 2007; 1043. 318. Olenchock BA, Wiviott SD, Murphy SA, Cannon CP, Rifai N, Braunwald E, Morrow DA. Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16. J Thromb Thrombolysis. 2008 Oct; 26(2):79-84. 319. Truong QA, Singh JP, Hoffmann U, Cannon CP. Case studies. 2007. 320. Scirica BM, Morrow DA, Cannon CP, de Lemos JA, Murphy S, Sabatine MS, Wiviott SD, Rifai N, McCabe CH, Braunwald E. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem. 2007 Oct; 53(10):1800-7. 321. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM. Diabetes and mortality following acute coronary syndromes. JAMA. 2007 Aug 15; 298(7):765-75. 322. Steinberg BA, Cannon CP, Hernandez AF, Pan W, Peterson ED, Fonarow GC. Medical therapies and invasive treatments for coronary artery disease by body mass: the "obesity paradox" in the Get With The Guidelines database. Am J Cardiol. 2007 Nov 1; 100(9):1331-5. 323. Cannon CP. Translating evidence into guidelines and applying them in practice: The long chain of quality. 2007. 324. Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, Yasko AW. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am. 2007 Aug; 89(8):1794-801. 325. Murphy SA, Cannon CP, Wiviott SD, de Lemos JA, Blazing MA, McCabe CH, Califf RM, Braunwald E. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). Am J Cardiol. 2007 Oct 1; 100(7):1047-51. 326. Apple FS, Wu AH, Jaffe AS, Panteghini M, Christenson RH, Cannon CP, Francis G, Jesse RL, Morrow DA, Newby LK, Storrow AB, Tang WH, Pagani F, Tate J, Ordonez-Llanos J, Mair J. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure. Circulation. 2007 Jul 31; 116(5):e95-8. 327. Tang WH, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, Storrow AB, Christenson RH, Apple FS, Ravkilde J, Wu AH. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation. 2007 Jul 31; 116(5):e99-109. 328. Pride YB, Buros JL, Lord E, Southard MC, Harrigan CJ, Ciaglo LN, Sabatine MS, Cannon CP, Gibson CM. Angiographic perfusion score in patients treated with PCI at late angiography following fibrinolytic administration for ST-segment elevation myocardial infarction is associated with morbidity and mortality at 30 days. J Thromb Thrombolysis. 2008 Oct; 26(2):106-12. 329. Cannon CP. Cardiosource 2.0-An editorial from Chris Cannon, MD, FACC, new cardiosouce editor-in-chief. 2007. 330. Ray KK, Cannon CP, Braunwald E. Recent trials of lipid lowering. Int J Clin Pract. 2007 Jul; 61(7):1145-59. 331. Gelfand EV, Cannon CP. Myocardial infarction: contemporary management strategies. J Intern Med. 2007 Jul; 262(1):59-77. 332. Cannon CP. Logging in at Cardiosource 2.0. Cardiology. 2007; 36(7):18-9. 333. Cannon CP. Introduction: rationale for tight control of hyperglycemia. Am J Cardiol. 2007 Jun 4; 99(11A):1H-4H. 334. Ray KK, Morrow DA, Sabatine MS, Shui A, Rifai N, Cannon CP, Braunwald E. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation. 2007 Jun 19; 115(24):3071-8. 335. Steinberg BA, Ballantyne CM, Bhatt DL, Montalescot G, Mehta S, O'Hagan P, Poole-Wilson PA, Cannon CP. An annual, prospective, international study of outpatients with cardiovascular disease or risk factors: design and methods of the CardioMonitor registry. Crit Pathw Cardiol. 2007 Jun; 6(2):72-5. 336. Normand AN, Cannon CP, Lewis VO, Lin PP, Yasko AW. Curettage of biopsy-diagnosed grade 1 periacetabular chondrosarcoma. Clin Orthop Relat Res. 2007 Jun; 459:146-9. 337. Cannon CP. Managing ST-segment elevation MI: An update on the alternatives. J Crit Illness. 2007; 5-6. 338. Alexander KP, Newby LK, Armstrong PW, Cannon CP, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007 May 15; 115(19):2570-89. 339. Alexander KP, Newby LK, Cannon CP, Armstrong PW, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007 May 15; 115(19):2549-69. 340. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL, Kaplan NM, O'Connor CM, O'Gara PT, Oparil S. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007 May 29; 115(21):2761-88. 341. Tickoo S, Roe MT, Peterson ED, Milford-Beland S, Ohman EM, Gibler WB, Pollack CV, Cannon CP. Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. Am J Cardiol. 2007 Jun 1; 99(11):1496-9. 342. Ray KK, Cannon CP, Morrow DA, Kirtane AJ, Buros J, Rifai N, McCabe CH, Gibson CM, Braunwald E. Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18. Eur Heart J. 2007 Apr; 28(7):806-13. 343. Cannon CP, Lin PP, Lewis VO, Yasko AW. Acetabular outcome after hip hemiarthroplasty in patients with tumors. Clin Orthop Relat Res. 2007 Apr; 457:183-7. 344. Tricoci P, Peterson ED, Chen AY, Newby LK, Harrington RA, Greenbaum AB, Cannon CP, Gibson CM, Hoekstra JW, Pollack CV, Ohman EM, Gibler WB, Roe MT. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). Am J Cardiol. 2007 May 15; 99(10):1389-93. 345. Cannon CP, Conti CR, Boden WE, Wenger NK. The paradigm of ischemic heart disease-implications for optimizing patient management. 2007. 346. Cannon CP. Managing multiple risk factors to target global cardiometabolic risk. 2007. 347. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AH, Christenson RH. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007 Apr 3; 115(13):e356-75. 348. Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH, Cannon CP, Francis G, Morrow DA, Ravkilde J, Storrow AB, Tang W. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. Clin Chem. 2007 Apr; 53(4):547-51. 349. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AH, Christenson RH, Apple FS, Francis G, Tang W. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem. 2007 Apr; 53(4):552-74. 350. Steinberg BA, Steg PG, Bhatt DL, Fonarow GC, Zeymer U, Cannon CP. Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry). Am J Cardiol. 2007 May 1; 99(9):1212-5. 351. Storey RF, Harrington RA, Husted S, Heptinstall S, Wilcox RG, Gurbel PA, Grande P, Wickens M, Peters G, Emanuelsson H, Cannon CP. AZD6140 suppresses platelet aggregation in clopidogrel-treated patients even in those with high aggregation levels. J Am Coll Cardiol. 2007; 49(9 (Suppl A)):208A. 352. Armani A, Qin J, Murphy SA, McCabe CH, Cannon CP. Effects of intensive vs standard statin therapy on lipids and inflammation in racial/ethnic groups. An analysis from PROVE-IT-TIMI 22. J Am Coll Cardiol. 2007; 49(9 (Suppl A)):408A. 353. Cannon CP, Rhee K, Bhatt DL, Boden WE. Use of aspirin among patients with atherothrombotic disease in the United States: The reduction of atherothrombosis for continued health (REACH) Registry. J Am Coll Cardiol. 2007; 49(9 (Suppl A)):409A. 354. Hernandez AF, Fonarow GC, Dai D, O'Brien SM, LaBresh KA, Schwamm LH, Cannon CP, GWTG Steering Committee. What is the best measure for rewarding quality of care: Defect-free vs composite scoring? An analysis from the American Heart Association's get with the guidelines-coronary artery disease (GWTG-CAD) program?. J Am Coll Cardiol. 2007; 49(9 (Suppl A)):291A. 355. Ray KK, Morrow DA, Cannon CP, Sabatine MS, Guo W, Rifai N, Braunwauld E. Von willebrand factor but not tissue factor or soluble CD40 ligand are associated with increased risk of recurrent events after ACS in PROVE-IT-TIMI 22. J Am Coll Cardiol. 2007; 49(9 (Suppl A)):188A. 356. Lemme SD, Kevin Raymond A, Cannon CP, Normand AN, Smith KC, Hughes DP. Primary tuberculosis of bone mimicking a lytic bone tumor. J Pediatr Hematol Oncol. 2007 Mar; 29(3):198-202. 357. Cannon CP. Multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program: Cardiovascular outcomes following long-term treatment with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. 2007. 358. McLean DS, Sabatine MS, Guo W, McCabe CH, Cannon CP. Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. J Thromb Thrombolysis. 2007 Oct; 24(2):85-91. 359. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2007 Feb 10; 369(9560):465-73. 360. Ray KK, Cannon CP. Lipid-independent pleiotropic effects of statins in the management of acute coronary syndromes. Curr Treat Options Cardiovasc Med. 2007 Feb; 9(1):46-51. 361. Lin PP, Pino ED, Normand AN, Deavers MT, Cannon CP, Ballo MT, Pisters PW, Pollock RE, Lewis VO, Zagars GK, Yasko AW. Periosteal margin in soft-tissue sarcoma. Cancer. 2007 Feb 1; 109(3):598-602. 362. Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. Eur J Cardiovasc Prev Rehabil. 2007 Feb; 14(1):3-11. 363. Lin PP, Jaffe N, Herzog CE, Costelloe CM, Deavers MT, Kelly JS, Patel SR, Madewell JE, Lewis VO, Cannon CP, Benjamin RS, Yasko AW. Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma. Cancer. 2007 Feb 1; 109(3):603-11. 364. Rich JD, Maraganore JM, Young E, Lidon RM, Adelman B, Bourdon P, Charenkavanich S, Hirsh J, Theroux P, Cannon CP. Heparin resistance in acute coronary syndromes. J Thromb Thrombolysis. 2007 Apr; 23(2):93-100. 365. Cannon CP. Cardiovascular disease and modifiable cardiometabolic risk factors. Clin Cornerstone. 2007; 8(3):11-28. 366. Opotowsky AR, McWilliams JM, Cannon CP. Gender differences in aspirin use among adults with coronary heart disease in the United States. J Gen Intern Med. 2007 Jan; 22(1):55-61. 367. Cannon CP. High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome. Clin Cornerstone. 2007; 8 Suppl 6:S14-23. 368. Cannon CP. Clopidogrel: who, when, and how? Rev Cardiovasc Med. 2007; 8 Suppl 3:S27-34. 369. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiovascular Medicine. 2007. 370. Cannon CP. Non-PCI Approaches in ACS: Guidelines for Risk Stratification and Medical Management. 2007. 371. Epidemiology, Physiopathology and Diagnosis of ACS. Cannon CP, Lewis RP, editors. Acute Coronary Syndrome Management Current Clinical Issues. 2007. 372. Non-ST-Segment Elevation ACS. Cannon CP, Lewis RP, editors. Acute Coronary Syndrome Management Current Clinical Issues. 2007. 373. Saw J, Exaire JE, Lee DS, Yadav JS, editors. Handbook of Complex Percutaneous Carotid Intervention. Cannon CP, series editor. Contemporary Cardiology. 2007. 374. Steinberg BA, Cannon CP. Managing cardiometabolic risk - a brief review. Cefalu WT, Cannon CP, editors. Atlas of Cardiometabolic Risk. 2007; 137-165.. 375. Acute Myocardial Infarction. Cannon CP, Lewis RP, editors. Acute Coronary Syndrome Management Current Medical Issues. 2007. 376. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AH, Christenson RH, National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines. Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007; e356-75. 377. Apple FS, Wu AH, Jaffe AS, Panteghini M, Christenson RH, Cannon CP, Francis G, Jesse RL, Morrow DA, Newby LK, Storrow AB, Tang WH, Pagani F, Tate J, Ordonez-Llanos J, Mair J, National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines. Analytical issues for biomarkers of heart failure. Circulation. 2007; e95-8. 378. Cefalu WT, Cannon CP, editors. Atlas of Cardiometabolic Risk. 2007. 379. Davidson MH, Toth PP, Maki KC. Therapeutic Lipidology. Cannon CP, series editor. Contemporary Cardiology. 2007. 380. Cannon CP. Contemporary Diagnosis and Management of the Acute Coronary Syndrome. 2007. 381. Cannon CP. ACS and antiplatelet management: Updated guidelines and current trials. Adv Stud Med. 2007; 7(17):540-5. 382. Ryan RJ, Cannon CP, Gibler WB. Non-ST elevation ACS in the Emergency Department. Critical Pathways in Cardiovascular Medicine. 2007; 27-38.. 383. Solomon SD. Essential Echocardiography. Cannon CP, series editor. Contemporary Cardiology. 2007. 384. Steinberg BA, Cannon CP, Bhatt DL, Montalescot G, Mehta S, O'Hagan, Poole-Wilson PA, Ballantyne CM. Contemporary Therapies for Diabetes in the Cardiovascular Populations of the US and Europe. Eur Heart J. 2007. 385. Penn MS, editor. Stem cells and myocardial regeneration. Cannon CP, series editor. Contemporary Cardiology. 2007. 386. Duckers HJ, Nabel EG, Serruys PW, editors. Essentials of Restenosis for the interventional cardiologist. Cannon CP, series editor. Contemporary Cardiology. 2007. 387. Khan MG, editor. Cardiac Drug Therapy. Cannon CP, series editor. Contemporary Cardiology. 2007. 388. Laine L, Curtis SP, Cryer B, Zhang Y, Cannon CP. Risk factors for NSAID-associated upper GI clinical events in a long-term double-blind study of 34, 701 arthritis patients. Eur League Against Rheum. 2007. 389. Kraus WE, Keteyian SJ, editors. Cardiac Rehabilitation. Cannon CP, series editor. Contemporary Cardiology. 2007. 390. Cannon CP, O'Gara PT. Critical pathways following thrombosis. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiovascular Medicine. 2007; 93-9.. 391. Cannon CP, O'Gara P, editors. Critical Pathways In Cardiovascular Medicine. 2007. 392. Kraus WE, Keteyian SJ, editors. Cardiac Rehabilitation. Cannon CP, series editor. Contemporary Cardiology. 2007. 393. Ray KK, Cannon CP. Non-traditional risk factors of cardiometabolic risk. Cefalu WT, Cannon CP, editors. Atlas of Cardiometabolic Risk. 2007; 87-103.. 394. Cannon CP, O'Gara PT. Cardiac catheterization and percutaneous coronary intervention. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiovascular Medicine. 2007; 155--9.. 395. Piazza G, Cannon CP. Clinical outcomes of patients with cardiometabolic risk factors. Cefalu WT, Cannon CP, editors. Atlas of Cardiometabolic Risk. 2007; 105-136.. 396. Ray KK, Cannon CP. Traditional metabolic risk factors. Cefalu WT, Cannon CP, editors. Atlas of Cardiometabolic Risk. 2007; 69-86.. 397. Verheugt FW, Montalescot G, Sabatine MS, Soulat L, Lambert Y, Lapostolle F, Adgey J, Cannon CP. Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial. J Thromb Thrombolysis. 2007 Jun; 23(3):173-9. 398. Wiviott SD, Cannon CP. The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Curr Opin Lipidol. 2006 Dec; 17(6):626-30. 399. Cannon CP, Bhatt DL. Clinical trials update from the annual scientific session of the American College of Cardiology. 2006; 98(12A):36Q-41Q. 400. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006 Nov 18; 368(9549):1771-81. 401. Cannon CP, Ballo MT, Zagars GK, Mirza AN, Lin PP, Lewis VO, Yasko AW, Benjamin RS, Pisters PW. Complications of combined modality treatment of primary lower extremity soft-tissue sarcomas. Cancer. 2006 Nov 15; 107(10):2455-61. 402. Cannon CP. Evolving management of ST-segment elevation myocardial infarction: update on recent data. Am J Cardiol. 2006 Dec 18; 98(12A):10Q-21Q. 403. Suk Danik J, Chasman DI, Cannon CP, Miller DT, Zee RY, Kozlowski P, Kwiatkowski DJ, Ridker PM. Influence of genetic variation in the C-reactive protein gene on the inflammatory response during and after acute coronary ischemia. Ann Hum Genet. 2006 Nov; 70(Pt 6):705-16. 404. Cannon CP. Introduction. Am J Cardiol. 2006; 98(10S1):S1. 405. Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, Cutlip DE, Bates ER, Frederick PD, Miller DP, Carrozza JP, Antman EM, Cannon CP, Gibson CM. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation. 2006 Nov 7; 114(19):2019-25. 406. Cannon CP, Bhatt DL. Clinical trials update from the annual scientific session of the American College of Cardiology 2006. Am J Cardiol. 2006 Dec 18; 98(12A):36Q-41Q. 407. Cannon CP, McLean DS. Critical pathways using platelet testing to potentially optimize the use of oral antiplatelet therapy. Am J Cardiol. 2006 Nov 20; 98(10A):33N-38N. 408. Ray KK, Cannon CP. Intensive statin therapy for treating acute coronary syndromes. Expert Opin Investig Drugs. 2006 Oct; 15(10):1151-9. 409. Scirica BM, Cannon CP, Cooper R, Aster RH, Brassard J, McCabe CH, Charlesworth A, Skene AM, Braunwald E. Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. J Thromb Thrombolysis. 2006 Oct; 22(2):95-102. 410. Ray KK, Cannon CP, Ganz P. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials? Am J Cardiol. 2006 Dec 4; 98(11A):18P-25P. 411. Ahmed S, Cannon CP, Murphy SA, Braunwald E. Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. Eur Heart J. 2006 Oct; 27(19):2323-9. 412. Tseng JF, Ballo MT, Langstein HN, Wayne JD, Cormier JN, Hunt KK, Feig BW, Yasko AW, Lewis VO, Lin PP, Cannon CP, Zagars GK, Pollock RE, Pisters PW. The effect of preoperative radiotherapy and reconstructive surgery on wound complications after resection of extremity soft-tissue sarcomas. Ann Surg Oncol. 2006 Sep; 13(9):1209-15. 413. Kugelmass AD, Sadanandan S, Lakkis N, Dibattiste PM, Robertson DH, Demopoulos LA, Gibson CM, Weintraub WS, Murphy SA, Cannon CP. Early invasive strategy improves outcomes in patients with acute coronary syndrome with previous coronary artery bypass graft surgery: a report from TACTICS-TIMI 18. Crit Pathw Cardiol. 2006 Sep; 5(3):167-72. 414. Tricoci P, Peterson ED, Mulgund J, Newby LK, Saucedo JF, Kleiman NS, Bhatt DL, Berger PB, Cannon CP, Cohen DJ, Hochman JS, Ohman EM, Gibler WB, Harrington RA, Smith SC, Roe MT. Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). Am J Cardiol. 2006 Nov 1; 98(9):1172-6. 415. Ray KK, Morrow DA, Shui A, Rifai N, Cannon CP. Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22). Am J Cardiol. 2006 Oct 1; 98(7):861-5. 416. Ray KK, Bach RG, Cannon CP, Cairns R, Kirtane AJ, Wiviott SD, McCabe CH, Braunwald E, Gibson CM. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J. 2006 Oct; 27(19):2310-6. 417. Gibson CM, Ly HQ, Murphy SA, Ciaglo LN, Southard MC, Stein EB, Buros JL, Sabatine MS, Cannon CP. Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28). Am J Cardiol. 2006 Sep 15; 98(6):761-3. 418. Mega JL, Morrow DA, Cannon CP, Murphy S, Cairns R, Ridker PM, Braunwald E. Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. J Thromb Thrombolysis. 2006 Aug; 22(1):71-6. 419. Cannon CP, Curtis SP, Bolognese JA, Laine L. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J. 2006 Aug; 152(2):237-45. 420. Wiviott SD, Cannon CP. Update on lipid-lowering therapy and LDL-cholesterol targets. Nat Clin Pract Cardiovasc Med. 2006 Aug; 3(8):424-36. 421. O'Donoghue M, de Lemos JA, Morrow DA, Murphy SA, Buros JL, Cannon CP, Sabatine MS. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation. 2006 Aug 8; 114(6):550-7. 422. Kirtane AJ, Vafai JJ, Murphy SA, Aroesty JM, Sabatine MS, Cannon CP, Gibson CM. Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy. Eur Heart J. 2006 Sep; 27(17):2040-5. 423. Akoum FH, Boxer R, Cannon CP, Pina IL, Scirica BM. Improving management of high-risk cardiovascular patients. 2006. 424. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006 Aug 1; 48(3):438-45. 425. Price MJ, Coleman JL, Steinhubl SR, Wong GB, Cannon CP, Teirstein PS. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol. 2006 Sep 1; 98(5):681-4. 426. Mehta RH, Roe MT, Mulgund J, Ohman EM, Cannon CP, Gibler WB, Pollack CV, Smith SC, Ferguson TB, Peterson ED. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. J Am Coll Cardiol. 2006 Jul 18; 48(2):281-6. 427. Scirica BM, Sabatine MS, Morrow DA, Gibson CM, Murphy SA, Wiviott SD, Giugliano RP, McCabe CH, Cannon CP, Braunwald E. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol. 2006 Jul 4; 48(1):37-42. 428. Cannon CP. Statins, diet, and low cholesterol. (Letter). JAMA. 2006; 295(21):2479-80. 429. McLean DS, Cannon CP. The clinical potential of a point-of-care assay to assess interindividual variability in platelet aggregation among patients taking clopidogrel. Crit Pathw Cardiol. 2006 Jun; 5(2):103-13. 430. Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P, Shui A, McCabe CH, Braunwald E. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2006 Jun 6; 47(11):2326-31. 431. Atar S, Cannon CP, Murphy SA, Rosanio S, Uretsky BF, Birnbaum Y. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial. Am Heart J. 2006 May; 151(5):976.e1-6. 432. Dumaine R, Gibson CM, Murphy SA, Southard M, Ly HQ, McCabe CH, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome. J Clin Hypertens (Greenwich). 2006 May; 8(5):315-22. 433. McLean DS, Cannon CP. A point-of-care assay to measure platelet aggregation in patients taking clopidogrel. Future Cardiol. 2006 May; 2(3):255-67. 434. Ly HQ, Kirtane AJ, Murphy SA, Buros J, Cannon CP, Braunwald E, Gibson CM. Association of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials). Am J Cardiol. 2006 Jul 1; 98(1):1-5. 435. Gelfand EV, Cannon CP. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol. 2006 May 16; 47(10):1919-26. 436. Tricoci P, Roe MT, Mulgund J, Newby LK, Smith SC, Pollack CV, Fintel DJ, Cannon CP, Bhatt DL, Gibler WB, Ohman EM, Peterson ED, Harrington RA. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med. 2006 Apr 10; 166(7):806-11. 437. Bhadriraju S, Ray KK, DeFranco AC, Barber K, Bhadriraju P, Murphy SA, Morrow DA, McCabe CH, Gibson CM, Cannon CP, Braunwald E. Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial. Am J Cardiol. 2006 Jun 1; 97(11):1573-7. 438. Ahmed S, Antman EM, Murphy SA, Giugliano RP, Cannon CP, White H, Morrow DA, Braunwald E. Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: impact of age (a meta-analysis of a decade of trials). J Thromb Thrombolysis. 2006 Apr; 21(2):119-29. 439. O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation. 2006 Apr 11; 113(14):1745-52. 440. Wiviott SD, de Lemos JA, Cannon CP, Blazing M, Murphy SA, McCabe CH, Califf R, Braunwald E. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation. 2006 Mar 21; 113(11):1406-14. 441. Steinberg BA, French WJ, Peterson ED, Frederick PD, Cannon CP. Missed diagnosis of the diagnosis codes: comparison of International Classification of Diseases, 9th Revision coding and ST- versus non-ST-elevation myocardial infarction diagnosis in the National Registry of Myocardial Infarction. Crit Pathw Cardiol. 2006 Mar; 5(1):59-63. 442. Gelfand EV, Cannon CP. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin Investig Drugs. 2006 Mar; 15(3):307-15. 443. Steinberg BA, O'Hagan P, Chadwell P, Turner G, Cannon CP. Statin use and low-density lipoprotein cholsterol goals in 2004: How are we doing applying national cholesterol education program III guidelines. J Am Coll Cardiol. 2006; 47(4):209A. 444. Husted S, Storey RF, Harrington RA, Sanders N, Peters G, Emanuelsson H, Cannon CP. The effects of AZD6140, the first oral reversible ADP receptor antagonist, compared with clopidogrel on biochemical markers in patients with acute coronary syndromes (ACS). J Am Coll Cardiol. 2006; 47(4):200A. 445. Ahmed S, Sabatine MS, Cannon CP, Murphy SA, Braunwald E, Gibson CM, the TIMI Study Group. Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis in CLARITY-TIMI 28. J Am Coll Cardiol. 2006; 47(4):159A. 446. Scirica BM, Sabatine MS, Cannon CP, McCabe CH, Braunwald E, Stone PH. Clopidogrel attenuates the complications associated with poor early reperfusion in patients with STEMI undergoing lysis in the CLARITY - TIMI 28. J Am Coll Cardiol. 2006; 47(4):213A. 447. Ahmed S, Cannon CP, Giugliano RP, Shui A, Murphy SA, Morrow DA, Antman EM, Braunwald E, Gibson CM. The independent and combined risks of diabetes and non-endstage renal impairment in non ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2006; 47(4):207A. 448. Steinberg BA, O'Hagan P, Chadwell P, Turner G, Cannon CP. Current trends in the prevalence of metabolic syndrome risk factors. J Am Coll Cardiol. 2006; 47(4):312A. 449. O'Donoghue M, Sabatine MS, Wiviott SD, Murphy SA, McCabe CH, Cannon CP, Braunwald E, Gibson CM. Association of TIMI risk score and extent of coronary artery disease in patients with ST-elevation myocardial infarction: A CLARITY TIMI-28 substudy. J Am Coll Cardiol. 2006; 47(4):222A. 450. Wiviott SD, Morrow DA, O'Donoghue M, Sabatine MS, Murphy SA, Cannon CP. The TIMI risk index for myocardial infarction predicts post-MI LV ejection fraction: A CLARITY - TIMI 28 substudy. J Am Coll Cardiol. 2006; 47(4):224A. 451. Smith EE, Cannon CP, Murphy S, Feske SK, Schwamm LH. Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. Am Heart J. 2006 Feb; 151(2):338-44. 452. Januzzi JL, Newby LK, Murphy SA, Pieper K, Antman EM, Morrow DA, Sabatine MS, Ohman EM, Cannon CP, Braunwald E. Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. Am Heart J. 2006 Feb; 151(2):360-6. 453. Cannon CP. Outcomes in patients with ECG changes. 2006. 454. Sabatine MS, Morrow DA, McCabe CH, Antman EM, Gibson CM, Cannon CP. Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarction. Am Heart J. 2006 Jan; 151(1):25-31. 455. Steinberg BA, Ballantyne CM, Bhatt DL, Mehta S, Poole-Wilson PA, O'Hagan P, Montalescot G, Cannon CP. International comparisons of the prevalence of obesity in patients with overt cardiovascular disease. Eur Heart J. 2006; P1509. 456. McLean DS, Cannon CP. A point-of-care assay to measure platelet aggregation in patients taking clopidogrel. Future Medicine. 2006; 2(3):255-67. 457. Bonaca MP, Morrow DA, Sabatine MS, Ray KK, Rifai N, Cannon CP. Elevated levels of placental growth factor (PIGF) and long term risk in patients with acute coronary syndrome in PROVE IT-TIMI 22. Circulation. 2006; 114(8):II-649. 458. McLean DS, Cannon CP. The clinical potential of a point-of-care assay to assess interindividual variability in platelet aggregation among patients taking clopidogrel. Critical Pathways Cardiol. 2006; 5(2):103-13. 459. Gibson CM, Kirtane AJ, Murphy SA, Rohrbeck S, Menon V, Lins J, Kazziha S, Rokos I, Shammas NW, Palabrica TM, Fish P, McCabe CH, Braunwald E, for the TIMI Study Group (Cannon CP, Co-Principal, Investigator). Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Results of the time to integrilin therapy in acute myocardial infarction (TITAN) - TIMI 34 Trial. Am Heart J. 2006; 152:668-75. 460. Wiviott SD, Morrow DA, Sabatine MS, Giugliano GR, Guo W, Jarolim P, Gibson CM, Cannon CP, Braunwald E. Baseline cystatin C measurement is a potent predictor of adverse cardiovascular outcomes following ACS: A PROVE IT - TIMI 22 analysis. Circulation. 2006; 114(18):II-418. 461. Cannon CP, Schwartz S. Cost-effectiveness of intensive therapy compared to moderate statin therapy in patients with acute coronary syndrome: Analysis from Canada, Germany and the UK. ISPOR. 2006. 462. Kociol RD, Cannon CP. Time to treatment in acute myocardial infarction. Literature Review. 2006; 1-8. 463. Cannon CP, Steinberg BA. Special report: Chronic stable angina: Past, present, and future. Cardiol Quarterly. 2006; 12. 464. Wolfe ML, Shui A, Harris M, Cannon CP, Rader DJ. On-treatment cholesteryl ester transfer protein mass and risk for MI in the PROVE-IT study. Circulation. 2006; 114(18):II-461. 465. Storey RF, Cannon CP, Harrington RA, Sandset PM, Heptinstall S, Wickens M, Peters G, Emanuelsson H, Price D, Husted S. AZD6140 Exerts greater inhibition of platelet aggregation than clopidogrel in patients with stable atherosclerotic disease or unstable coronary disease. Circulation. 2006; 114(18):II-698. 466. McLean DS, Cannon CP. A point-of-care assay to measure platelet aggregation in patients taking clopidogrel. Future Medicine. 2006; 2(3):1-13. 467. Cannon CP, Vierck E. The Complete Idiot's Guide: The Anti-Inflammation Diet. 2006. 468. Morrow DA, editor. Cardiovascular Biomarkers, Pathophysiology and Disease Management. Cannon CP, series editor. Contemporary Cardiology. 2006. 469. Steinberg BA, Fonarow GC, Hernandez AF, Liang L, Peterson ED, Cannon CP, GWTG Scientific Advisory Committee and Investigators. Metabolic syndrome in patients with CAD: Is it more than obesity? Analysis of 79,677 hospitalizations in get with the guidelines. Circulation. 2006; 114(18):II-894. 470. Wiviott SD, Cannon CP. Update on lipid-lowering therapy and LDL-cholesterol targets. Nature Clinical Practice. 2006; 3(8):424-36. 471. Ranganathan N, Sivaciyan V, Saksena FB, editors. The art and science of cardiac physical examination. Cannon CP, series editor. Contemporary Cardiology. 2006. 472. Gelfand EV, Cannon CP. Management of unstable angina and non-ST-elevation myocardial infarction. Irwin RS, Rippe JM, editors. Manual of Intensive Care Medicine. 2006; 190-4. 473. Foody JM, editor. Preventive Cardiology. Cannon CP, series editor. Contemporary Cardiology. 2006. 474. Cannon CP, Ganz, LJ, Stone PH, Becker RC. Complicated myocardial infarction. Irwin RS, Rippe JM, editors. Manual of Intensive Care Medicine. 2006; 202-10. 475. Gelfand EV, Cannon CP. Acute coronary syndromes. Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SW, editors. Hemostasis and Thrombosis. 2006; 1387-404.. 476. Cannon CP. Update to International Classification of Diseases, 9th Revision codes: distinguishes STEMI from NSTEMI. Crit Pathw Cardiol. 2005 Dec; 4(4):185-6. 477. Steinberg BA, Braganza AJ, Eminowicz G, Dibattiste PM, Flaker GC, Murphy SA, Cannon CP. Are statins being underdosed in clinical practice? Data from TACTICS-TIMI 18. Crit Pathw Cardiol. 2005 Dec; 4(4):169-73. 478. Cannon, CP. The Johns Hopkins distinguished author series for cardiology: Acute coronary syndromes. 2005. 479. Cannon CP. Interview with: Christopher Cannon, MD. 2005. 480. Cannon CP. Practice implications of endpoint trials in CV risk factor management. 2005. 481. Cannon CP. The IDEAL cholesterol: lower is better. JAMA. 2005 Nov 16; 294(19):2492-4. 482. Sabatine MS, Morrow DA, Montalescot G, Dellborg M, Leiva-Pons JL, Keltai M, Murphy SA, McCabe CH, Gibson CM, Cannon CP, Antman EM, Braunwald E. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial. Circulation. 2005 Dec 20; 112(25):3846-54. 483. Ryan JW, Peterson ED, Chen AY, Roe MT, Ohman EM, Cannon CP, Berger PB, Saucedo JF, DeLong ER, Normand SL, Pollack CV, Cohen DJ. Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Registry. Circulation. 2005 Nov 15; 112(20):3049-57. 484. Cannon CP. Acute coronary syndromes: risk stratification and initial management. Cardiol Clin. 2005 Nov; 23(4):401-9, v. 485. Ray KK, Cannon CP. Optimal goals for statin use in patients with coronary artery disease. Curr Opin Cardiol. 2005 Nov; 20(6):525-9. 486. Cannon CP. Clopidogrel as adjunctive reperfusion therapy (CLARITY): Thrombolysis in myocardial infarction (TIMI) 28. 2005. 487. Cannon CP. The need for a national heart attack treatment strategy. 2005. 488. Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol. 2005 Oct 18; 46(8):1425-33. 489. Ray KK, Cannon CP, Cairns R, Morrow DA, Rifai N, Kirtane AJ, McCabe CH, Skene AM, Gibson CM, Ridker PM, Braunwald E. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005 Oct 18; 46(8):1417-24. 490. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005 Oct 18; 46(8):1405-10. 491. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005 Oct 18; 46(8):1411-6. 492. Levine GN, Lincoff AM, Ferguson JJ, Mahaffey KW, Goodman SG, Cannon CP, Theroux P, Fox KA. Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade. Catheter Cardiovasc Interv. 2005 Oct; 66(2):149-57. 493. Dupuis J, Tardif JC, Rouleau JL, Ricci J, Arnold M, Lonn E, Roux R, Title LM, Amyot R, Bonafede N, Woo A, Cannon CP. Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial). Am J Cardiol. 2005 Nov 1; 96(9):1207-13. 494. Ray KK, Cannon CP. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects? Am J Cardiol. 2005 Sep 5; 96(5A):54F-60F. 495. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Lewis BS, Murphy SA, McCabe CH, Braunwald E. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005 Sep 14; 294(10):1224-32. 496. Moghbeli N, Kirtane AJ, Ray KK, Murphy SA, Gibson CM, Braunwald E, Cannon CP. C-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 trial). Am J Cardiol. 2005 Sep 1; 96(5):635-8. 497. Cannon CP. Update on ACS from the ESC 2005. 2005. 498. Reid IR, Tonkin A, Cannon CP. Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial--secondary analysis of a randomized controlled trial. Bone. 2005 Aug; 37(2):190-1. 499. Gibler WB, Cannon CP, Blomkalns AL, Char DM, Drew BJ, Hollander JE, Jaffe AS, Jesse RL, Newby LK, Ohman EM, Peterson ED, Pollack CV. Practical implementation of the Guidelines for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction in the emergency department. Ann Emerg Med. 2005 Aug; 46(2):185-97. 500. Cannon CP, Mehta SR, Aranki SF. Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery. Ann Thorac Surg. 2005 Aug; 80(2):768-79. 501. Cannon CP. Early invasive vs conservative strategies in non-ST-elevation acute coronary syndromes: What has been learned from recent trials?. 2005. 502. Cannon CP, Murphy SA, Braunwald E. Intensive lipid lowering with atorvastatin in coronary disease. N Engl J Med. 2005 Jul 7; 353(1):93-6; author reply 93-6. 503. Pinto DS, Skolnick AH, Kirtane AJ, Murphy SA, Barron HV, Giugliano RP, Cannon CP, Braunwald E, Gibson CM. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005 Jul 5; 46(1):178-80. 504. Mehta SR, Cannon CP, Fox KA, Wallentin L, Boden WE, Spacek R, Widimsky P, McCullough PA, Hunt D, Braunwald E, Yusuf S. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. 2005 Jun 15; 293(23):2908-17. 505. Kirtane AJ, Leder DM, Waikar SS, Chertow GM, Ray KK, Pinto DS, Karmpaliotis D, Burger AJ, Murphy SA, Cannon CP, Braunwald E, Gibson CM. Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. J Am Coll Cardiol. 2005 Jun 7; 45(11):1781-6. 506. Cannon CP. Implementation of critical pathways in the "real world". Crit Pathw Cardiol. 2005 Jun; 4(2):110-4. 507. Gurjeva OS, Roe MT, Murphy SA, Moliterno DJ, Cannon CP. Unfortunate impact of age on the management and outcomes of unstable angina and non-ST elevation myocardial infarction (The GUARANTEE Registry). Crit Pathw Cardiol. 2005 Jun; 4(2):81-7. 508. Ray KK, Cannon CP. Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials. Expert Opin Pharmacother. 2005 Jun; 6(6):915-27. 509. Morrow DA, Cannon CP. Brigham and Women's Hospital admission order set for unstable angina/non-ST elevation myocardial infarction. Crit Pathw Cardiol. 2005 Jun; 4(2):107-9. 510. Scirica BM, Cannon CP. Treatment of elevated cholesterol. Circulation. 2005 May 31; 111(21):e360-3. 511. Gibler WB, Cannon CP, Blomkalns AL, Char DM, Drew BJ, Hollander JE, Jaffe AS, Jesse RL, Newby LK, Ohman EM, Peterson ED, Pollack CV. Practical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department: a scientific statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in Collaboration With the Society of Chest Pain Centers. Circulation. 2005 May 24; 111(20):2699-710. 512. Januzzi JL, Buros J, Cannon CP. Peripheral arterial disease, acute coronary syndromes, and early invasive management: the TACTICS TIMI 18 trial. Clin Cardiol. 2005 May; 28(5):238-42. 513. Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol. 2005 May 17; 45(10):1644-8. 514. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, Cairns R, Skene AM. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005 Apr 21; 352(16):1646-54. 515. Gurjeva OS, Bukhman G, Murphy S, Cannon CP. Treatment and outcomes of eastern Europeans with coronary syndromes in OPUS-TIMI 16. Int J Cardiol. 2005 Apr 8; 100(1):101-7. 516. Gomberg-Maitland M, Murphy SA, Moliterno DJ, Cannon CP. Are we appropriately triaging patients with unstable angina? Am Heart J. 2005 Apr; 149(4):613-8. 517. Sabatine MS, Blake GJ, Drazner MH, Morrow DA, Scirica BM, Murphy SA, McCabe CH, Weintraub WS, Gibson CM, Cannon CP. Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment. Circulation. 2005 Mar 15; 111(10):1217-24. 518. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005 Mar 24; 352(12):1179-89. 519. Ray KK, Cannon CP. Time to benefit: an emerging concept for assessing the efficacy of statin therapy in cardiovascular disease. Crit Pathw Cardiol. 2005 Mar; 4(1):43-5. 520. Smith CS, Cannon CP, McCabe CH, Murphy SA, Bentley J, Braunwald E. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial. Am Heart J. 2005 Mar; 149(3):444-50. 521. Cannon CP. What is the optimal timing of clopidogrel in acute coronary syndromes? Crit Pathw Cardiol. 2005 Mar; 4(1):46-50. 522. Lader EW, Cannon CP. How to join a clinical trial. Crit Pathw Cardiol. 2005 Mar; 4(1):26-9. 523. Gibson CM, Kirtane AJ, Boundy K, Ly H, Karmpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients. J Am Coll Cardiol. 2005 Feb 1; 45(3):357-62. 524. Cantor WJ, Goodman SG, Cannon CP, Murphy SA, Charlesworth A, Braunwauld E, Langer A. Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial. Am Heart J. 2005 Feb; 149(2):275-83. 525. Sabatine MS, McCabe CH, Gibson CM, Cannon CP. Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. Am Heart J. 2005 Feb; 149(2):227-33. 526. Kirtane AJ, Kosmidou I, Karmpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Braunwald E, Gibson CM. Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy. Am J Cardiol. 2005 Feb 1; 95(3):337-42. 527. Kirtane AJ, Martinezclark P, Rahman AM, Ray KK, Karmpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Roe MT, Harrington RA, Ohman EM, Braunwald E, Gibson CM. Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005 Jan 18; 45(2):321-3. 528. Kirtane AJ, Weisbord A, Karmpaliotis D, Murphy SA, Giugliano RP, Cannon CP, Antman EM, Ohman EM, Roe MT, Braunwald E, Gibson CM. Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. Am J Cardiol. 2005 Jan 15; 95(2):224-7. 529. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005 Jan 6; 352(1):20-8. 530. Dokainish H, Pillai M, Murphy SA, DiBattiste PM, Schweiger MJ, Lotfi A, Morrow DA, Cannon CP, Braunwald E, Lakkis N. Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: a TACTICS-TIMI-18 substudy. J Am Coll Cardiol. 2005 Jan 4; 45(1):19-24. 531. Cannon CP. The endocannabinoid system: a new approach to control cardiovascular disease. Clin Cornerstone. 2005; 7(2-3):17-26. 532. Fang JC, Couper GS, editors. Surgical management of congestive heart failure. Cannon CP, series editor. Contemporary Cardiology. 2005; 328. 533. Scirica BM, Sabatine MS, Murphy SA, Kirtane J, Aroesty J, Cannon CP, Gibson CM. Improved findings on late angiography are associated with lower rates of new Q-waves in patients receiving fibrinolysis for ST elevation myocardial infarction - Results from CLARITY-TIMI 28. Circulation. 2005; 112(17):II-693. 534. Tcheng JE, editor. Primary angioplasty in acute myocardial infarction. Cannon CP, series editor. Contemporary Cardiology. 2005; 182. 535. Wiviott SD, Cannon CP. Unstable angina non-ST-elevation myocardial infarction in the elderly. Gerstenblith G, editor. Cardiovascular Disease in the Elderly. 2005; 141-58. 536. Ray KK, Cannon CP, Morrow DA, TIMI Study Group. CRP is additive and independent of apo B/A1 ratio in explaining the clinical benefits of atorvastatin 80mg in ACS patients in PROVE IT-TIMI 22. Circulation. 2005; 112(17):II-483-4. 537. Herrmann HC, editor. Interventional cardiology-percutaneous noncoronary intervention. Cannon CP, series editor. Contemporary Cardiology. 2005; 433. 538. Rose E, McCabe CH, Cairns R, Cannon CP, Braunwald E. Dramatic benefit of intensive statin therapy in women: Results from PROVE IT - TIMI 22. J Am Coll Cardiol. 2005; 45(Suppl A):12. 539. Ray KK, Cannon CP, Gibson CM, Cairns R, Kirtane AJ, McCabe CH, Braunwald E. What are the future targets of therapy beyond intensive statin therapy? An analysis from PROVE IT-TIMI 22. Eur Heart J. 2005. 540. Ray KK, Cannon CP, Cairns R, Wiviott SD, Kirtane AJ, Sabatine MS, McCabe CH, Braunwald E, Gibson CM. Beyond LDL control: Additional benefits of better control of hypertension and glycemia in patients on statin therapy: An analysis from PROVE IT-TIMI 22. J Am Coll Cardiol. 2005; 45(Suppl A):332. 541. Cannon CP. Unstable angina: Medical treatment. Lewis RP, O'Gara PT, Parmley WW, editors. ACCSAP VI: Adult Clinical Cardiology Self-assessment Program. 2005. 542. Constant J, editor. Essentials of bedside cardiology. Cannon CP, series editor. Contemporary Cardiology. 2005; 298. 543. Bugiardini R, Manfrini O, Murphy SA, De Ferrari GM, Cannon CP. Long-term prognosis of nonobstructive coronary artery disease in the setting of acute coronary syndrome: A TIMI 22 Substudy. J Am Coll Cardiol. 2005; 45(Suppl A):208. 544. Cannon CP. C-reactive Protein. 2005. 545. Cannon CP. Commentary on early post-thrombolysis catherization may be preferable to a conservative strategy for people with myocardial infarction. Evidence-based Cardiovascular Medicine. 2005; 9:55-6. 546. Hasdai D, Berger PB, Batter A, Holmes DR, editors. Cardiogenic shock-diagnosis and treatment. Cannon CP, series editor. Contemporary Cardiology. 2005; 381. 547. Cannon CP. Latest advances in aggressive lipid management. Formulary. 2005; 40:3-12. 548. Cannon CP. Implementation of crtical pathways in the "Real World". Crit Pathways Cardiol. 2005; 4(2):110-4. 549. Cannon CP. Expert column: Lessons learned (so far) from the PROVE IT - TIMI 22 trial. 2005. 550. Scirica BM, Murphy S, Wiviott SD, Morrow DA, Sabatine MS, Gibson CM, Cannon CP. Chest Pain at presentation and delayed resolution of pain patients admitted with non-ST segment elevation acute coronary syndromes predicts short-term outcomes. J Am Coll Cardiol. 2005; 45(Suppl A):199. 551. Gelfand EV, Cannon CP. Does anti-infective therapy reduce cardiovascular event rates. Contagion. 2005; 2(10):1-5. 552. Deo R, Cannon CP, de Lemos JA. Rosendorf C, editor. ST segment elevation myocardial infarction. Essential Cardiology. 2005; 489-520. 553. Cannon CP. ACS at the 2005 ACC. 2005. 554. Ray KK, Cannon CP, Rader DJ, Cairns R, McCabe CH, Sacks FM, Braunwald E. Baseline ApoB predicts benefits of intensive statin therapy in patients with ACS: An analysis from PROVE IT-TIMI 22. Eur Heart J. 2005. 555. Kirtane AJ, Sabatine MS, Aroesty JM, Murphy SA, Scirica BM, Pinto DS, Southard M, Stein E, Cannon CP, Braunwald E, Gibson CM. Differences between streptokinase and fibrin-specific fibrinolytic therapy with co-administered with adjunctive clopidogrel: A CLARITY-TIMI 28 substudy. Circulation. 2005; 112(17):II-567. 556. Sabatine MS, Cannon CP. Recent advances with clopidogrel in acute myocardial infarction. Acute Coronary Syndromes. 2005; 7(2):56-60. 557. Gerstenblith G, editor. Cardiovascular disease in the elderly. Cannon CP, series editor. Contemporary Cardiology. 2005; 417. 558. Laham RD, Baim DS, editors. Angiogenesis and direct myocardial revascularization. Cannon CP, series editor. Contemporary Cardiology. 2005; 357. 559. Ballantyne CM, Feldman T, Ricker PM, Stone NJ, Cannon CP. Lower is better (on LDL and CRP). Medical Crossfire Special Edition. 2005; 6:121. 560. Cannon CP. C-reactive protein: A marker for assessing and managing cardiac risk. J Respiratory Diseases. 2005; 26(7):290-4. 561. The Occluded Artery Trial (OAT) Research Group (Cannon CP, Morbidity and Mortality Committee, Member OAT). Design and methodology of the occcluded artery trial (OAT). Am Heart J. 2005; 150:627-42. 562. Cannon CP, Libby P, Smith S, Ballantyne CM. Advances in lipid management. 2005; 1-30. 563. Cannon CP, Hawkins D, McKeever A. Guide to cardiovascular events. Cardiology Special Edition. 2005; 11:39-49. 564. Cannon CP. Treating both cholesterol and inflammation. 2005. 565. Cannon CP. Unstable Angina: Clinical presentation. Lewis RP, O'Gara PT, Parmley WW, editors. ACCSAP VI: Adult Clinical Cardiology Self-assessment Program. 2005. 566. Schoepf JU, editor. CT of the heart. Cannon CP, series editor. Contemporary Cardiology. 2005; 407. 567. Khan MG, editor. Heart disease diagnosis and therapy: A practical approach. Cannon CP, series editor. Contemporary Cardiology. 2005; 529. 568. Cannon CP, Ballantyne CM, Feldman T, Ridker PM, Stone NJ. Lower is better (on LDL and CRP) but how can we meet the challenge?. 2005. 569. Wiviott SD, Cannon CP, Morrow DA, Scirica BM, McCabe CH, Braunwald E. Elevations in creatine kinase (CK) with intensive statin treatment: a PROVE IT-TIMI 22 Substudy. J Am Coll Cardiol. 2005; 45(Suppl A):413. 570. Runge MS, Patterson C, editors. Principles of molecular cardiology. Cannon CP, series editor. Contemporary Cardiology. 2005; 617. 571. Cannon CP. A new addition to the treatment of STEMI: The CLARITY TIMI-28 COMMITT/CCS-2 Trials. 2005. 572. Cannon CP. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. 2005. 573. Wiviott SD, Cannon CP, Ray KK, Murphy S, Darius H, Castaigne A, Velasco JA, McCabe CH, Gibson CM. Seasonal variations in lipid values in patients following acs: PROVE IT-TIMI 22. J Am Coll Cardiol. 2005; 45(Suppl A):394. 574. Ornato JP, Peberdy MA, editors. Cardiopulmonary resuscitation. Cannon CP, series editor. Contemporary Cardiology. 2005; 764. 575. Weintraub WS, editor. Cardiovascular health care economics. Cannon CP, series editor. Contemporary Cardiology. 2005; 436. 576. Dasta J, Cannon CP. Confronting challenges in aggressive lipid lowering: A managed care perspective. Formulary. 2005; 40:3-14. 577. Quinn M, Fitzgerald G, editors. Platelet function. Cannon CP, series editor. Contemporary Cardiology. 2005; 397. 578. Cannon CP. Meeting today's treatment goals in lipid lowering. 2005. 579. Ray KK, Cannon CP, Morrow DA, Cairns R, Braunwald E. Percutaneous intervention for ACS is associated with a long-term reduction in CRP: An analysis from PROVE IT-TIMI 22. Eur Heart J. 2005. 580. Karha J, Gibson CM, Murphy SA, Dibattiste PM, Cannon CP. Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction. Am J Cardiol. 2004 Dec 15; 94(12):1537-9. 581. Ray KK, Cannon CP. Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology. Curr Opin Lipidol. 2004 Dec; 15(6):637-43. 582. Turakhia MP, Murphy SA, Pinto TL, Antman EM, Giugliano RP, Cannon CP, Braunwald E, Gibson CM. Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am J Cardiol. 2004 Dec 1; 94(11):1406-10. 583. Bhatt DL, Roe MT, Peterson ED, Li Y, Chen AY, Harrington RA, Greenbaum AB, Berger PB, Cannon CP, Cohen DJ, Gibson CM, Saucedo JF, Kleiman NS, Hochman JS, Boden WE, Brindis RG, Peacock WF, Smith SC, Pollack CV, Gibler WB, Ohman EM. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004 Nov 3; 292(17):2096-104. 584. Karmpaliotis D, Turakhia MP, Kirtane AJ, Murphy SA, Kosmidou I, Morrow DA, Giugliano RP, Cannon CP, Antman EM, Braunwald E, Gibson CM. Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am J Cardiol. 2004 Nov 1; 94(9):1113-7. 585. Gibson CM, Dumaine RL, Gelfand EV, Murphy SA, Morrow DA, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J. 2004 Nov; 25(22):1998-2005. 586. Ray KK, Cannon CP. Pathological changes in acute coronary syndromes: the role of statin therapy in the modulation of inflammation, endothelial function and coagulation. J Thromb Thrombolysis. 2004 Oct; 18(2):89-101. 587. Morrow DA, Sabatine MS, Antman EM, Cannon CP, Braunwald E, Theroux P. Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). Am J Cardiol. 2004 Sep 15; 94(6):774-6. 588. Menon V, Harrington RA, Hochman JS, Cannon CP, Goodman SD, Wilcox RG, Schünemann HJ, Ohman EM. Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):549S-575S. 589. Cannon C. Overview of clinical trials. J Invasive Cardiol. 2004 Sep; 16 Suppl E:7E-10E. 590. Gibson CM, Murphy SA, Kirtane AJ, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Sep 1; 44(5):980-7. 591. Fonarow G, Cannon C, Epstein A. Questions and answers. J Invasive Cardiol. 2004 Sep; 16 Suppl E:16E-17E. 592. Cannon CP. Revascularisation for everyone? Eur Heart J. 2004 Sep; 25(17):1471-2. 593. Sadanandan S, Cannon CP, Gibson CM, Murphy SA, DiBattiste PM, Braunwald E. A risk score to estimate the likelihood of coronary artery bypass surgery during the index hospitalization among patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Aug 18; 44(4):799-803. 594. Wiviott SD, Morrow DA, Frederick PD, Giugliano RP, Gibson CM, McCabe CH, Cannon CP, Antman EM, Braunwald E. Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Aug 18; 44(4):783-9. 595. Gibson CM, Singh KP, Murphy SA, DiBattiste PM, Demopoulos LA, Cannon CP, Braunwald E. Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy). Am J Cardiol. 2004 Aug 15; 94(4):492-4. 596. Sadanandan S, Cannon CP, Chekuri K, Murphy SA, Dibattiste PM, Morrow DA, de Lemos JA, Braunwald E, Gibson CM. Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Aug 4; 44(3):564-8. 597. Bach RG, Cannon CP, Weintraub WS, DiBattiste PM, Demopoulos LA, Anderson HV, DeLucca PT, Mahoney EM, Murphy SA, Braunwald E. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med. 2004 Aug 3; 141(3):186-95. 598. Wylie JV, Murphy SA, Morrow DA, de Lemos JA, Antman EM, Cannon CP. Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18. Am Heart J. 2004 Jul; 148(1):173-80. 599. Gibson CM, Bigelow B, James D, Tepper MR, Murphy SA, Kirtane AJ, Giugliano RP, Cannon CP, Antman EM. Association of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction. Am J Cardiol. 2004 Jul 1; 94(1):108-11. 600. Morrow DA, Antman EM, Murphy SA, Assmann SF, Giugliano RP, Cannon CP, Michael Gibson C, McCabe CH, Barron HV, Van De Werf F, Braunwald E. The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies. Eur Heart J. 2004 Jul; 25(13):1139-45. 601. Kirtane AJ, Bui A, Murphy SA, Karmpaliotis D, Kosmidou I, Boundy K, Rahman A, Pinto DS, Aroesty JM, Giugliano RP, Cannon CP, Antman EM, Gibson CM. Association of epicardial and tissue-level reperfusion with left ventricular end-diastolic pressures in ST-elevation myocardial infarction. J Thromb Thrombolysis. 2004 Jun; 17(3):177-84. 602. Cannon CP. Risk stratification and the management of non-ST-segment elevation acute coronary syndromes: the role of antiplatelet therapy. Crit Pathw Cardiol. 2004 Jun; 3(2):83-6. 603. Moyer P, Feldman J, Levine J, Beshansky J, Selker HP, Barnewolt B, Brown DF, Cardoza JP, Grossman SA, Jacobs A, Kerman BJ, Kimmelstiel C, Larson R, Losordo D, Pearlmutter M, Pozner C, Ramirez A, Rosenfield K, Ryan TJ, Zane RD, Cannon CP. Implications of the mechanical (PCI) vs thrombolytic controversy for ST segment elevation myocardial infarction on the organization of emergency medical services: the Boston EMS experience. Crit Pathw Cardiol. 2004 Jun; 3(2):53-61. 604. Lader EW, Cannon CP, Ohman EM, Newby LK, Sulmasy DP, Barst RJ, Fair JM, Flather M, Freedman JE, Frye RL, Hand MM, Jesse RL, Van de Werf F, Costa F. The clinician as investigator: participating in clinical trials in the practice setting. Circulation. 2004 Jun 1; 109(21):2672-9. 605. Lader EW, Cannon CP, Ohman EM, Newby LK, Sulmasy DP, Barst RJ, Fair JM, Flather M, Freedman JE, Frye RL, Hand MM, Jesse RL, Van de Werf F, Costa F. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis. Circulation. 2004 Jun 1; 109(21):e305-7. 606. Herrmann HC, Murphy SA, Dibattiste PM, Delucca PT, Demopoulos LA, Gibson CM, Cannon CP. Greater benefit of early invasive strategy for unstable angina and non-ST elevation myocardial infarction in United States compared with non-United States patients: a TACTICS-TIMI 18 substudy. Crit Pathw Cardiol. 2004 Jun; 3(2):95-100. 607. Byrne CE, Fitzgerald A, Cannon CP, Fitzgerald DJ, Shields DC. Elevated white cell count in acute coronary syndromes: relationship to variants in inflammatory and thrombotic genes. BMC Med Genet. 2004 Jun 1; 5:13. 608. Lader EW, Cannon CP, Ohman EM, Newby LK, Sulmasy DP, Barst RJ, Fair JM, Flather M, Freedman JE, Frye RL, Hand MM, Jesse RL, Van de Werf F, Costa F. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design. Circulation. 2004 Jun 1; 109(21):e302-4. 609. Cannon CP. Interview with: Christopher Cannon, MD. 2004. 610. Gibson CM, Karha J, Murphy SA, de Lemos JA, Morrow DA, Giugliano RP, Roe MT, Harrington RA, Cannon CP, Antman EM, Califf RM, Braunwald E. Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. J Am Coll Cardiol. 2004 Apr 7; 43(7):1170-6. 611. McCullough PA, Gibson CM, Dibattiste PM, Demopoulos LA, Murphy SA, Weintraub WS, Neumann FJ, Khanal S, Cannon CP. Timing of angiography and revascularization in acute coronary syndromes: an analysis of the TACTICS-TIMI-18 trial. J Interv Cardiol. 2004 Apr; 17(2):81-6. 612. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 Apr 8; 350(15):1495-504. 613. Wiviott SD, Cannon CP, Morrow DA, Murphy SA, Gibson CM, McCabe CH, Sabatine MS, Rifai N, Giugliano RP, DiBattiste PM, Demopoulos LA, Antman EM, Braunwald E. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation. 2004 Feb 10; 109(5):580-6. 614. Sabatine MS, Morrow DA, Giugliano RP, Murphy SA, Demopoulos LA, DiBattiste PM, Weintraub WS, McCabe CH, Antman EM, Cannon CP, Braunwald E. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Circulation. 2004 Feb 24; 109(7):874-80. 615. Cannon CP. Utilization of guidelines and computer-based technology to achieve optimal care in atherothrombotic vascular disease. J Thromb Thrombolysis. 2004 Feb; 17(1):45-9. 616. Gelfand EV, Cannon CP. Antibiotics for secondary prevention of coronary artery disease: an ACES hypothesis but we need to PROVE IT. Am Heart J. 2004 Feb; 147(2):202-9. 617. Kovar D, Cannon CP, Bentley JH, Charlesworth A, Rogers WJ. Does initial and delayed heart rate predict mortality in patients with acute coronary syndromes? Clin Cardiol. 2004 Feb; 27(2):80-6. 618. Cannon CP. Cost-effectiveness of clopidogrel. Pharmacoeconomics. 2004; 22 Suppl 4:1-3. 619. Cannon CP. Atherothrombosis: Bridging the Gap Between Clinical Evidence and Current Practice. 2004. 620. Hutter A, Abramson W, Califf RM Cannon CP. ACC conversations with experts. 2004. 621. Cannon CP, Peacock WF, Reiner JS. IMPACT: Optimal management of the AMI patient: Medical decision point. 2004. 622. Edwards NM, Chen JM, Mazzeo PA, editors. Cardiac transplantation. Cannon CP, series editor. Contemporary Cardiology. 2004; 286. 623. Wackers FJT, Bruni W, Zaret BL. Nuclear cardiology, The basics: How to set up and maintain a laboratory. Cannon CP, series editor. Contemporary Cardiology. 2004; 293. 624. Mehta RH, Montoye CK, Faul J, Nagle DJ, Kure J, Raj E, Fattal P, Sharriff S, Amlani M, Changezi H, Skorcz S, Bailey N, La Tarte M, McLean D, Savoy S, Werner P, Baker PL, Defranco A, Eagle K, Cannon CP on behalf of GAP Steering Committee of the American College of Cardiology (CP Cannon, GAP Steering Committee Member). Enhancing quality of care for acute myocardial infraction: Shifting the focus of improvement from key indicators to process of care and tool use. J Am Coll Cardiol. 2004; 43:2167-73.. 625. Cannon CP. Acute coronary syndromes II. 2004. 626. Cannon CP. Big news on cholesterol. 2004. 627. Cannon CP, Peterson ED. Changing the model of care for patients with acute coronary syndromes. 2004. 628. Cannon CP. Atherothrombosis: Bridging the gap between clinical evidence and current practice. 2004. 629. Menon V, Harrington RA, Hochman J, Cannon CP, Goodman SD, Wilcox RG, Schunemann H, Ohman EM. Thrombolysis and adjunctive therapy in acute myocardial infarction. Chest. 2004; 126:549S-575S. 630. Cannon CP. Forward. Gertsch M, editor. Two-step approach to diagnosis. 2004; 607. 631. Cannon CP. ACC 2004 PROVE IT. 2004. 632. Gibson CM, Sabatine MS, Murphy E, Morrow DA, Wiviott SD, Smith S, McCabe CH, Cannon CP, Braunwald E. Association of intensive lipid lowering with reductions in target vessel revascularization (clinical restenois) and non-target vessel revascularization (lesion progression): A PROVE IT TIMI 22 Substudy. Circulation. 2004; 110(Suppl III):696. 633. Ridker PM, Cannon CP, Pasternak R, Sacks F. "How low can you go? Pearls from the pros.". 2004. 634. Sabatine MS, Wiviott SD, Morrow DA, McCabe CH, Cannon CP. High-dose atorvastatin asssociated with worse glycemic control: A PROVE-IT TIMI 22 Substudy. Circulation. 2004; 110(Suppl III):834. 635. Cannon CP. Innovative directions in the future role of antiplatelet agents. 2004. 636. Cannon CP, Feske SK. Ten-year survival after first-ever stroke in the perth community stroke study. 2004. 637. Martinezclark P, Karmpaliotis D, Murphy S, Wiviott SD, Bigelow B, Kosmidou I, Chang A, Cannon CP, Giugliano R, Gibson CM. The association of race with angiographic and clinical outcomes following fibrinolytic administration. J Am Coll Cardiol. 2004; 43(Suppl A):305. 638. Cannon CP, Januzzi JL. Peripheral arterial disease in people with diabetes. 2004. 639. Cannon CP. Efficacy of percutaneous coronary intervention after thrombolysis for acute ST-elevation (Q wave) myocardial infarction. 2004. 640. Cannon CP. Guidelines for unstable angina and non-ST-segment elevation myocardial infarction. Bhatt DL, Flather MD, editors. Handbook of Acute Coronary Syndromes. 2004; 223-40. 641. Stein RA, Oz MC, editors. Complementary and alternative cardiovascular medicine. Cannon CP, series editor. Contemporary Cardiology. 2004; 286. 642. Cannon CP, Hawkins D, Wallace-Hixson J. Guide to antithrombotic agents. Pharmacy Practice News Special Edition. 2004; 57-62. 643. Wiviott SD, Sabatine MS, Morrow D, Dumaine R, Murphy S, Boundy KE, Cannon CP, Gibson CM. Distinct modes of cardiovascular death associated with impaired epicardial and myocardial perfusion following fibrinolysis for ST elevation myocardial infarction. J Am Coll Cardiol. 2004; 43(Suppl A):290. 644. Kloner RA, editor. Heart disease and erectile dysfunction. Cannon CP, series editor. Contemporary Cardiology. 2004. 645. Cannon CP, Golden WE. Secondary prevention in patients with unstable angina and non-ST-segment elevation myocardial infarction: Which drugs are mandatory?. Consultant. 2004; 44:1053-6. 646. Herrmann HC, Murphy SA, DiBattiste P, DeLucca PT, Demopoulos L, Gibson CM, Cannon CP. Greater benefit and early invasive strategy for unstable angina and non-ST elevation myocardial infarction ain United States compated with non-United States patients: A TACTICS-TIMI 18 Substudy. Crit Path Cardiol. 2004; 3:95-100.. 647. Cannon CP, Eckardt JJ, Kabo JM, Ward WG, Kelly CM, Wirganowicz PZ, Asavamongkolkul A, Nieves R, Eilber FR. Custom cross-pin fixation of 32 tumor endoprostheses stems. Clin Orthop Relat Res. 2003 Dec; (417):285-92. 648. Cannon CP. The next step in cardiovascular protection. Atheroscler Suppl. 2003 Dec; 4(5):3-9. 649. Fonarow GC, Abraham WT, Gheorghiade M, Cannon CP, Sackner-Bernstein JD, Udelson JE, Konstam MA. Role of beta-blocker therapy in the postmyocardial infarction patient with and without left ventricular dysfunction consensus guideline. Crit Pathw Cardiol. 2003 Dec; 2(4):239-46. 650. Budaj A, Brieger D, Steg PG, Goodman SG, Dabbous OH, Fox KA, Avezum A, Cannon CP, Mazurek T, Flather MD, Van De Werf F. Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). Am Heart J. 2003 Dec; 146(6):999-1006. 651. Gibson CM, Pinto DS, Murphy SA, Morrow DA, Hobbach HP, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol. 2003 Nov 5; 42(9):1535-43. 652. Januzzi JL, Cannon CP, Theroux P, Boden WE. Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention. Am Heart J. 2003 Nov; 146(5):764-74. 653. Cannon CP. Treatment algorithms and critical pathways for acute coronary syndromes. Semin Vasc Med. 2003 Nov; 3(4):425-32. 654. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van De Werf F, Avezum A, Goodman SG, Flather MD, Fox KA. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003 Oct 27; 163(19):2345-53. 655. Karha J, Murphy SA, Kirtane AJ, de Lemos JA, Aroesty JM, Cannon CP, Antman EM, Braunwald E, Gibson CM. Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction. Am J Cardiol. 2003 Oct 15; 92(8):913-8. 656. Eckardt JJ, Kabo JM, Kelly CM, Ward WG, Cannon CP. Endoprosthetic reconstructions for bone metastases. Clin Orthop Relat Res. 2003 Oct; (415 Suppl):S254-62. 657. Moscucci M, Fox KA, Cannon CP, Klein W, López-Sendón J, Montalescot G, White K, Goldberg RJ. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003 Oct; 24(20):1815-23. 658. Cannon CP. Oral platelet glycoprotein IIb/IIIa receptor inhibitors--part II. Clin Cardiol. 2003 Sep; 26(9):401-6. 659. Cannon CP, Braunwald E. Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) acute coronary syndromes Critical Pathway Toolkit. Crit Pathw Cardiol. 2003 Sep; 2(3):153-77. 660. Cannon CP. PROVE-IT TIMI 22 Study: potential effects on critical pathways for acute coronary syndrome. Crit Pathw Cardiol. 2003 Sep; 2(3):188-96. 661. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, Gibson CM, Cannon CP, Braunwald E, Schönbeck U. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation. 2003 Sep 2; 108(9):1049-52. 662. Cannon CP. Oral platelet glycoprotein IIb/IIIa receptor inhibitors--Part I. Clin Cardiol. 2003 Aug; 26(8):358-64. 663. Morrow DA, Rifai N, Sabatine MS, Ayanian S, Murphy SA, de Lemos JA, Braunwald E, Cannon CP. Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes. Clin Chem. 2003 Aug; 49(8):1396-8. 664. Gibson CM, Karha J, Murphy SA, James D, Morrow DA, Cannon CP, Giugliano RP, Antman EM, Braunwald E. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol. 2003 Jul 2; 42(1):7-16. 665. Cannon CP. Elderly patients with acute coronary syndromes: higher risk and greater benefit from antiplatelet therapy and/or interventional therapies. Am J Geriatr Cardiol. 2003 Jul-Aug; 12(4):259-62. 666. Cannon CP, Turpie AG. Unstable angina and non-ST-elevation myocardial infarction: initial antithrombotic therapy and early invasive strategy. Circulation. 2003 Jun 3; 107(21):2640-5. 667. Gibson CM, Kirtane AJ, Murphy SA, Karha J, Cannon CP, Giugliano RP, Roe MT, Harrington RA, Ohman EM, Antman EM. Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture. J Thromb Thrombolysis. 2003 Jun; 15(3):189-96. 668. Wong GC, Frisch D, Murphy SA, Sabatine MS, Pai R, James D, Kraimer N, Katsiyiannis PT, Marble SJ, DiBattiste PM, Demopoulos LA, Gourlay SG, Barron HV, Cannon CP, Gibson CM. Time for contrast material to traverse the epicardial artery and the myocardium in ST-segment elevation acute myocardial infarction versus unstable angina pectoris/non-ST-elevation acute myocardial infarction. Am J Cardiol. 2003 May 15; 91(10):1163-7. 669. Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Gibson CM, Cannon CP, Braunwald E. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol. 2003 Apr 16; 41(8):1264-72. 670. Pinto DS, Lorenz DP, Murphy SA, Marble SJ, DiBattiste PM, Demopoulos LA, Cannon CP, Gibson CM. Association of an activated clotting time < or =250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy). Am J Cardiol. 2003 Apr 15; 91(8):976-8, A4. 671. Cotter G, Cannon CP, McCabe CH, Michowitz Y, Kaluski E, Charlesworth A, Milo O, Bentley J, Blatt A, Krakover R, Zimlichman R, Reisin L, Marmor A, Lewis B, Vered Z, Caspi A, Braunwald E. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. Am Heart J. 2003 Apr; 145(4):622-7. 672. Serrano CV, Nicolau JC, Venturinelli M, Baracioli LM, Anders RJ, Cannon CP, Ramires JA. Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes. Cardiovasc Drugs Ther. 2003 Mar; 17(2):129-32. 673. Cannon CP. Foreword to lessons learned. Crit Pathw Cardiol. 2003 Mar; 2(1):54. 674. Cannon C. Improving acute coronary syndrome care: the ACC/AHA guidelines and critical pathways. J Invasive Cardiol. 2003 Mar; 15 Suppl B:22B-27B; discussion 27B-29B. 675. Cannon CP. Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: insights from the TACTICS TIMI-18 trial. J Am Coll Cardiol. 2003 Feb 19; 41(4 Suppl S):43S-48S. 676. de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, McCabe CH, Cannon CP, Braunwald E. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003 Feb 11; 107(5):690-5. 677. Bahit MC, Cannon CP, Antman EM, Murphy SA, Gibson CM, McCabe CH, Braunwald E. Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry. Am Heart J. 2003 Jan; 145(1):109-17. 678. Cannon CP. Critical pathways for acute myocardial infarction. Rev Cardiovasc Med. 2003; 4 Suppl 3:S47-53. 679. Fonarow GC, Abraham WT, Cannon CP, Gheorghiade M, Sackner-Bernstein JD, Udelson JE. Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction. Rev Cardiovasc Med. 2003; 4 Suppl 3:S54-9. 680. Cannon CP. Case study: Acute coronary syndrome. 2003. 681. Cannon CP. Practical applications of the ACC/AHA guidelines for unstable angina and non-ST-segment elevation myocardial infarction. Pharmacy Practice News Special Edition. 2003; 47-50. 682. Gussak I, Antzelevitch C, editors. Cardiac repolarization bridging basic and clinical science. Commerce Series Edition Contemporary Cardiology. 2003; 548. 683. Edwards NM, Maurer MS, Wellner RB, editors. Aging, heart disease, and it's management facts and controversies. Cannon CP, series editor. Contemporary Cardiology. 2003; 389. 684. Young J, Fonarow G, Hill J, Cannon CP, Heywood T, Peacock F, Berstein-Sackner J. Heart failure. 2003. 685. Cannon CP, Lincoff AM, Zidar M, Dippel E, Gibson CM, Popma J, Topol E. Thrombocardiology. 2003. 686. Coffman JD, Eberhardt RT, editors. Peripheral arterial disease diagnosis and tretment. Cannon CP, series editor. Contemporary Cardiology. 2003; 356. 687. Bhadriraju S, Defranco AC, Barber K, Murphy S, Gibson CM, DiBattiste P, Cannon CP. Major bleeding incidence after coronary artery bypass grafting in patients with unstable angina/non-ST elevation myocardial infarction based on coronary artery bypass graft timing in TACTICS-TIMI 18. J Am Coll Cardiol. 2003; 41:374A. 688. Cogan J, Cannon CP, de Lemos J. Treatment of unstable angina and non-ST elevation myocardial infarction. Llevadot J, editor. Acute Coronary Syndromes. 2003; 229-55. 689. Cannon CP, Denard SJ, Ferguson J, Gibson CM, Harrington R, Peterson ED, Popma J, Roe M, Tcheng JE. GP IIb/IIIa inhibitors: Examining the evidence. 2003. 690. Cannon CP. Optimizing care of the post-myocardial infarction low-ef patient. 2003. 691. Cannon CP, Mehta S. Early and late effects of clopidogrel in patients with acute coronary syndromes. 2003. 692. Cannon CP. Statin use in acute coronary syndromes: The next step in cardiovascular protection. 2003. 693. Cannon CP. Platelet glycoprotein IIb/IIIa inhibitors and an invasive strategy. Lincoff AM, editor. Contempory Cardiology: Platelet Glyocoprotein IIa/IIIb Inhibitors in Cardiovascular Disease. 2003; 263-73. 694. Cannon CP. Case study: A woman with rest chest discomfort: What is the optimal treatment?. 2003. 695. Cannon CP. New guidelines for the management of unstable angina and non-ST-elevation myocardial infarction. Cardiology Rounds. 2003; 1-7. 696. Cannon CP, Steinhubl S, Topol E, Easton D. Clinical implications of CREDO: New evidence for long-term dual antiplatelet therapy. 2003. 697. Lincoff AM, editor. Platelet glycoprotein IIb/IIIa inhibitors in cardiovascular disease. Cannon CP, series editor. Contemporary Cardiology. 2003; 476. 698. Cannon CP. Bivalirudin: Efficacy and cost effectiveness in PCI. Coron Artery Dis. 2003; 3. 699. Cannon CP, Hamm CW. Correspondence soluble CD40 ligand in acute coronary syndromes. 2003. 700. Sharis PJ, Cannon CP. Evidence-based Cardiology. 2003; 370. 701. Cannon CP. Antithrombostic therapy. 2003. 702. Cannon CP, Gibson CM. Equivalence trials: Understanding the statistical and clinical issues. 2003. 703. Cannon CP, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. 2003. 704. Cannon CP, Braunwald E. The spectrum of myocardial ischemia: The paradigm of acute coronary syndromes. Cannon CP, editor. Contemporary Cardiology: Management of Acute Coronary Syndromes. 2003; 3-18. 705. Cannon CP, Ferguson J, Kereiakes D, Roe M. Taking ACS to the bedside. 2003. 706. Cannon CP, Braunwald E. AHA/ACC 2002 guideline update for the management of patients with unstable angina and non-ST-segment-elevation myocardial infarction. 2003. 707. Weintraub WS, editor. Cardiovascular health care economics. Cannon CP, series editor. Contemporary Cardiology. 2003; 436. 708. Cannon CP, Topol EJ. Randomized, double blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebovascular disease. 2003. 709. Greenbaum AB, Kleiman NS, Berger PB, Cohen DJ, Cannon CP, Brindis R, Li Y, Roe MT, Harrington RA, Peterson E, Gibler WB, Ohman EM. Clinical trials in acute myocardial infarction and acute coronary syndrome. Transcatheter Cardiovascular Therapeutics. 2003. 710. Cannon CP, editor. Management of Acute Coronary Syndromes. 2003; 781. 711. Cannon CP. Cannon Chronicles: The CREDO trial. 2003. 712. Cannon CP. Cannon chronicles: Guidelines for CRP. 2003. 713. Cannon CP. Role of newer antiplatelet and antithrombotic agents. 2003. 714. Constant J, editor. Essentials of Bedside Cardiology. Cannon CP, series editor. Contemporary Cardiology. 2003. 715. Cannon CP, Hawkins D, Wallace-Hixson J. Guide to cardiovascular agents. Cardiology Special Edition. 2003; 9:27-37. 716. Fuster V, Cannon CP, Ferguson J, Weber M. Confirming knowledge. 2003. 717. Cannon CP, Walls RM. Is it safe to send this patient home ed markers of ACS move upstream?. J Emergency Med. 2003; 7. 718. Cannon CP. Quality of care in atherothrombosis: From acute to long-term care. 2003. 719. Cannon CP, Topol E. Cannon chronicles: Aspirin therapy: What is the appropriate dose?. 2003. 720. Cannon CP. Advantages and hazards of early revascularization. Theroux P, editor. Acute Coronary Syndromes Companion to Braunwald's Heart Disease. 2003; 752. 721. Cannon CP, Fonarow GC. ASC Update. Strive. 2003. 722. Jordan M, Dotani MI, Dumaine R, Wong G, Aroesty JM, Cannon CP, McCabe C, Braunwald E, Gibson CM. Association of multivessel disease, inflammatory markers and impaired tissue level perfusion in the setting of acute coronary syndromes: A TACTICS-TIMI 18 substudy. Circulation. 2003; 108(Suppl I):2157. 723. Cannon CP, Topol EJ, Steinhubl S. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. 2003. 724. Cannon CP. Platelet glycoprotein IIb/IIIa inhibitors and an invasive strategy. Lincoff AM, editor. Platelet glycoprotein IIb/IIIa inhibitors in Cardiovascular Medicine. 2003; 263-73. 725. Cannon CP, Creager MA. Critical issues in peripheral arterial disease detection management. 2003. 726. Cannon CP, O'Gara P. Critical pathways for acute coronary syndromes. Cannon CP, editor. Contemporary Cardiology: Management of Acute Coronary Syndromes. 2003; 745-69. 727. Harrington R, Ferguson J, Tcheng JE, Cannon CP, Denardo S, Gibson CM, Peterson E. Interventional. 2003. 728. Bhatt D, Cannon CP, Peacock F, Reiner J. Evolving treatment strategies in acute myocardial infarction. 2003. 729. Cannon CP, Kearon C. Comparison of low-intensity warafin therapy with conventional-intensity warafin therapy for long-term prevention of recurrent venous thromboembolism. 2003. 730. Wong GC, Murphy S, Morrow D, Giugliano R, Cannon CP, De Lemos J, Sabatine MS, Gibson CM. A simple ECG method using high-risk infarct territory is superior to ECGs using summed ST elevation for assessing risk in ST elevation myocardial infarction. J Am Coll Cardiol. 2003; 41:402A. 731. Fuster V, Cannon CP, Ferguson J, Weber M. ACC 2003: Sportif II and ascot. 2003. 732. Cannon CP, Rikers PM. AHA/CDC scientific statement-markers of inflammation and cardiovascular disease: Application to clinical and public health practice. 2003. 733. Cannon CP. Recent update to the ACC/AHA guidelines for the management of patients with UA/NSTEMI. American College Cardiology Oregon Chapter Newsletter. 2003; 8. 734. Glaser R, Herrmann HC, Murphy SA, Demopoulos LA, DiBattiste PM, Cannon CP, Braunwald E. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA. 2002 Dec 25; 288(24):3124-9. 735. Brassard JA, Curtis BR, Cooper RA, Ferguson J, Komocsar W, Ehardt M, Kupfer S, Maurath C, Swabb E, Cannon CP, Aster RH. Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology. Thromb Haemost. 2002 Dec; 88(6):892-7. 736. Lakkis N, Tsyboulev V, Gibson CM, Murphy SA, Weintraub WS, DiBattiste PM, Cannon CP. Outcome of patients with acute coronary syndrome admitted to hospitals with or without onsite cardiac catheterization laboratory: a TACTICS-TIMI 18 substudy. Crit Pathw Cardiol. 2002 Dec; 1(4):232-7. 737. Januzzi JL, Cannon CP, DiBattiste PM, Murphy S, Weintraub W, Braunwald E. Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). Am J Cardiol. 2002 Dec 1; 90(11):1246-9. 738. Sabatine MS, Morrow DA, Cannon CP, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Braunwald E, Gibson CM. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18 trial)substudy. J Am Coll Cardiol. 2002 Nov 20; 40(10):1761-8. 739. Sharis PJ, Cannon CP, Rogers WJ, McCabe C, Murphy S, Gibson CM, Stone PH, Braunwald E. Predictors of mortality, coronary angiography, and revascularization in unstable angina pectoris and acute non-ST elevation myocardial infarction (the TIMI III Registry). Am J Cardiol. 2002 Nov 15; 90(10):1154-6. 740. Freedman JE, Becker RC, Adams JE, Borzak S, Jesse RL, Newby LK, O'Gara P, Pezzullo JC, Kerber R, Coleman B, Broderick J, Yasuda S, Cannon C. Medication errors in acute cardiac care: An American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Acute Cardiac Care, Council on Cardiopulmonary and Critical Care, Council on Cardiovascular Nursing, and Council on Stroke. Circulation. 2002 Nov 12; 106(20):2623-9. 741. Mahoney EM, Jurkovitz CT, Chu H, Becker ER, Culler S, Kosinski AS, Robertson DH, Alexander C, Nag S, Cook JR, Demopoulos LA, DiBattiste PM, Cannon CP, Weintraub WS. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA. 2002 Oct 16; 288(15):1851-8. 742. Scirica BM, Cannon CP, McCabe CH, Murphy SA, Anderson HV, Rogers WJ, Stone PH, Braunwald E. Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification. Am J Cardiol. 2002 Oct 15; 90(8):821-6. 743. Cannon CP. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am J Cardiol. 2002 Oct 1; 90(7):760-2. 744. Murphy SA, Chen C, Cannon CP, Antman EM, Gibson CM. Impact of gender on angiographic and clinical outcomes after fibrinolytic therapy in acute myocardial infarction. Am J Cardiol. 2002 Oct 1; 90(7):766-70. 745. Angeja BG, de Lemos J, Murphy SA, Marble SJ, Antman EM, Cannon CP, Braunwald E, Gibson CM. Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. Am Heart J. 2002 Oct; 144(4):649-56. 746. Cannon CP. Evidence-based risk stratification to target therapies in acute coronary syndromes. Circulation. 2002 Sep 24; 106(13):1588-91. 747. Kleiman NS, Lakkis N, Cannon CP, Murphy SA, DiBattiste PM, Demopoulos LA, Weintraub WS, Braunwald E. Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes. J Am Coll Cardiol. 2002 Sep 18; 40(6):1044-50. 748. Brener SJ, Murphy SA, Gibson CM, DiBattiste PM, Demopoulos LA, Cannon CP. Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes. Am J Cardiol. 2002 Sep 15; 90(6):631-3. 749. Scirica BM, Cannon CP, Gibson CM, Murphy SA, Moliterno DJ, Anderson HV, Aguirre FV, Granger CB, Lambrew CT, Rabbani LE, Sapp SK, Booth JE, Ferguson JJ, Braunwald E. Assessing the effect of publication of clinical guidelines on the management of unstable angina and non-ST elevation myocardial infarction in the TIMI III (1990-1993) and the GUARANTEE (1995-1996) Registries. Crit Pathw Cardiol. 2002 Sep; 1(3):150-8. 750. Scirica BM, Cannon CP, Antman EM, Murphy SA, Morrow DA, Sabatine MS, McCabe CH, Gibson CM, Braunwald E. Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry. Am J Cardiol. 2002 Aug 1; 90(3):303-5. 751. de Lemos JA, Morrow DA, Gibson CM, Murphy SA, Sabatine MS, Rifai N, McCabe CH, Antman EM, Cannon CP, Braunwald E. The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies. J Am Coll Cardiol. 2002 Jul 17; 40(2):238-44. 752. Wong GC, Morrow DA, Murphy S, Kraimer N, Pai R, James D, Robertson DH, Demopoulos LA, DiBattiste P, Cannon CP, Gibson CM. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Circulation. 2002 Jul 9; 106(2):202-7. 753. Murphy SA, Gibson CM, Van de Werf F, McCabe CH, Cannon CP. Comparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT I). Am J Cardiol. 2002 Jul 1; 90(1):51-4. 754. Cannon CP, Baim DS. Expanding the reach of primary percutaneous coronary intervention for the treatment of acute myocardial infarction. J Am Coll Cardiol. 2002 Jun 5; 39(11):1720-2. 755. Cannon CP. Oral glycoprotein IIb/IIIa inhibition--great idea, but it didn't work. Am J Med. 2002 Jun 1; 112(8):673-5. 756. Bahit MC, Murphy SA, Gibson CM, Cannon CP. Critical pathway for acute ST-segment elevation myocardial infarction: estimating its potential impact in the TIMI 9 Registry. Crit Pathw Cardiol. 2002 Jun; 1(2):107-12. 757. Cannon CP. Palm Pilot programs to improve quality of care in acute coronary syndromes. Crit Pathw Cardiol. 2002 Jun; 1(2):113-5. 758. Angeja BG, Kermgard S, Chen MS, McKay M, Murphy SA, Antman EM, Cannon CP, Braunwald E, Gibson CM. The smoker's paradox: insights from the angiographic substudies of the TIMI trials. J Thromb Thrombolysis. 2002 Jun; 13(3):133-9. 759. Kloner RA, Poole K, Shook T, Przyklenk K, Perritt K, Cannon CP. Comparison of acute myocardial infarct size in patients > or =65 years versus < 65 years in the prethrombolytic period versus the thrombolytic period. Am J Cardiol. 2002 Jun 1; 89(11):1291-3. 760. Cannon CP, Hand MH, Bahr R, Boden WE, Christenson R, Gibler WB, Eagle K, Lambrew CT, Lee TH, MacLeod B, Ornato JP, Selker HP, Steele P, Zalenski RJ. Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program. Am Heart J. 2002 May; 143(5):777-89. 761. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 2002 Apr 23; 105(16):1909-13. 762. Cannon CP. Primary percutaneous coronary intervention for all? JAMA. 2002 Apr 17; 287(15):1987-9. 763. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002 Apr 16; 105(15):1760-3. 764. Cannon CP, McCabe CH, Belder R, Breen J, Braunwald E. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol. 2002 Apr 1; 89(7):860-1. 765. Cannon CP. Enoxaparin in ST elevation MI - a bright future. Eur Heart J. 2002 Apr; 23(8):591-2. 766. Cannon CP, Ornato JP. How to develop a critical pathway: the acute coronary syndromes: Acute Cardiac Team to Implement Optimal Treatments Now (ACS ACTION) Program. Crit Pathw Cardiol. 2002 Mar; 1(1):53-60. 767. Cannon CP, Bahit MC, Haugland JM, Henry TD, Schweiger MJ, McKendall GR, Shah PK, Murphy S, Gibson CM, McCabe CH, Antman EM, Braunwald E. Underutilization of evidence-based medications in acute ST elevation myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry. Crit Pathw Cardiol. 2002 Mar; 1(1):44-52. 768. Cannon CP. To cath or not to cath? That used to be the question. Am Heart J. 2002 Mar; 143(3):377-80. 769. Cannon CP. Critical Pathways in Cardiology: a journal of evidence-based medicine: translating evidence into practice. Crit Pathw Cardiol. 2002 Mar; 1(1):1-2. 770. Cannon CP. Critical pathway for unstable angina and non-ST elevation myocardial infarction: February 2002. Crit Pathw Cardiol. 2002 Mar; 1(1):12-21. 771. Sharayeva ML, Tcheng JE, Cannon CP. Assessment of compliance with the American College of Cardiology/American Heart Association guidelines for patients with acute coronary syndromes admitted to a tertiary care hospital coronary care unit. Crit Pathw Cardiol. 2002 Mar; 1(1):22-5. 772. Leebeek FW, Boersma E, Cannon CP, van de Werf FJ, Simoons ML. Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable. Eur Heart J. 2002 Mar; 23(6):444-57. 773. Omland T, de Lemos JA, Morrow DA, Antman EM, Cannon CP, Hall C, Braunwald E. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol. 2002 Feb 15; 89(4):463-5. 774. Gibson CM, Chen M, Angeja BG, Murphy SA, Marble SJ, Barron HV, Cannon CP. Precordial ST-segment depression in inferior myocardial infarction is associated with slow flow in the non-culprit left anterior descending artery. J Thromb Thrombolysis. 2002 Feb; 13(1):9-12. 775. Kenny D, Muckian C, Fitzgerald DJ, Cannon CP, Shields DC. Platelet glycoprotein Ib alpha receptor polymorphisms and recurrent ischaemic events in acute coronary syndrome patients. J Thromb Thrombolysis. 2002 Feb; 13(1):13-9. 776. Cannon C. Clopidogrel and percutaneous coronary intervention. Lancet. 2002 Jan 12; 359(9301):169. 777. Shields DC, Fitzgerald AP, O'Neill PA, Muckian C, Kenny D, Moran B, Cannon CP, Byrne CE, Fitzgerald DJ. The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists. Pharmacogenomics J. 2002; 2(3):182-90. 778. Bhatt D, Cannon CP, Peacock F, Reiner J . AMI 2002: Discovering optimal treatment pathways. 2002. 779. Cannon CP. A new standard of care in acute coronary syndromes. 2002. 780. Cannon CP, Ferguson J, Ohman M. Thrombocardiology series. 2002. 781. Cannon CP. Advances in the understanding of acute coronary syndrome. 2002. 782. Cannon CP, Cohen DE, Radar D. Targeting multiple pathways for optimal cholestrol management. 2002. 783. Cannon CP. New approaches to the prevention on atherothrombotic events in patients with vascular disease. 2002. 784. Fuster V, Cannon CP, Ferguson J, Weber M. ESC. 2002. 785. Fuster V, Pickering T, Cannon CP, Ferguson J, Weber M. ALLHAT and ALLHAT-LLT. 2002. 786. Harrington R, Cannon CP, Topol E, Rose M. Defining optimal care for patients with acute coronary syndromes. 2002. 787. Cannon CP. Guideline for UA/NSTEMI. 2002. 788. Cannon CP, Ornato JP. How to develop a critical pathway: The ACS ACTION program. Crit Pathw Cardiol. 2002; 1:53-60. 789. Cannon CP. New approaches to the prevention of atherothrombotic events in patients with vascular disease. 2002. 790. Cannon CP. Unstable Angina: Treatment strategies. Lewis RP, O'Gara PT, Parmley WW, editors. ACCSAP V: Adult Clinical Cardiology Self-assessment Program. 2002. 791. Harrington R, Cannon CP. Global effort to transform outcomes of acute coronary syndromes (GET ACS) day in review. 2002. 792. Cannon CP, Granger CB, Armstrong PW, Roe M. Implementing a critical pathway based on the ACC/AHA guidelines. 2002. 793. Giugliano RP, Cannon CP. Antiplatelet therapy. Antman EM, editor. Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease. 2002; 601-54. 794. Cannon CP. Implications of upstream GP IIb/IIIa inhibition and stenting in the invasive management of UA/NSTEMI: A comparison of TIMI IIIB and TACTICS-TIMI 18. 2002. 795. Murphy S, Guigliano RP, Wong G, Cannon CP, Antman E, Gibson CM. Comparison of frequency and outcomes of investigator assessed recurrent MI versus clinical event committee (CEC) adjudicated recurrent MI in acute MI trials: A TIMI 14 and TIMI 9 substudy. J Am Coll Cardiol. 2002; 39:279A. 796. Cannon CP. Commentary on SYMPHONY II. Evid Based Cardiovasc Med. 2002. 797. Cannon CP. Integrating GP IIb/IIIa inhibition and an early invasive strategy for optimal management of acute coronary syndromes. 2002. 798. Cannon CP. Unstable angina: Clinical presentation. Lewis RP, O'Gara PT, Parmley WW, editors. ACCSAP V: Adult Clinical Cardiology Self-assessment Program. 2002. 799. Cannon CP, Noble JR. Aspirin and clopidogrel is not better than aspirin IIb/IIIa inhibitor for non-ST elevation in acute coronary syndrome. 2002. 800. Cannon CP. Unstable angina/non-ST-elevation myocardial infarction. Intensive Care Medicine. 2002; 377-99. 801. Cannon CP. Awesome 2002 ACC/AHA. 2002. 802. Cannon CP, King S, Ohman M. Day in review-inhibiting platelets in the cath lab. 2002. 803. Cannon CP. Efficacy of percutaneous coronary intervention after thrombolysis for acute ST elevation (Q wave) myocardial infarction. 2002. 804. Cannon CP. Unstable angina: Medical treatment. Lewis RP, O'Gara PT, Parmley WW, editors. ACCSAP V: Adult Clinical Cardiology Self-assessment Program. 2002. 805. Fuster V, Cannon CP, Ferguson J, Weber M. Aspirin, ICDs, and MRA. 2002. 806. Cannon CP, Fuster V. Anticoagulant and fibrinolytic therapy for acute coronary syndromes. Antman EM, editor. Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease. 2002; 669-93. 807. Fuster V, Pickering T, Cannon CP, Ferguson J, Weber M. AHA 2002: Part I. 2002. 808. Bombardier C, Cannon CP. Placing the evidence in perspective: Cardiovascular and renal risks with pharmacologic therapy in osteoarthritis. 2002. 809. Cannon CP. Practical applications of the 2002 ACC/AHA guidelines for unstble angina and non-ST-segment elevation myocardial infarction. Cardio Special Edition. 2002; 8:29-36. 810. Cannon CP. Acute coronary syndrome: A new paradigm for emergency management. 2002. 811. Steg PG, Dabbous O, Cohen-Solal A, Aumont M, Cannon CP, Lopez-Sendon J, Budaj A, Klein W. Determinants and outcomes of congestive heart failure complicating acute coronary syndromes: observations from the global registry of acute coronary events. J Am Coll Cardiol. 2002; 39:154A. 812. Mehta RH, Montoye CK, Gallogly M, Baker P, Lount A, Faul J, Roychoudhury C, Borzak S, Fox S, Franklin M, Freundl M, Kline-Rogers E, Lalonde T, Orza M, Parrish R, Satwicz M, Smith MJ, Sabotka P, Winston S, Roiba AA, Eagle KA, on behalf of the GAP Steering Committee of the American College of Cardiology (CP Cannon, GAP Steering Committee Member). Improving quality of care of acute myocardial infarction: The guideline applied in practice (GAP) initiative in Southeast Michigan. JAMA. 2002; 287:1269-1276.. 813. King S, Cannon CP, Mehta SR, Roe M. Integrating antiplatelet therapy with early invasive management for acute coronary syndromes. 2002. 814. Gibson CM, Morrow D, Vicari R, Wong GC, Demopoulos L, DiBattiste P, Murphy S, Cannon CP, Braunwald E. Elevated C reactive protein (CRP) is associated with a higher risk of thrombotic occlusion and poorer flow following percutaneous coronary intervention in patients with acute coronary syndromes: A TACTICS TIMI 18 angiographic substudy. J Am Coll Cardiol. 2002; 39:304A. 815. Marks DS, Gudapati SB, Kleczka J, Murphy S, Cannon CP, Braunwald E. Electrocardiographic left ventricular hypertrophy is associated with mortality and left ventricular rupture in patients with acute myocardial infarction. J Am Coll Cardiol. 2002; 39:331A. 816. Wong SA, Kraimer N, Pai R, James D, Murphy SA, Cannon CP, Gibson CM for the TACTICS-TIMI 18 Study Group. Elevations in Troponin T are associated with abnormal tissue level perfusion: A TACTICS-TIMI 18 Substudy. Circulation. 2002; 106:202-7.. 817. Cannon CP. Platelet glyocoprotein IIb/IIIa inhibition in acute coronary syndromes. Goldhaber SZ, Ridker PM, editors. Thrombosis and Thromboembolism. 2002; 101-24. 818. Cannon CP. News in ACS from AHA. 2002. 819. Cannon CP. Percutaneous coronary intervention in the clopidogrel in unstable angina to prevent recurrent events (PCI-cure) trial. Cardio Scientific Update. 2002. 820. Cannon CP. The clopidogrel in unstable angina to prevent recurrent events (CURE) trial. Pfeffer M, editor. Cardiology Scientific Updates. 2002; 1-6. 821. Sekaran NK, Moliterno DJ, Ferguson JJ, Every N, Anderson HV, Aguirre FV, French WJ, Sapp S, Booth JE, Granger CB, Cannon CP. "Hot" unstable angina--is it worse than subacute unstable angina? Results from the GUARANTEE Registry. J Thromb Thrombolysis. 2001 Dec; 12(3):207-16. 822. O'Connor FF, Shields DC, Fitzgerald A, Cannon CP, Braunwald E, Fitzgerald DJ. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood. 2001 Dec 1; 98(12):3256-60. 823. Cannon CP, Battler A, Brindis RG, Cox JL, Ellis SG, Every NR, Flaherty JT, Harrington RA, Krumholz HM, Simoons ML, Van De Werf FJ, Weintraub WS, Mitchell KR, Morrisson SL, Brindis RG, Anderson HV, Cannom DS, Chitwood WR, Cigarroa JE, Collins-Nakai RL, Ellis SG, Gibbons RJ, Grover FL, Heidenreich PA, Khandheria BK, Knoebel SB, Krumholz HL, Malenka DJ, Mark DB, Mckay CR, Passamani ER, Radford MJ, Riner RN, Schwartz JB, Shaw RE, Shemin RJ, Van Fossen DB, Verrier ED, Watkins MW, Phoubandith DR, Furnelli T. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol. 2001 Dec; 38(7):2114-30. 824. Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, Robertson DH, Hille DA, DeLucca PT, DiBattiste PM, Demopoulos LA, Weintraub WS, Braunwald E. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001 Nov 21; 286(19):2405-12. 825. Kloner RA, Das S, Poole WK, Perrit R, Muller J, Cannon CP, Braunwald E. Seasonal variation of myocardial infarct size. Am J Cardiol. 2001 Nov 1; 88(9):1021-4. 826. Schweiger MJ, Cannon CP, Murphy SA, Gibson CM, Cook JR, Giugliano RP, Changezi HU, Antman EM, Braunwald E. Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). Am J Cardiol. 2001 Oct 15; 88(8):831-6. 827. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001 Oct 4; 345(14):1014-21. 828. Morrow DA, Antman EM, Parsons L, de Lemos JA, Cannon CP, Giugliano RP, McCabe CH, Barron HV, Braunwald E. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA. 2001 Sep 19; 286(11):1356-9. 829. Bray PF, Cannon CP, Goldschmidt-Clermont P, Moyé LA, Pfeffer MA, Sacks FM, Braunwald E. The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol. 2001 Aug 15; 88(4):347-52. 830. de Lemos JA, Morrow DA, Gibson CM, Murphy SA, Rifai N, Tanasijevic M, Giugliano RP, Schuhwerk KC, McCabe CH, Cannon CP, Antman EM, Braunwald E. Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. Am J Cardiol. 2001 Aug 15; 88(4):353-8. 831. Cannon CP. Importance of TIMI 3 flow. Circulation. 2001 Aug 7; 104(6):624-6. 832. Srinivas VS, Cannon CP, Gibson CM, Antman EM, Greenberg MA, Tanasijevic MJ, Murphy S, de Lemos JA, Sokol S, Braunwald E, Mueller HS. Myoglobin levels at 12 hours identify patients at low risk for 30-day mortality after thrombolysis in acute myocardial infarction: a Thrombolysis in Myocardial Infarction 10B substudy. Am Heart J. 2001 Jul; 142(1):29-36. 833. Cannon CP, Goldhaber SZ, Hand M. National heart attack alert program: Highlights. Chestsoundings. 2001; 15:17. 834. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001 Jun 21; 344(25):1879-87. 835. Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP, Antman EM, Braunwald E. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001 May 29; 103(21):2550-4. 836. Giugliano RP, McCabe CH, Antman EM, Cannon CP, Van de Werf F, Wilcox RG, Braunwald E. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J. 2001 May; 141(5):742-50. 837. Kloner RA, Shook T, Cannon CP, Przyklenk K. Ischemic preconditioning: implications for the geriatric heart. Am J Geriatr Cardiol. 2001 May-Jun; 10(3):145-8; quiz 149-51. 838. Cannon CP, Nelson SD, Panosian CB, Seeger LL, Eilber FR, Eckardt JJ. Soft tissue echinococcosis: a report of two cases and review of the literature. Clin Orthop Relat Res. 2001 Apr; (385):186-91. 839. O'Rourke RA, Hochman JS, Cohen MC, Lucore CL, Popma JJ, Cannon CP. New approaches to diagnosis and management of unstable angina and non-ST-segment elevation myocardial infarction. Arch Intern Med. 2001 Mar 12; 161(5):674-82. 840. Cannon CP, McCabe CH, Wilcox RG, Bentley JH, Braunwald E. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators. Am J Cardiol. 2001 Mar 1; 87(5):636-9, A10. 841. Cannon CP. TIMI risk calculator. 2001. 842. Gibson CM, Murphy SA, Marble SJ, McCabe CH, Antman EM, Cannon CP, Braunwald E. Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? TIMI Study Group. Am J Cardiol. 2001 Feb 15; 87(4):450-3, A6. 843. Ohman EM, Harrington RA, Cannon CP, Agnelli G, Cairns JA, Kennedy JW. Intravenous thrombolysis in acute myocardial infarction. Chest. 2001 Jan; 119(1 Suppl):253S-277S. 844. Wang-Clow F, Fox NL, Cannon CP, Gibson CM, Berioli S, Bluhmki E, Danays T, Braunwald E, Van De Werf F, Stump DC. Determination of a weight-adjusted dose of TNK-tissue plasminogen activator. Am Heart J. 2001 Jan; 141(1):33-40. 845. Cannon CP. Critical pathways for thrombolysis in myocardial infarction. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiology. 2001; 57-66. 846. Topol EJ, Cannon CP, Moliterno D. Latest clinical updates: Long-term outcome following contemporary PCI. 2001. 847. Braunwald E, Aghababian R, Anand S, Cannon CP, Popma JJ, Tierstein P. Strategies and therapies for reducing ischemic and vascular events (STRIVE). 2001. 848. Otten MHC, Murphy SA, Angela G, Hynes CA, Lim JS, Luu LL, Kermgard SR, Marble SJ, Cannon CP, Braunwald E, Gibson CM. Kinetics of myocardial perfusion in the setting of ST segment elevation acute myocardial infarction vs unstable angina/non-Q wave MI. J Am Coll Cardiol. 2001; 37(Suppl A):333. 849. Sadanandan S, Cannon CP, DiBattiste PM, Demopoulos LA, Robertson D, Kugelmass AD, for the TACTICS - TIMI 18 Investigators . Outcomes of patients with spontaneous versus post pci CK-MB elevation: data from TACTICS-TIMI 18 trial. Circulation. 2001; 104(Suppl II):697. 850. Cannon CP, O'Gara PT. Critical pathway for unstable angina. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiology. 2001; 131-41. 851. Cannon CP, Gibson CM, Lincoff AM. Determining the combination therapy in acute myocardial infarction. 2001. 852. White WB, editor. Blood pressure monitoring in cardiovascular medicine and therapeutics. Cannon CP, series editor. Contemporary Cardiology. 2001; 308. 853. Cannon CP, Braunwald E. Unstable angina. Braunwald E, Zipes DP, Libby P, editors. Heart Disease: A Textbook of Cardiovascular Medicine. 2001; 1232-63. 854. Cannon CP. Commentary on new biomarkers for predicting acute cardiac events. Evidence Based Cardiov Med. 2001; 5:6. 855. Cannon CP. Commentary on cost-effectiveness of GP IIb/IIIa inhibitors. J Evidence Based Healthcare. 2001; 5:87-8. 856. Fuster V, Cannon CP, Ferguson J, Weber M. Opening doors to new therapies: Clinical trials at AHA. 2001. 857. Ganz LI, editor. Management of cardiac arrhythmias. Cannon CP, series editor. Contemporary Cardiology. 2001. 858. Cannon CP. Clopidogrel continuing education teleconference workbook. 2001. 859. Cannon CP. Participating in clinical trials after fellowship ends. Cardiovasc Fellows Forum. 2001; 2:12-3. 860. Cannon CP. New developments in acute coronary syndromes. 2001. 861. Cannon CP. Commentary on glycoprotein IIb/IIIa inhibitors to reduce combined endpoints in acute coronary syndromes. ACP Journal Club. 2001; (March/April):49. 862. Cannon CP. Invasive vs conservative strategies in UA/NSTEMI: The right TACTICS in 2001. 2001. 863. Topol EJ, Cannon CP, Van de Werf F, Ferguson JJ, Califf RM. Acute coronary syndromes: The 360 degree view. 2001. 864. de Lemos JA, Cannon CP, Stone PH. Acute myocardial infarction. Rosendorff E, editor. Essential Cardiology. 2001; 463-504. 865. Cannon CP, Weintraub WS, Demopoulos L, Vicari R, Bazzino O, Ali N, Robertson DH, DeLucca PT, DiBattiste P, Rifai N, Braunwald E, for the TACTICS-TIMI 18 Investigators. High-sensitivity C-reactive protein (hs-CRP) to predict 6 month mortality and relative benefit of invasive vs. conservative strategy in patients with unstable angina: Primary results of the TACTICS-TIMI 18 C-Reactive Protein substudy. J Am Coll Cardiol. 2001; 37(Suppl A):315A. 866. Cannon CP, McCallister BD. Integrating IIb/IIIa inhibition and early invasive strategy for optimal management of ACS. 2001. 867. Morrow DA, Cannon CP. Chest pain and biomarkers: Has troponin supplanted CK-MB?. ACC Curr J Rev. 2001; (Jan/Feb):18-21. 868. Morrow DA, Cannon CP. Low-molecular-weight heparin in the treatment of acute coronary syndromes. Emerg Med. 2001; 33. 869. Armstrong P, Gibler B, Cannon CP, Cohen E, Calder L. Determining therapy by risk stratification in ACS. 2001. 870. Watkins SP, de Lemos JA, Tokol G, Mahoney E, Yegin A, Alexopoulos C, Goldsman D, Goldsman P, Bunt T, Deuson R, Cannon CP, Hamm C, Weintraub W. Cost-effectiveness analysis of tirofiban use in acute coronary syndromes. Circulation. 2001; 104(Suppl II):798. 871. Cannon CP. What's hot in acute coronary syndromes?. 2001. 872. Cannon CP. What are right TACTICS for treatment acute coronary syndromes?. 2001. 873. Cannon CP. Commentary on GUSTO IV-ACS. Evid Based Cardiovasc Med. 2001; 5:131. 874. Foody JM, editor. Preventive cardiology: Strategies for the prevention and treatment of coronary artery disease. Cannon CP, series editor. Contemporary Cardiology. 2001; 366. 875. Cannon CP. TIMI risk calculator. 2001. 876. Cannon CP, O'Gara PT. Goals, design and implementation of critical pathways in cardiology. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiology. 2001; 3-6. 877. Jurkovitz C, Mahoney EM, Chu H, Robertson DH, Demopoulos L, DiBattiste P, Alexander C, Cannon CP, Weintraub WS. The effect of conservative vs. invasive strategy on outcomes of acute coronary syndromes in diabetics. Diabetes. 2001. 878. Simon DI, Rogers C, editors. Vascular disease and injury: Preclinical research. Cannon CP, series editor. Contemporary Cardiology. 2001; 347. 879. Cannon CP. Cath lab for all patient with unstable angina or non-ST-segment elevation myocardial infarction?. 2001. 880. Cannon CP, Fuster V. Thrombogenesis, antithrombotic and thrombolytic therapy. Fuster V, Alexander RW, O'Rourke R, Roberts RA, King SB III, Wellens HJJ, editors. Hurst's the Heart. 2001; 1373-436. 881. Cannon CP. Antithrombotic therapy within three months of acute coronary syndromes. 2001. 882. Cannon CP, Moliterno DJ. New pharmacologic strategies for acute myocardial infarction. 2001. 883. Cannon CP, Richards CF. Emergency department critical pathways for acute coronary syndromes. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiology. 2001; 15-22. 884. Cannon CP, Ornato J. ACS ACTION: Acute cardiac team to improve optimal treatment now. 2001. 885. Cannon CP, Gibson CM, Braunwald E, Antman EM, Ornato J. Integrating the TIMI risk score into ACS. 2001. 886. Cannon CP, McCabe CH, Antman EM, Bentley J, Rifai N, Braunwald E. Are there high-risk patients who are troponin negative? Further risk stratification with the TIMI risk score in patients with acute coronary syndromes: Results from OPUS-TIMI 16. J Am Coll Cardiol. 2001; 37(Suppl A):326. 887. Cannon CP, Gibson CM, Topol EJ, Ornato JP, Weintraub WS, King S. New pathways for aggressive management of ACS. 2001. 888. Topol EJ, Cannon CP, Moliterno D. Provocative new data in PCI. 2001. 889. Cannon CP, Alharethi R, O'Gara PT. Critical pathways for acute coronary syndromes. Becker RC, Alpert JS, editors. Cardiovascular Medicine: Practice and Management. 2001; 263-74. 890. Cannon CP. TIMI risk calculator. 2001. 891. Stone GW, Cannon CP, Chronos NA, Ferguson JJ, Gibson CM, King SB, Yeung AC. Therapeutic strategies in acute coronary syndromes: An integrated approach. 2001. 892. Cannon CP, O'Gara PT, editors. Critical Pathways in Cardiology. 2001; 259. 893. Cannon CP. ACS: Tiroban study shows routine catheterization best. 2001. 894. Johnstone MT, Veves A, editors. Diabetes and cardiovascular disease. Cannon CP, series editor. Contemporary Cardiology. 2001; 438. 895. Gibson CM, Murphy S, Cannon C, Braunwald E. Balloon size in percutaneous intervention is associated with abnormal myocardial perfusion: A TACTICS-TIMI 18 angiographic substudy. Eur Heart J. 2001; 22(Suppl):285. 896. Cannon CP, Topol EJ. Getting it right from the start: Unlocking the ER and CCU. 2001. 897. Cannon CP. Case presentation in hypertension. 2001. 898. Jurkovitz C, Mahoney EM, Spertus J, Chu H, Alexander C, Robertson D, Demopoulos L, DiBattiste P, Cannon C, Weintraub WS. Changes in Seattle Angina Questionnaire (SAQ) following treatment for acute coronary syndromes: A follow-up evaluation from the TACTICS-TIMI 18 trial. Eur Heart J. 2001; 22(Suppl):718. 899. Mahoney EM, Jurkovitz C, Chu H, Alexander C, Demopoulos L, DiBattiste P, Robertson D, Cannon C, Weintraub WS. Length of stay for the treatment of acute coronary syndromes: international experience from the TACTICS-TIMI 18 trial. Eur Heart J. 2001; 22(Suppl):223. 900. Cannon CP, Weintraub WS, Demopoulos L, DiBattiste P, Robertson DH, DeLucca PT, McCabe CH, Antman EM, Braunwald E, for the TACTICS-TIMI 18 Investigators. TIMI risk score to predict 6 month mortality, recurrent cardiac events, and relative benefit of invasive vs. conservative strategy in patients with unstable angina: Results from TACTICS-TIMI 18. J Am Coll Cardiol. 2001; 37(Suppl A):335. 901. Gibson CM, Anshelevich M, Murphy S, Luu L, Hynes C, Kliris J, Kermgard S, Otten MH, Antman EM, Cannon CP, Braunwald E. Impact of injections during diagnostic coronary arteriography on coronary patency in the setting of acute myocardial infarction from the TIMI trials. Thrombolysis In Myocardial Infarction. Am J Cardiol. 2000 Dec 15; 86(12):1378-9, A5. 902. Cannon CP. Exploring the issues of appropriate dosing in the treatment of acute myocardial infarction: potential benefits of bolus fibrinolytic agents. Am Heart J. 2000 Dec; 140(6 Suppl):S154-60. 903. Morrow DA, Antman EM, Tanasijevic M, Rifai N, de Lemos JA, McCabe CH, Cannon CP, Braunwald E. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol. 2000 Nov 15; 36(6):1812-7. 904. Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CM. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation. 2000 Nov 7; 102(19):2329-34. 905. Cannon CP. Multimodality reperfusion therapy for acute myocardial infarction. Am Heart J. 2000 Nov; 140(5):707-16. 906. Cannon CP. Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials. Clin Cardiol. 2000 Nov; 23 Suppl 6:VI-14-7. 907. Richards CF, Cannon CP. Reducing medication errors: potential benefits of bolus thrombolytic agents. Acad Emerg Med. 2000 Nov; 7(11):1285-9. 908. Cannon CP, Sayah AJ, Walls RM. ER TIMI-19: testing the reality of prehospital thrombolysis. J Emerg Med. 2000 Oct; 19(3 Suppl):21S-25S. 909. Cannon CP. Elderly Patients with Acute Coronary Syndromes: Higher Risk and Greater Benefit from Antithrombotic and Interventional Therapies. Am J Geriatr Cardiol. 2000 Oct; 9(5):265-270. 910. McKay CR, Rich MW, Vlietstra RE, Kitzman DW, Fleg JL, Krumholz HM, Lakatta EG, Cooke JP, Cannon CP, Ezekowitz MD, Frohlich ED, Jalife J, Kass DA, Kottke BA, Muller JE, Saltin B, Shen WK, Somers VK. Executive Summary: Pivotal Research in Cardiovascular Syndromes in the Elderly. Am J Geriatr Cardiol. 2000 Oct; 9(5):243-250. 911. Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, Lopez-Sendon J, Toman J, Charlesworth A, Anders RJ, Alexander JC, Skene A, Braunwald E. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000 Jul 11; 102(2):149-56. 912. Llevadot J, Giugliano RP, McCabe CH, Cannon CP, Antman EM, Murphy S, Gibson CM. Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials). Am J Cardiol. 2000 Jun 15; 85(12):1409-13. 913. Cannon CP, Gibson CM, Lambrew CT, Shoultz DA, Levy D, French WJ, Gore JM, Weaver WD, Rogers WJ, Tiefenbrunn AJ. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000 Jun 14; 283(22):2941-7. 914. Coulter SA, Cannon CP, Ault KA, Antman EM, Van de Werf F, Adgey AA, Gibson CM, Giugliano RP, Mascelli MA, Scherer J, Barnathan ES, Braunwald E, Kleiman NS. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. Circulation. 2000 Jun 13; 101(23):2690-5. 915. Zalenski RJ, Selker HP, Cannon CP, Farin HM, Gibler WB, Goldberg RJ, Lambrew CT, Ornato JP, Rydman RJ, Steele P. National Heart Attack Alert Program position paper: chest pain centers and programs for the evaluation of acute cardiac ischemia. Ann Emerg Med. 2000 May; 35(5):462-71. 916. Modi NB, Fox NL, Clow FW, Tanswell P, Cannon CP, Van de Werf F, Braunwald E. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. J Clin Pharmacol. 2000 May; 40(5):508-15. 917. Cannon CP. Thrombolysis medication errors: benefits of bolus thrombolytic agents. Am J Cardiol. 2000 Apr 27; 85(8A):17C-22C. 918. Cannon CP. Bridging the gap with new strategies in acute ST elevation myocardial infarction: bolus thrombolysis, glycoprotein IIb/IIIa inhibitors, combination therapy, percutaneous coronary intervention, and "facilitated" PCI. J Thromb Thrombolysis. 2000 Apr; 9(3):235-41. 919. Holmes MB, Sobel BE, Cannon CP, Schneider DJ. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction. Am J Cardiol. 2000 Feb 15; 85(4):491-3, A10. 920. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, Braunwald E. Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy. J Am Coll Cardiol. 2000 Feb; 35(2):358-62. 921. Every NR, Hochman J, Becker R, Kopecky S, Cannon CP. Critical pathways : a review. Committee on Acute Cardiac Care, Council on Clinical Cardiology, American Heart Association. Circulation. 2000 Feb 1; 101(4):461-5. 922. Cannon CP. Defining acute myocardial infarction by ST segment deviation. Eur Heart J. 2000 Feb; 21(4):266-7. 923. Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, McCabe CH, Van De Werf F, Braunwald E. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000 Jan 18; 101(2):125-30. 924. Braunwald E, Califf RM, Cannon CP, Fox KA, Fuster V, Gibler WB, Harrington RA, King SB, Kleiman NS, Theroux P, Topol EJ, Van de Werf F, White HD, Willerson JT. Redefining medical treatment in the management of unstable angina. Am J Med. 2000 Jan; 108(1):41-53. 925. Loscalzo J, Vita JA, editors. Nitric oxide and the cardiovascular system. Cannon CP, series editor. Contemporary Cardiology. 2000; 601. 926. Cannon CP. Application of the NHAAP guidelines in chest pain emergency department. 2000. 927. Cannon CP. What is new in acute coronary syndromes?. 2000. 928. Cannon CP. The 4th global use of strategies to open occluded arteries in acute coronary syndromes (GUSTO IV-ACS): What happened?. Pfeffer M, editor. Cardiology Scientific Update. 2000; 1-6. 929. Cannon CP, Ganz LI, Stone PH. Complicated myocardial infarction. Irwin RS, Cerra FB, Rippe JM, editors. Manual of Intensive Care Medicine. 2000. 930. Cannon CP, Gibson CM, Lambrew CT, Tiefenbrunn AJ, Sun H, Malmgren HJ, Frederick P, Every NR, Zalenski R, for the NRMI 2 and 3 Investigators. Longer thrombolysis door-to-needle times are associated with increased mortality in acute myocardial infarction: An analysis of 85,589 patients in the national registry of myocardial infarction 2+3. J Am Coll Cardiol. 2000; 35(Suppl A):376. 931. Cannon CP. Combination thrombolytic and antiplatelet therapy. 2000. 932. Sharis P, Cannon CP, McCabe CH, Charlesworth A. Prior aspirin use is a univariate, but NOT a multivariate predictor of 1 year mortality in 10,302 patients with acute coronary syndromes: Results from OPUS-TIMI 16. J Am Coll Cardiol. 2000; 35(Suppl A):391. 933. Cannon CP. Optimizing fibrinolytic therapy in acute myocardial infarction. 2000. 934. Cannon CP. Unresolved question in acute coronary syndromes: Rationale for the PROVE IT trial: Future directions in atherosclerosis. 2000. 935. Cannon CP. New antiplatelet therapies. 2000. 936. Cannon CP, Ganz LI, Stone PH, Becker RC. Complicated myocardial infarction. Irwin RS, Cerra FB, Rippe JM, editors. Manual of Intensive Care Medicine. 2000; 185-93. 937. Cannon CP. TACTICS TIMI 18. 2000. 938. Cannon CP. Case study: Combination GP IIb/IIIa inhibitor plus reduced-dose thrombolytic therapy for acute myocardial infarction. 2000. 939. Cannon CP, Stone PH. Acute myocardial infarction. Carruthers SG, Hoffman BB, Melmon KL, Nierenberg, DW, editors. Melmon and Morrelli's Clinical Pharmacology: Basic Principles in Therapeutics. 2000; 131-56. 940. de Lemos JA, Cannon CP. Angina and coronary heart disease. Sirtori C, editor. Clinical Pharmacology. 2000; 269-85. 941. Cannon CP. The success and failure of glycoprotein IIb/IIIa receptor blockers. 2000. 942. Braunwald E, Topol EJ, Cannon CP, Jesse RL, Ohman EM, White HD. Acute coronary syndromes town hall meeting: Applying clinical trials to clinical practice. 2000. 943. Cannon CP. Pharmacology overview platelet glycoprotein IIb/IIIa inhibitors. 2000. 944. Cannon CP. Case history: Non-ST elevation myocardial infarction. 2000. 945. Cannon CP. A 1999 approach to unstable angina. 2000. 946. Cannon CP. Targeting high-risk patient subsets in acute coronary syndromes: Greater benefit from antithrombotic and interventional therapies. ACS. 2000; 3:42-50. 947. The ESPRIT Investigators. Enhanced supression of the platelet IIb/IIIa receptor with integrilin therapy: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial (CP Cannon, Chairman, Data Safety Monitoring Board). Lancet. 2000; 356:2037-44.. 948. Cannon CP. Breaking the thrombolytic barrier: Combining glycoprotein IIb/IIIa receptor inhibitors with thrombolytic therapy in the treatment of acute myocardial infarction. Cardiovasc Rev Rep. 2000; 21:595-601. 949. Cannon CP. Emerging role of clopidogrel as the cornerstone of treatment in acute coronary syndromes. Cannon CP, editor. Presentations in Focus: Extending Antiplatelet Protection: Optimal Strategies to Reduce Thrombotic Risk. 2000. 950. Cannon CP. Quick reference cards: ACC/AHA unstable angina guidelines. 2000. 951. Gibson CM, Murphy SA, Rizzo MJ, Ryan KA, Marble SJ, McCabe CH, Cannon CP, van de Werf F, Braunwald E. Is the corrected TIMI frame count an independent predictor of adverse outcome?. Circulation. 2000; 102:e19. 952. Quality of Care and Outcomes Research in CVD and Stroke Working Groups (Cannon CP, Member, Acute Myocardial Infarction Working Group). Measuring and improving quality of care. A report for the AHA/ACC First Scientific Forum on Assessment of Healthcare Quality in Cardiovascular Disease and Stroke. Circulation. 2000; 101:1483-93. 953. Cannon CP. Thrombolytic medication dosing errors. 2000. 954. Moliterno D, Cannon CP, Ohman EM, Spinler SA. Improving strategies and outcomes. The Evolving Management of Atherothrombotic and Occlusive Vascular Diseases. 2000. 955. Cannon CP. The evolving story of oral platelet glycoprotein IIb/IIIa inhibitors. Curr Opin Card Pulm Renal Invest Drug. 2000; 2:114-23. 956. Cannon CP. Oral platelet glycoprotein IIb/IIIa receptor blockers. In: Ferguson JJ, Chronos NAF, Harrington RA, editors. Antiplatelet Therapy in Clinical Practice. 2000; 163-80. 957. Cannon CP. Global use of strategies: To open occluded arteries (GUSTO) IV in acute coronary syndromes (ACS): What happened?. 2000. 958. Cannon CP, Farkouh M, Gibler B. Guidelines in chest pain emergency departments: The experience and future. 2000. 959. Cannon CP. Late-breaking trial of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: ESPRIT, PARAGON B, and Second Symphony Series. Pfeffer MA, series editor. Cardiology Scientific Update. 2000. 960. Cannon CP, Giugliano RP. TNK-tPA (tenecteplase): The single bolus thrombolytic agent for the new millenium. Pfeffer MA, series editor. Cardiology Scientific Update. 2000. 961. Cannon CP. Acute coronary syndromes: More aggressive is better. 2000. 962. Cannon CP. Evidence points to role of bolus fibrinolytic agents in reducing medication errors. New Era Reperfusion. 2000; 4:1-7. 963. Cannon CP. Oral platelet glycoprotein IIb/IIIa receptor inhibitors: Why have they failed so far?. 2000. 964. Sharis PJ, Cannon DP, editors. Evidence-based Cardiology. 2000; 368. 965. Scirica BM, Moliterno DJ, Every NR, Anderson HV, Aguirre FV, Granger CB, Lambrew CT, Rabbani LE, Sapp SK, Booth JE, Ferguson JJ, Cannon CP. Racial differences in the management of unstable angina: results from the multicenter GUARANTEE registry. Am Heart J. 1999 Dec; 138(6 Pt 1):1065-72. 966. Cannon CP. Glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST segment elevation myocardial infarction. Coron Artery Dis. 1999 Dec; 10(8):561-6. 967. Scirica BM, Moliterno DJ, Every NR, Anderson HV, Aguirre FV, Granger CB, Lambrew CT, Rabbani LE, Arnold A, Sapp SK, Booth JE, Ferguson JJ, Cannon CP. Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry). The GUARANTEE Investigators. Am J Cardiol. 1999 Nov 15; 84(10):1145-50. 968. Cannon CP. Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction. J Am Coll Cardiol. 1999 Nov 1; 34(5):1395-402. 969. Gibson CM, Cannon CP, Murphy SA, Adgey AA, Schweiger MJ, Sequeira RF, Grollier G, Fox NL, Berioli S, Weaver WD, Van de Werf F, Braunwald E. Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators. Am J Cardiol. 1999 Nov 1; 84(9):976-80. 970. Gibson CM, Murphy S, Menown IB, Sequeira RF, Greene R, Van de Werf F, Schweiger MJ, Ghali M, Frey MJ, Ryan KA, Marble SJ, Giugliano RP, Antman EM, Cannon CP, Braunwald E. Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1999 Nov 1; 34(5):1403-12. 971. Cannon CP. Diagnosis and management of patients with unstable angina. Curr Probl Cardiol. 1999 Nov; 24(11):681-744. 972. Gibson CM, Ryan KA, Murphy SA, Mesley R, Marble SJ, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction. J Am Coll Cardiol. 1999 Oct; 34(4):974-82. 973. Cannon CP. Low molecular weight heparin in acute coronary syndromes. Curr Cardiol Rep. 1999 Sep; 1(3):206-11. 974. Tanasijevic MJ, Cannon CP, Antman EM, Wybenga DR, Fischer GA, Grudzien C, Gibson CM, Winkelman JW, Braunwald E. Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the Thrombolysis in Myocardial Infarction study (TIMI) 10B. J Am Coll Cardiol. 1999 Sep; 34(3):739-47. 975. Cannon CP. Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction. Clin Cardiol. 1999 Aug; 22(8 Suppl):IV30-6. 976. Cannon CP. Combination therapy for acute myocardial infarction: glycoprotein IIb/IIIa inhibitors plus thrombolysis. Clin Cardiol. 1999 Aug; 22(8 Suppl):IV37-43. 977. Cannon CP. Breaking the therapeutic barriers: new strategies for acute coronary syndromes. Clin Cardiol. 1999 Aug; 22(8 Suppl):IV1-2. 978. Cannon CP, Sayah AJ, Walls RM. Prehospital thrombolysis: an idea whose time has come. Clin Cardiol. 1999 Aug; 22(8 Suppl):IV10-9. 979. Modi NB, Novotny W, Reimann JD, Cannon CP, Braunwauld E. Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndrome. J Clin Pharmacol. 1999 Jul; 39(7):675-84. 980. Gibson CM, Ryan KA, Kelley M, Rizzo MJ, Mesley R, Murphy S, Swanson J, Marble SJ, Dodge JT, Giugliano RP, Cannon CP, Antman EM. Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results. The TIMI Study Group. Am Heart J. 1999 Jun; 137(6):1179-84. 981. Van de Werf F, Cannon CP, Luyten A, Houbracken K, McCabe CH, Berioli S, Bluhmki E, Sarelin H, Wang-Clow F, Fox NL, Braunwald E. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am Heart J. 1999 May; 137(5):786-91. 982. Gibson CM, Murphy SA, Rizzo MJ, Ryan KA, Marble SJ, McCabe CH, Cannon CP, Van de Werf F, Braunwald E. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation. 1999 Apr 20; 99(15):1945-50. 983. Cannon CP. Advances in the medical management of acute coronary syndromes. J Thromb Thrombolysis. 1999 Apr; 7(2):171-89. 984. Dracup KA, Cannon CP. Combination treatment strategies for management of acute myocardial infarction: New directions with current therapies. Crit Care Nur. 1999; Suppl:3-15. 985. Ault KA, Cannon CP, Mitchell J, McCahan J, Tracy RP, Novotny WF, Reimann JD, Braunwald E. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1999 Mar; 33(3):634-9. 986. Cannon CP, Dingemanse J, Kleinbloesem CH, Jannett T, Curry KM, Valcke CP. Automated heparin-delivery system to control activated partial thromboplastin time: evaluation in normal volunteers. Circulation. 1999 Feb 16; 99(6):751-6. 987. Becker RC, Hochman JS, Cannon CP, Spencer FA, Ball SP, Rizzo MJ, Antman EM. Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study. J Am Coll Cardiol. 1999 Feb; 33(2):479-87. 988. Weintraub WS, Culler SD, Kosinski A, Becker ER, Mahoney E, Burnette J, Spertus JA, Feeny D, Cohen DJ, Krumholz H, Ellis SG, Demopoulos L, Robertson D, Boccuzzi SJ, Barr E, Cannon CP. Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban]] and Determine Cost of Therapy with Invasive or Conservative Strategy)-TIMI 18 trial. Am J Cardiol. 1999 Feb 1; 83(3):317-22. 989. Cannon CP. Timely thrombolysis: synergism to open arteries and reduce mortality rates. Am Heart J. 1999 Jan; 137(1):1-3. 990. Tanasijevic MJ, Cannon CP, Antman EM. The role of cardiac troponin-I (cTnI) in risk stratification of patients with unstable coronary artery disease. Clin Cardiol. 1999 Jan; 22(1):13-6. 991. Kizer JR, Cannon CP, McCabe CH, Mueller HS, Schweiger MJ, Davis VG, Perritt R, Antman EM. Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Infarct Size. Thrombolysis in Myocardial Infarction. Am Heart J. 1999 Jan; 137(1):79-92. 992. Cannon CP, Johnson EB, Cermignani M, Scirica BM, Sagarin MJ, Walls RM. Emergency department thrombolysis critical pathway reduces door-to-drug times in acute myocardial infarction. Clin Cardiol. 1999 Jan; 22(1):17-20. 993. Lincoff AM, Topol EJ, editors. Platelet glycoprotein IIb/IIIa inhibitors in cardiovascular disease. Cannon CP, series editor. Contemporary Cardiology. 1999; 368. 994. Cannon CP. Bolus thrombolysis in the new millennium. 1999. 995. Cannon CP. Overcoming thrombolytic resistance. 1999. 996. Tanasijevic MJ, Cannon CP, Antman EM, Wybenga DR, Fischer GA, Grudzien C, Gibson CM, Winkelman JW, Braunwald E for the TIMI 10B Investigators. Myoglobin, CK-MB and cardiac troponin - I - 60 minute ratios predict infarct related artery patency after thrombolysis for acute myocardial infarction: Results from TIMI 10B. J Am Coll Cardiol. 1999; 34:739-47.. 997. Hochman JS, Becker RC, Berger PP, Borzak S, Califf RM, Cannon CP, Every NR, Gibler WB, Grines CL, Kopecky SL, Newby LK, Ohman EM, O'Neill WW, Ornato JP Weaver WD. Best practices for treating acute myocardial infarction. 1999. 998. Cannon CP, O'Gara PT. Critical pathways for acute coronary syndromes. 1999. 999. de Lemos JA, Cannon CP. Improving reperfusion in acute myocardial infarction: Glycoprotein IIb/IIIa receptor inhibitors and percutaneous revascularization as adjuncts to thrombolytic therapy. 1999. 1000. Cannon CP. The era of platelet glycoprotein IIb/IIIa inhibition: Overview. Cor Art Dis. 1999; 10:545-6. 1001. Cannon CP. Expanding the treatment paradigm for acute myocardial infarction with GP IIb/IIIa inhibitors. New Era of Reperfusion. 1999; 3:1-12. 1002. Casey M, Fornari C, Bozovich GE, Iglesias Varela ML, Mautner B, Cannon CP. Increased expression of platelet p-selectin in patients treated with oral orbofiban in the OPUS TIMI 16 Study. Circulation. 1999; 100(Suppl I):681. 1003. Cannon CP, Ornato JP, Antman EM, Braunwald E, Topol EJ, Willerson JT. New perspectives in cardiac care: Thrombolysis 98. 1999. 1004. Cannon CP. Clinical value of the troponins in acute coronary syndromes. 1999. 1005. Cannon CP, Herrmann H, Ohman EM, Coussement PK, Moliterno DJ, Topol EJ. Bolus thrombolytics erduce medication errors. Medi-Fax. 1999. 1006. Cannon CP, Loscalzo J. Thrombolytic and antithrombotic therapies for acute coronary syndromes. Gorlin R, Dangas GD, Toutouzas PK, Konstadoulakis MM, editors. Contemporary Concepts in Cardiology: Pathophysiology and Clinical Management. 1999; 142-175. 1007. Blake TM, editor. Annoted atlas of electrocardiography. Cannon CP, series editor. Contemporary Cardiology. 1999; 368. 1008. Cannon CP. Case study: "The heart attack" or "A midsummer's night drive". 1999. 1009. Cannon CP. Review of Textbook of Cardiovascular Medicine. Circulation. 1999; 100:566-7. 1010. Cannon CP, Braunwald E. The spectrum of myocardial ischemia: The paradigm of acute coronary syndromes. Cannon CP, editor. Management of Acute Coronary Syndromes. 1999; 3-18. 1011. Cannon CP. The international TIMI 14 trial: Final results. 1999. 1012. Cannon CP. Low molecular weight heparin in acute coronary syndromes. 1999. 1013. Cannon CP. Sibrafiban. Drugs. 1999; 57:231-2. 1014. Cannon CP. Optimizing the medical management of acute coronary syndromes. J Thromb Thrombolysis. 1999; 7:171-89. 1015. Ericsson CD, Cannon CP, Deutsch E. Unstable angina: Diagnosis and management. 1999. 1016. Cannon CP. A balanced approach to reperfusion therapy. 1999. 1017. Fisher G, Cannon CP, Tanasijevic M. Clinical effectiveness of cardiac markers as indicators of coronary artery patency after thrombolysis for acute myocardial infarction. 1999. 1018. Fox NL, Cannon CP, Berioli S, Wang-Clow F, Danays T, Sarelin H, Braunwald E, Van de Werf F. Rates of serious bleeding requiring transfusion in AMI patients treated with TNK-tPA. J Am Coll Cardiol. 1999; 33(Suppl A):353. 1019. Cannon CP. Case study: Use of combination IIb/IIIa inhibition and reduced dose thrombolysis for acute myocardial infarction. 1999. 1020. Cannon CP, Caprini JA, Merli GJ, Hawkins D. Differentiation of low molecular weight heparins: Clinical and economic implications of treatment. 1999. 1021. Cannon CP, editor. Management of Acute Coronary Syndromes. 1999. 1022. Oz MC, Goldstein DJ, editors. Minimally invasive cardiac surgery. Cannon CP, series editor. Contemporary Cardiology. 1999; 237. 1023. Cannon CP, Barnathan E, Fowles R, Jordan R. ReoPro: A powerful and versatile agent in ACS. 1999. 1024. Kereiakes DJ, Cannon CP. Oral platelet glycoprotein IIb/IIIa blockade. Lincoff AM, Topol EJ, editors. Platelet IIb/IIIa Inhibitors in Cardiology. 1999; 287-314. 1025. Cannon CP, Rizzo MJ, Antman EM, McCabe CH, Gibson CM, Braunwald E. Validation of a multivariate model for risk stratification in acute MI: Results from TIMI 9B. J Am Coll Cardiol. 1999; 33(Suppl A):396. 1026. Cannon CP, O'Gara PT. Critical pathways in acute coronary syndromes. Cannon CP, editor. Management of Acute Coronary Syndromes. 1999; 611-27. 1027. Cannon CP. Platelet glycoprotein IIb/IIIa receptor inhibitors in the management of acute coronary syndromes and coronary intervention. Braunwald E, editor. Heart Disease Updates. 1999; 1-10. 1028. Coulter SA, McCabe CH, Giugliano RP, Cutler SS, Charlesworth A, Chew PH, Cannon CP. Dosing errors and outcomes in patients receiving single bolus compared to bolus + infusion thrombolytic regimens: An InTIME-II Study. Circulation. 1999; 100(Suppl I):791. 1029. Cannon CP. The era of platelet glycoprotein IIb/IIIa inhibition. Cannon CP, editor. Cor Art Dis. 1999; 10:545-94. 1030. Cannon CP. Thrombolysis and medication errors. 1999. 1031. Cannon CP. Focus on fragmin. 1999. 1032. Cannon CP. New strategies for the treatment of acute coronary syndromes. Pfeffer MA, series editor. Cardiology Scientific Update. 1999. 1033. Cannon CP. The TIMI 11B troponin substudy. 1999. 1034. Cannon CP, Braunwald E. TIMI IIB. Fuster V, Nash IS, editors. Efficacy of Myocardial Infarction Therapy: An Evaluation of Clinical Trials Evidence. 1999; 437-452. 1035. Cannon CP. Thrombolysis and medication errors. 1999. 1036. Cannon CP. Door-to-balloon time versus mortality in patients with acute myocrdial infarction treated with primary angioplasty. 1999. 1037. Cannon CP. Clinical trial updates in coronary artery disease. Curr Op Cardiol. 1999; 14:359. 1038. Cannon CP, Gibson CM, McCabe CH, Adgey AA, Schweiger MJ, Sequeira RF, Grollier G, Giugliano RP, Frey M, Mueller HS, Steingart RM, Weaver WD, Van de Werf F, Braunwald E. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation. 1998 Dec 22-29; 98(25):2805-14. 1039. Cannon CP. The Ten Most Commonly Asked Questions about Platelet Glycoprotein IIb/IIIa Receptor Antagonists. Cardiol Rev. 1998 Oct; 6(5):252-254. 1040. Cannon CP, Weintraub WS, Demopoulos LA, Robertson DH, Gormley GJ, Braunwald E. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction. Am J Cardiol. 1998 Sep 15; 82(6):731-6. 1041. Cannon CP. Advances in the medical management of acute coronary syndromes. Curr Opin Cardiol. 1998 Sep; 13(5):327-47. 1042. Kloner RA, Przyklenk K, Shook T, Cannon CP. Protection Conferred by Preinfarct Angina is Manifest in the Aged Heart: Evidence from the TIMI 4 Trial. J Thromb Thrombolysis. 1998 Sep; 6(2):89-92. 1043. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med. 1998 Sep 1; 129(5):394-405. 1044. Every NR, Cannon CP, Granger C, Moliterno DJ, Aguirre FV, Talley JD, Booth J, Sapp S, Ferguson JJ. Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE Registry. Global Unstable Angina Registry and Treatment Evaluation. J Am Coll Cardiol. 1998 Aug; 32(2):387-92. 1045. Cannon CP. Time to treatment of acute myocardial infarction revisited. Curr Opin Cardiol. 1998 Jul; 13(4):254-66. 1046. Cannon CP, Smith M. Advances in Alliteration in Acute Myocardial Infarction: From "Time to Treatment" to "Onset to Opening" J Thromb Thrombolysis. 1998 Jul; 6(1):5-7. 1047. Sagarin MJ, Cannon CP, Cermignani MS, Scirica BM, Walls RM. Delay in thrombolysis administration: causes of extended door-to-drug times and the asymptote effect. J Emerg Med. 1998 Jul-Aug; 16(4):557-65. 1048. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, Braunwald E. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1998 Jun; 31(7):1460-5. 1049. Goel M, Dodge Jr , Rizzo M, McLean C, Ryan KA, Daley WL, Cannon CP, Gibson CM. The Open Artery Hypothesis: Past, Present, and Future. J Thromb Thrombolysis. 1998 May; 5(2):101-112. 1050. Canon CP. "Super-aggressive" management of acute myocardial infarction. Medical Roundtable. 1998; 3-4. 1051. Cannon CP. The right mix for improve acute myocardial infarction survival: Pre-hospital bolus thrombolysis, lytics + PTCA + GP IIb/IIIa inhibitors. Medical Roundtable. 1998. 1052. Cannon CP. Bolus thrombolysis: r-PA, t-PA, n-PA. Medical Roundtable. 1998; 4-5. 1053. Kloner RA, Shook T, Antman EM, Cannon CP, Przyklenk K, Yoo K, McCabe CH, Braunwald E. Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9B. Circulation. 1998 Mar 24; 97(11):1042-5. 1054. Borzak S, Cannon CP, Kraft PL, Douthat L, Becker RC, Palmeri ST, Henry T, Hochman JS, Fuchs J, Antman EM, McCabe C, Braunwald E. Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia. Am J Cardiol. 1998 Mar 15; 81(6):678-81. 1055. Cannon CP. Reteplase was not better than alteplase in reducing 30-day mortality among patients with acute MI. Evid Based Cardiovasc Med. 1998 Mar; 2(1):16-7. 1056. Cannon CP. Double-bolus alteplase was not equivalent to accelerated infusion in patients with acute MI. Evid Based Cardiovasc Med. 1998 Mar; 2(1):16-7. 1057. Wieczorek RR, Price MR, Cannon C. A pharmacology review for private duty nurses using computers and self learning concepts. J Nurs Staff Dev. 1998 Mar-Apr; 14(2):95-7. 1058. Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. Circulation. 1998 Feb 3; 97(4):340-9. 1059. Antman EM, Sacks DB, Rifai N, McCabe CH, Cannon CP, Braunwald E. Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy. J Am Coll Cardiol. 1998 Feb; 31(2):326-30. 1060. Modi NB, Eppler S, Breed J, Cannon CP, Braunwald E, Love TW. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. Thromb Haemost. 1998 Jan; 79(1):134-9. 1061. Tracy RP, Kleiman NS, Thompson B, Cannon CP, Bovill EG, Brown RG, Collen D, Mahan E, Mann KG, Rogers WJ, Sopko G, Stump DC, Williams DO, Zaret BL. Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. Am Heart J. 1998 Jan; 135(1):29-37. 1062. Cannon CP. ST depression V1-V2: Anterior ischemia of posterior infarction?. 1998. 1063. Cannon CP. Aggrastat to treat unstable angina. Curr Pract Med. 1998; 1:55-58. 1064. Ericsson CD, Cannon CP, Deutsch E. Unstable angina: Diagnosis and management. 1998. 1065. Block PC, Cannon CP. IIb/IIIa inhibition in acute coronary syndromes. 1998. 1066. de Lemos JA, Cannon CP. Reocclusion after AMI: Glycoprotein IIb/IIIa receptor inhibitors and percutaneous revascularization as adjuncts to thrombolytic therapy. Callif RM, editor. Thrombolytic Therapy: New Standards of AMI/ACS Care, Part 6: Patients with Complicating Cardiac Conditions. 1998; 3-11. 1067. Cannon CP. Incorporating IIb/IIIa inhibitors into today's critical pathways. 1998. 1068. Cannon CP. What is the evidence that chest pain centers improve outcomes and cost-effectiveness?. 1998. 1069. Cannon CP. Spectrum of acute coronary syndromes: The paradigm of myocardial ischemia. 1998. 1070. Cannon CP. Commentary on GUSTO III and COBALT. Evidence-based Cardiovascular Medicine. 1998; 2:17. 1071. Cannon CP, Bray PF, Ault KA, Rizzo MJ, Braunwald E. PIA2 polymorphism of the platelet IIb/IIIa receptor: Increased risk of early recurrent ischemic events in acute coronary syndromes, increased platelet aggregability, and effective platelet inhibition by an oral IIb/IIIa inhibitor: Results from TIMI 12. Circulation. 1998; 98(Suppl I):171. 1072. Cannon CP. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Cardiology Rounds. 1998; 2:1-8. 1073. Boden WE, O'Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zoble RG, Wexler LF, Pepine CJ, Ferry DR, Chow BK, Lavori PW, for the Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators (CP Cannon, Chairman, Endpoints Committee) . Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative strategy. N Engl J Med. 1998; 338:1785-92.. 1074. Cannon CP, Krakowski FM. Diagnosis and therapy of acute myocardial infarction: Today's look at tomorrow's therapies and outcomes. 1998. 1075. Cannon CP. Prehospital management of acute myocardial infarction. Topol EJ, editor. Cardiovascular Thrombosis: Thrombocardiology and Thromboneurology. 1998; 485-98. 1076. Rizzo MJ, Ryan K, Cannon CP, Braunwald E. Onset of chest pain between 6PM and 6AM is associated with poorer outcomes following thrombolysis. Circulation. 1998; 98(Suppl I):764. 1077. Callas PW, Tracy RP, Bovill EG, Cannon CP, Braunwald E. The association of anticoagulant protein concentrations with acute myocardial infarction in the Thrombolysis In Myocardial Infarction Phase II (TIMI II) Trial. J Thromb Thrombolysis. 1998; 5:53-60.. 1078. Cannon CP. Bolus thrombolysis: r-PA, t-PA, n-PA and TNK-tPA. New Era of Reperfusion. 1998; 2:1-3. 1079. Cannon CP. Case history of non-ST elevation myocardial infarction. 1998. 1080. Gibson CM, Dodge JT, Goel M, Al-Mousa EN, Rizzo M, McLean C, Ryan K, Sparano A, Marble SJ, Daley WL, Cannon CP, Antman EM. Angioplasty guidewire velocity: a new simple method to calculate absolute coronary blood velocity and flow. Am J Cardiol. 1997 Dec 15; 80(12):1536-9. 1081. Cannon CP. Clinical perspectives on the use of composite endpoints. Control Clin Trials. 1997 Dec; 18(6):517-29; discussion 546-9. 1082. Nichol G, Walls R, Goldman L, Pearson S, Hartley LH, Antman E, Stockman M, Teich JM, Cannon CP, Johnson PA, Kuntz KM, Lee TH. A critical pathway for management of patients with acute chest pain who are at low risk for myocardial ischemia: recommendations and potential impact. Ann Intern Med. 1997 Dec 1; 127(11):996-1005. 1083. Tanasijevic MJ, Cannon CP, Wybenga DR, Fischer GA, Grudzien C, Gibson CM, Winkelman JW, Antman EM, Braunwald E. Myoglobin, creatine kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction: results from TIMI 10A. Am Heart J. 1997 Oct; 134(4):622-30. 1084. Cannon CP, Sharis PJ, Schweiger MJ, McCabe CH, Diver DJ, Shah PK, Sequeira RF, Greene RM, Perritt RL, Poole WK, Braunwald E. Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5). Thrombosis In Myocardial Infarction. Am J Cardiol. 1997 Sep 15; 80(6):696-9. 1085. Gibson CM, Marble SJ, Rizzo MJ, Moynihan J, McLean C, Ryan K, Sparano A, Piana RN, McCabe C, Cannon CP. Relation between injections before 90-minute angiography and coronary patency: results of the thrombolysis in myocardial infarction 4 trial. Am Heart J. 1997 Sep; 134(3):351-4. 1086. Cannon CP, McCabe CH, Stone PH, Rogers WJ, Schactman M, Thompson BW, Pearce DJ, Diver DJ, Kells C, Feldman T, Williams M, Gibson RS, Kronenberg MW, Ganz LI, Anderson HV, Braunwald E. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia. J Am Coll Cardiol. 1997 Jul; 30(1):133-40. 1087. Gibson CM, Cannon CP, Greene RM, Sequeira RF, Margorien RD, Leya F, Diver DJ, Baim DS, Braunwald E. Rescue angioplasty in the thrombolysis in myocardial infarction (TIMI) 4 trial. Am J Cardiol. 1997 Jul 1; 80(1):21-6. 1088. Hochman JS, McCabe CH, Stone PH, Becker RC, Cannon CP, DeFeo-Fraulini T, Thompson B, Steingart R, Knatterud G, Braunwald E. Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB. TIMI Investigators. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1997 Jul; 30(1):141-8. 1089. Anderson HV, Gibson RS, Stone PH, Cannon CP, Aguirre F, Thompson B, Knatterud GL, Braunwald E. Management of unstable angina pectoris and non-Q-wave acute myocardial infarction in the United States and Canada (the TIMI III Registry). Am J Cardiol. 1997 Jun 1; 79(11):1441-6. 1090. Cannon CP. Acute myocardial infarction - the first 73 hours. 1997. 1091. Bovill EG, Tracy RP, Knatterud GL, Stone PH, Nasmith J, Gore JM, Thompson BW, Tofler GH, Kleiman NS, Cannon C, Braunwald E. Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial). Am J Cardiol. 1997 Feb 15; 79(4):391-6. 1092. Cannon CP, McCabe CH, Stone PH, Schactman M, Thompson B, Theroux P, Gibson RS, Feldman T, Kleiman NS, Tofler GH, Muller JE, Chaitman BR, Braunwald E. Circadian variation in the onset of unstable angina and non-Q-wave acute myocardial infarction (the TIMI III Registry and TIMI IIIB). Am J Cardiol. 1997 Feb 1; 79(3):253-8. 1093. Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, Breed J, Modi NB, Fox NL, Tracy RP, Love TW, Braunwald E. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation. 1997 Jan 21; 95(2):351-6. 1094. Cannon CP. TNK-tPA: Easier thrombolysis?. 1997. 1095. Ornato JP, Cannon CP, Gibler WB, Gonzales ER. Critical pathways for the evaluation and treatment of chest pain. 1997. 1096. Cannon CP, Antman EA. Heparin and low molecular weight heparin in acute coronary syndromes and angioplasty. Cardiology Clinics: Annual of Drug Therpay. Crawford MH, editor. 1997; 105-19. 1097. Antman EM, Tanasijevic MJ, Cannon CP. Cardiac troponins in acute coronary syndromes. N Engl J Med. 1997; 336:1259. 1098. Cannon CP, Hutter AM. The TIMI 10B and ASSENT-I trials with TNK-tPA. 1997. 1099. Oberg KC, Cannon CP, Plutzky J. Focus on reteplase: A newly approved third-generation thrombolytic agent for the treatment of acute myocardial infarction. Formulary. 1997; 32:37-45. 1100. Cannon CP. The glycoprotein IIb/IIIa inhbitors in the treatment of acute coronary syndromes. New Era of Reperfusion. 1997; 1:1-8. 1101. Braunwald E, Cannon CP. Predictive survival markers as surrogate end points in thrombolytic trials of acute myocardial infarction. Thrombolytic Therapy: New Standards of Care. Califf RM, editor. 1997; 3-10. 1102. Cannon CP. Teaching case of non-ST elevation myocardial infarction. 1997. 1103. Thrombolysis in myocardial infarction (TIMI) 11A Trial Investigators. Dose ranging trial of enoxaparin for unstable angina: Results of TIMI 11A. J Am Coll Cardiol. 1997; 29:1474-82.. 1104. Block PC, Cannon CP, Hochman JS. Thrombolytic strategy in myocardial infarction. 1997. 1105. Cannon CP. Teaching case of acute myocardial infarction. 1997. 1106. Ornato JP, Cannon CP, Gibler WB, Gonzales ER. Critical pathways for the evaluation and treatment of chest pain. 1997. 1107. Cannon CP, Goldhaber SZ. Cardiovascular risk stratification of pulmonary embolism. Am J Cardiol. 1996 Nov 15; 78(10):1149-51. 1108. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996 Oct 31; 335(18):1342-9. 1109. Scharfstein JS, Abendschein DR, Eisenberg PR, George D, Cannon CP, Becker RC, Sobel B, Cupples LA, Braunwald E, Loscalzo J. Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in Myocardial Infarction. Am J Cardiol. 1996 Sep 1; 78(5):503-10. 1110. Birnbaum Y, Kloner RA, Sclarovsky S, Cannon CP, McCabe CH, Davis VG, Zaret BL, Wackers FJ, Braunwald E. Distortion of the terminal portion of the QRS on the admission electrocardiogram in acute myocardial infarction and correlation with infarct size and long-term prognosis (Thrombolysis in Myocardial Infarction 4 Trial). Am J Cardiol. 1996 Aug 15; 78(4):396-403. 1111. Becker RC, Cannon CP, Bovill EG, Tracy RP, Thompson B, Knatterud GL, Randall A, Braunwald B. Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB Trial) Am J Cardiol. 1996 Jul 15; 78(2):142-7. 1112. Kloner RA, Gibson M, Cannon C, Braunwald E. Preinfarction angina. N Engl J Med. 1996 Jul 4; 335(1):59-60; author reply 60-1. 1113. Braunwald E, Cannon CP. Non-Q wave and ST segment depression myocardial infarction: is there a role for thrombolytic therapy? J Am Coll Cardiol. 1996 May; 27(6):1333-4. 1114. Becker RC, Cannon CP, Tracy RP, Thompson B, Bovill EG, Desvigne-Nickens P, Randall AM, Knatternud G, Braunwald E. Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators. Am Heart J. 1996 Mar; 131(3):421-33. 1115. Gibson CM, Cannon CP, Daley WL, Dodge JT, Alexander B, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996 Mar 1; 93(5):879-88. 1116. Walls RM, Cannon CP, Teich J. Thrombolysis "door-to-drug" interval. Acad Emerg Med. 1996 Mar; 3(3):285; author reply 286-7. 1117. Cannon CP. Time to Treatment: A Crucial Factor in Thrombolysis and Primary Angioplasty. J Thromb Thrombolysis. 1996; 3(3):249-255. 1118. Cannon CP, Braunwald E. Time to Reperfusion: The Critical Modulator in Thrombolysis and Primary Angioplasty. J Thromb Thrombolysis. 1996; 3(2):117-125. 1119. Kloner RA, Gibson CM, Cannon CP, Braunwald E. Preinfarction antina. N Engl J Med. 1996; 335:59-60. 1120. Moliterno DJ, Aguirre FV, Cannon CP, Every NR, Granger CB, Sapp SK, Booth JE, Ferguson JJ, forthe GUARANTEE Investigators. The global unstable angina registry and treatment evaluation (GUARANTEE) study. Circulation. 1996; 94(Suppl I):195. 1121. Becker RC, Hebert J, Hurley T, Ma Y, Cannon CP, for the TIMI 5 Hemostasis and Thrombosis Study Group. Early PTT measurement are not a surrogate for in vivo thrombin inhibition among patients receiving thrombolytic therapy and adjunctive anticoagulation. J Am Coll Cardiol. 1996; 27(Suppl A):11-12. 1122. Antman EM, McCabe CH, Cannon CP, Barbash GI, Mueller HS, Gallo P. Prevention of Q-wave development with thrombolytic therapy does not predict better short-term prognosis. Circulation. 1996; 94(Suppl I):381. 1123. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial. Circulation. 1996; 94:911-21.. 1124. Cannon CP. Time as an adjunctive agent to thrombolysis. Clinical Courier. 1996; 14:4-5. 1125. Cannon CP. Hirulog. In: Messerli FH, editor. Cardiovascular Drug Therapy. 1996; 1498-505. 1126. Kloner RA, Gibson CM, Cannon CP, Braunwald E. Preinfarction angina (letter). N Eng J Med. 1996; 335:59-60.. 1127. Cannon CP. New thrombolytic and antithrombotic approaches: TNK, hirudin, low molecular weight heparin. 1996. 1128. Anderson HV, Cannon CP, Stone PH, Williams DO, McCabe CH, Knatterud GL, Thompson B, Willerson JT, Braunwald E. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol. 1995 Dec; 26(7):1643-50. 1129. Hall C, Cannon CP, Forman S, Braunwald E. Prognostic value of N-terminal proatrial natriuretic factor plasma levels measured within the first 12 hours after myocardial infarction. Thrombolysis in Myocardial Infarction (TIMI) II Investigators. J Am Coll Cardiol. 1995 Nov 15; 26(6):1452-6. 1130. Boisjolie CR, Sharkey SW, Cannon CP, Brunette D, Haugland JM, Thatcher JL, Henry TD. Impact of a thrombolysis research trial on time to treatment for acute myocardial infarction in the emergency department. Am J Cardiol. 1995 Aug 15; 76(5):396-8. 1131. Fuchs J, Cannon CP. Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. Circulation. 1995 Aug 15; 92(4):727-33. 1132. Cannon CP. Thrombin inhibitors in acute myocardial infarction. Cardiol Clin. 1995 Aug; 13(3):421-33. 1133. Cannon CP, Walls RM. Waiting for Godot: use of chemical markers in the emergency department evaluation of chest pain. J Emerg Med. 1995 Jul-Aug; 13(4):533-5. 1134. Cannon CP, Braunwald E. Hirudin: initial results in acute myocardial infarction, unstable angina and angioplasty. J Am Coll Cardiol. 1995 Jun; 25(7 Suppl):30S-37S. 1135. Cannon CP, Thompson B, McCabe CH, Mueller HS, Kirshenbaum JM, Herson S, Nasmith JB, Chaitman BR, Braunwald E. Predictors of non-Q-wave acute myocardial infarction in patients with acute ischemic syndromes: an analysis from the Thrombolysis in Myocardial Ischemia (TIMI) III trials. Am J Cardiol. 1995 May 15; 75(15):977-81. 1136. Cannon CP. Improved management of unstable angina and non-Q-wave MI. Contemp Intern Med. 1995 May; 7(5):11-2, 15-6, 19-24. 1137. Cannon CP, Braunwald E, McCabe CH, Antman EM. The Thrombolysis in Myocardial Infarction (TIMI) trials: the first decade. J Interv Cardiol. 1995 Apr; 8(2):117-35. 1138. Gibson CM, Cannon CP, Piana RN, Breall JA, Sharaf B, Flatley M, Alexander B, Diver DJ, McCabe CH, Flaker GC, et al. Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol. 1995 Mar 1; 25(3):582-9. 1139. Cannon CP, Goldhaber SZ. The importance of rapidly treating patients with acute myocardial infarction. Chest. 1995 Mar; 107(3):598-600. 1140. Zahger D, Cercek B, Cannon CP, Jordan M, Davis V, Braunwald E, Shah PK. How do smokers differ from nonsmokers in their response to thrombolysis? (the TIMI-4 trial) Am J Cardiol. 1995 Feb 1; 75(4):232-6. 1141. Cannon CP. Hirudin in Acute Myocardial Infarction. J Thromb Thrombolysis. 1995; 1(3):259-267. 1142. Cannon CP. Optimizing the Treatment of Unstable Angina. J Thromb Thrombolysis. 1995; 2(3):205-218. 1143. Kloner RA, Shook T, Przyklenk K, Davis VG, Junio L, Matthews RV, Burstein S, Gibson M, Poole WK, Cannon CP, et al. Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? Circulation. 1995 Jan 1; 91(1):37-45. 1144. Cannon CP, Tracy R. Clotting for the Clinician: An Overview of Thrombosis and Antithrombotic Therapy. J Thromb Thrombolysis. 1995; 2(2):95-106. 1145. Henry TD, Becker RC, Cannon CP, McCabe CH, Loscalzo J, for the TIMI 5 Investigators. Is there a circadian variation in anticoagulant response to hirudin following acute myocardial infarction. J Am Coll Cardiol. 1995; 310A. 1146. Lee LV, for the TIMI 6 Investigators. Initial experience with hirudin and streptokinase in acute myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) 6 Trial. Am J Cardiol. 1995; 75:7-13.. 1147. Cannon CP, Tracy R. Clotting for the clinician: An overview of thrombosis and antithrombotic therapy. J Thromb Thrombolysis. 1995; 2:95-106. 1148. Zahger D, Cercek B, Cannon CP, Jordan M, Shah PK, for the TIMI-4 Investigators. Thrombolytic therapy for acute myocardial infraction in patients with prior coronary bypass surgery: Results from the Thrombolysis In Myocardial Infarction (TIMI) 4 Trial. J Thromb Thrombolysis. 1995; 2:45-50.. 1149. Cannon CP, Ganz LI, Stone PH. Complicated myocardial infarction. Rippe JM, Irwin RS, Fink MP, Cerra FB, editors. Intensive Care Medicine. 1995; 477-99. 1150. Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK, Sequeira RF, Leya F, Kirshenbaum JM, Magorien RD, et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol. 1994 Dec; 24(7):1602-10. 1151. Cannon CP. Advances in the treatment of acute MI. Contemp Intern Med. 1994 Aug; 6(8):11-5, 20-6. 1152. Flaker GC, Bartolozzi J, Davis V, McCabe C, Cannon CP. Use of a standardized heparin nomogram to achieve therapeutic anticoagulation after thrombolytic therapy in myocardial infarction. TIMI 4 investigators. Thrombolysis in Myocardial Infarction. Arch Intern Med. 1994 Jul 11; 154(13):1492-6. 1153. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol. 1994 Apr; 23(5):993-1003. 1154. Becker RC, Cannon CP. Hirudin: Its Biology and Clinical Use. J Thromb Thrombolysis. 1994; 1(1):7-16. 1155. Cannon CP, Braunwald E. GUSTO, TIMI and the case for rapid reperfusion. Acta Cardiol. 1994; 49(1):1-8. 1156. Cannon CP, Antman EM, Walls R, Braunwald E. Time as an Adjunctive Agent to Thrombolytic Therapy. J Thromb Thrombolysis. 1994; 1(1):27-34. 1157. Cannon CP. Adjunctive agents for myocardial infarction thrombolysis. 1994. 1158. Cannon CP, Becker RC, Loscalzo J, Gallo P, Henis M, Edwards SJ, McCabe CH, Braunwald E, for the TIMI 5 Investigators. Usefulness of APTT to predict bleeding for hirudin (and heparin). Circulation. 1994; 90(Part 2):563. 1159. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB Trial. Circulation. 1994; 89:1545-56.. 1160. Anderson HV, Williams DO, Powers E, Cannon CP, Stone P, Sharaf B, Thompson B, Schactman M, Willerson JT, for the TIMI-IIIB Investigators. Coronary thrombus seen on early angiography in unstable angina non-Q-wave MI: TIMI-IIIB results. Circulation. 1994; 90(Part 2):664. 1161. Cannon CP, Antman EM, Walls R, Braunwald E. Time: An adjunctive agent to thrombolysis. 1994. 1162. Cannon CP, Antman EM, Walls R, Braunwald E: Le Temps. Un adjuvant a la thrombolyse. 1994. 1163. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation. 1994; 90:1624-30.. 1164. Cannon CP. Pharmacology of thrombolytic, anticoagulant, and antiplatelet agents. 1994. 1165. Cannon CP, McCabe CH, Braunwald E. The thrombolysis in myocardial infarction (TIMI) trials. Becker RC, editor. Modern Era of Coronary Thrombolysis. 1994; 53-67. 1166. Becker R, Tracy R, Bovill E, Thompson B, Randall A, Cannon CP, Braunwald E. Should PTT assays be standardized in multicenter clinical trials designed to investigate the benefits of heparin. J Am Coll Cardiol. 1994; 57A. 1167. Braunwald E, Cannon CP, McCabe CH. Use of composite endpoints in thrombolysis trials of acute myocardial infarction. Am J Cardiol. 1993 Dec 16; 72(19):3G-12G. 1168. Smith SR, Kubacki VB, Rakhit A, Martin LL, Schaffer AV, Jasani MK, Hefty DJ, Johnston T, Cannon C, Bennett WM, et al. Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity. Transplantation. 1993 Dec; 56(6):1422-6. 1169. Cannon CP, Maraganore JM, Loscalzo J, McAllister A, Eddings K, George D, Selwyn AP, Adelman B, Fox I, Braunwald E, et al. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol. 1993 Apr 1; 71(10):778-82. 1170. Barr SA, Zaret BL, Cannon CP, Wackers FJT, and the TIMI 4 and 5 Investigators. Does decreasing defect size in serial quantitative planar Tc-99 sestamibi imaging following thrombolytic therapy for acute myocardial infarction correlate with improved left ventricular function. Circulation. 1993; 88(I):486. 1171. Wackers FJT, Cannon CP, McMahon M, Zaret BL, and TIMI Investigators. Natural history of serial intrahospital quantitative planar Tc-99 sestamibi imaging following thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol. 1993; 21(Suppl A):249. 1172. Cannon CP. Pharmacology of anticoagulation. Cardiac Surgery: State of the Art Reviews. 1993; 1-20. 1173. Braunwald E, Cannon CP, McCabe CH. An approach to evaluating thrombolytic therapy in acute myocardial infarction. The 'unsatisfactory outcome' end point. Circulation. 1992 Aug; 86(2):683-7. 1174. Abendschein DR, Puleo PR, Cannon CP, and the TIMI IV and V Investigators. Noninvasive detection of early coronary artery patency based on plasma MM and MB creatine kinase (CK) isoforms. Circulation. 1992; 86(Suppl I):266. 1175. Liaw CW, Cannon C, Power MD, Kiboneka PK, Rubin LL. Identification and cloning of two species of cadherins in bovine endothelial cells. EMBO J. 1990 Sep; 9(9):2701-8. 1176. Van Adelsberg J, Edwards JC, Herzlinger D, Cannon C, Rater M, al-Awqati Q. Isolation and culture of HCO3- -secreting intercalated cells. Am J Physiol. 1989 May; 256(5 Pt 1):C1004-11. 1177. Van Adelsberg J, Edwards JC, Herzlinger D, Cannon C, Rater M, Al-Awqati Q. Isolation and culture of HC03 secreting cells. Am J Physiol (Cell Physiol). 1989; 256:C1004-11.. 1178. Cannon C, van Adelsberg J, Kelly S, Al-Awqati Q. Carbon-dioxide-induced exocytotic insertion of H+ pumps in turtle-bladder luminal membrane: role of cell pH and calcium. Nature. 1985 Apr 4-10; 314(6010):443-6. 1179. Cannon C, Van Adelsberg J, Kelly S, Al-Awqati Q. Carbon dioxide-induced exocytotic insertion of H+ pumps in the turtle-bladder membrane: Role of cell pH and cell calcium. Nature. 1985; 314:443-6.. 1180. Al-Awqati Q, Gluck S, Reeves W, Cannon C. Regulation of proton transport in urinary epithelia. J Exp Biol. 1983 Sep; 106:135-41. 1181. Gluck S, Cannon C, Al-Awqati Q. Exocytosis regulates urinary acidification in turtle bladder by rapid insertion of H+ pumps into the luminal membrane. Proc Natl Acad Sci U S A. 1982 Jul; 79(14):4327-31. 1182. Gluck S, Cannon C, Al-Awqati Q. Exocytosis regulates rinary acidification in the turtle bladder by rapid insertion of H+ pumps into the luminal membrane. Proc Natl Acad Sci USA. 1982; 79:4327-31.

Send Feedback to the BWH Biomedical Research Institute.

Quick Links

EDIT YOUR PROFILE

Department

View all Research Faculty in the Department of Medicine

Division

View all Research Faculty: Cardiovascular